#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=On the integrity of functional brain networks in schizophrenia, Parkinson’s disease, and advanced age: Evidence from connectivity-based single-subject classification
#Text=Previous whole-brain functional connectivity studies achieved successful classifications of patients and healthy controls but only offered limited specificity as to affected brain systems.
1-1	0-2	On	_
1-2	3-6	the	_
1-3	7-16	integrity	_
1-4	17-19	of	_
1-5	20-30	functional	_
1-6	31-36	brain	_
1-7	37-45	networks	_
1-8	46-48	in	_
1-9	49-62	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-10	62-63	,	_
1-11	64-73	Parkinson	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[1]
1-12	73-74	’	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[1]
1-13	74-75	s	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[1]
1-14	76-83	disease	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[1]
1-15	83-84	,	_
1-16	85-88	and	_
1-17	89-97	advanced	_
1-18	98-101	age	_
1-19	101-102	:	_
1-20	103-111	Evidence	_
1-21	112-116	from	_
1-22	117-135	connectivity-based	_
1-23	136-150	single-subject	_
1-24	151-165	classification	_
1-25	166-174	Previous	_
1-26	175-186	whole-brain	_
1-27	187-197	functional	_
1-28	198-210	connectivity	_
1-29	211-218	studies	_
1-30	219-227	achieved	_
1-31	228-238	successful	_
1-32	239-254	classifications	_
1-33	255-257	of	_
1-34	258-266	patients	_
1-35	267-270	and	_
1-36	271-278	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]
1-37	279-287	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]
1-38	288-291	but	_
1-39	292-296	only	_
1-40	297-304	offered	_
1-41	305-312	limited	_
1-42	313-324	specificity	_
1-43	325-327	as	_
1-44	328-330	to	_
1-45	331-339	affected	_
1-46	340-345	brain	_
1-47	346-353	systems	_
1-48	353-354	.	_

#Text=Here, we examined whether the connectivity patterns of functional systems affected in schizophrenia (SCZ), Parkinson’s disease (PD), or normal aging equally translate into high classification accuracies for these conditions.
2-1	355-359	Here	_
2-2	359-360	,	_
2-3	361-363	we	_
2-4	364-372	examined	_
2-5	373-380	whether	_
2-6	381-384	the	_
2-7	385-397	connectivity	_
2-8	398-406	patterns	_
2-9	407-409	of	_
2-10	410-420	functional	_
2-11	421-428	systems	_
2-12	429-437	affected	_
2-13	438-440	in	_
2-14	441-454	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]
2-15	455-456	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]
2-16	456-459	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]
2-17	459-460	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]
2-18	460-461	,	_
2-19	462-471	Parkinson	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[4]
2-20	471-472	’	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[4]
2-21	472-473	s	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[4]
2-22	474-481	disease	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[4]
2-23	482-483	(	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[4]
2-24	483-485	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[4]
2-25	485-486	)	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[4]
2-26	486-487	,	_
2-27	488-490	or	_
2-28	491-497	normal	_
2-29	498-503	aging	_
2-30	504-511	equally	_
2-31	512-521	translate	_
2-32	522-526	into	_
2-33	527-531	high	_
2-34	532-546	classification	_
2-35	547-557	accuracies	_
2-36	558-561	for	_
2-37	562-567	these	_
2-38	568-578	conditions	_
2-39	578-579	.	_

#Text=We compared classification performance between pre-defined networks for each group and, for any given network, between groups.
3-1	580-582	We	_
3-2	583-591	compared	_
3-3	592-606	classification	_
3-4	607-618	performance	_
3-5	619-626	between	_
3-6	627-638	pre-defined	_
3-7	639-647	networks	_
3-8	648-651	for	_
3-9	652-656	each	_
3-10	657-662	group	_
3-11	663-666	and	_
3-12	666-667	,	_
3-13	668-671	for	_
3-14	672-675	any	_
3-15	676-681	given	_
3-16	682-689	network	_
3-17	689-690	,	_
3-18	691-698	between	_
3-19	699-705	groups	_
3-20	705-706	.	_

#Text=Separate support vector machine classifications of 86 SCZ patients, 80 PD patients, and 95 older adults relative to their matched healthy/young controls, respectively, were performed on functional connectivity in 12 task-based, meta-analytically defined networks using 25 replications of a nested 10-fold cross-validation scheme.
4-1	707-715	Separate	_
4-2	716-723	support	_
4-3	724-730	vector	_
4-4	731-738	machine	_
4-5	739-754	classifications	_
4-6	755-757	of	_
4-7	758-760	86	_
4-8	761-764	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-9	765-773	patients	_
4-10	773-774	,	_
4-11	775-777	80	_
4-12	778-780	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
4-13	781-789	patients	_
4-14	789-790	,	_
4-15	791-794	and	_
4-16	795-797	95	_
4-17	798-803	older	_
4-18	804-810	adults	_
4-19	811-819	relative	_
4-20	820-822	to	_
4-21	823-828	their	_
4-22	829-836	matched	_
4-23	837-844	healthy	_
4-24	844-845	/	_
4-25	845-850	young	_
4-26	851-859	controls	_
4-27	859-860	,	_
4-28	861-873	respectively	_
4-29	873-874	,	_
4-30	875-879	were	_
4-31	880-889	performed	_
4-32	890-892	on	_
4-33	893-903	functional	_
4-34	904-916	connectivity	_
4-35	917-919	in	_
4-36	920-922	12	_
4-37	923-933	task-based	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-38	933-934	,	_
4-39	935-952	meta-analytically	_
4-40	953-960	defined	_
4-41	961-969	networks	_
4-42	970-975	using	_
4-43	976-978	25	_
4-44	979-991	replications	_
4-45	992-994	of	_
4-46	995-996	a	_
4-47	997-1003	nested	_
4-48	1004-1006	10	_
4-49	1006-1007	-	_
4-50	1007-1011	fold	_
4-51	1012-1028	cross-validation	_
4-52	1029-1035	scheme	_
4-53	1035-1036	.	_

#Text=Classification performance of the various networks clearly differed between conditions, as those networks that best classified one disease were usually non-informative for the other.
5-1	1037-1051	Classification	_
5-2	1052-1063	performance	_
5-3	1064-1066	of	_
5-4	1067-1070	the	_
5-5	1071-1078	various	_
5-6	1079-1087	networks	_
5-7	1088-1095	clearly	_
5-8	1096-1104	differed	_
5-9	1105-1112	between	_
5-10	1113-1123	conditions	_
5-11	1123-1124	,	_
5-12	1125-1127	as	_
5-13	1128-1133	those	_
5-14	1134-1142	networks	_
5-15	1143-1147	that	_
5-16	1148-1152	best	_
5-17	1153-1163	classified	_
5-18	1164-1167	one	_
5-19	1168-1175	disease	_
5-20	1176-1180	were	_
5-21	1181-1188	usually	_
5-22	1189-1204	non-informative	_
5-23	1205-1208	for	_
5-24	1209-1212	the	_
5-25	1213-1218	other	_
5-26	1218-1219	.	_

#Text=For SCZ, but not PD, emotion-processing, empathy, and cognitive action-control networks distinguished patients most accurately from controls.
6-1	1220-1223	For	_
6-2	1224-1227	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-3	1227-1228	,	_
6-4	1229-1232	but	_
6-5	1233-1236	not	_
6-6	1237-1239	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
6-7	1239-1240	,	_
6-8	1241-1259	emotion-processing	_
6-9	1259-1260	,	_
6-10	1261-1268	empathy	_
6-11	1268-1269	,	_
6-12	1270-1273	and	_
6-13	1274-1283	cognitive	_
6-14	1284-1298	action-control	_
6-15	1299-1307	networks	_
6-16	1308-1321	distinguished	_
6-17	1322-1330	patients	_
6-18	1331-1335	most	_
6-19	1336-1346	accurately	_
6-20	1347-1351	from	_
6-21	1352-1360	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-22	1360-1361	.	_

#Text=For PD, but not SCZ, networks subserving autobiographical or semantic memory, motor execution, and theory-of-mind cognition yielded the best classifications.
7-1	1362-1365	For	_
7-2	1366-1368	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
7-3	1368-1369	,	_
7-4	1370-1373	but	_
7-5	1374-1377	not	_
7-6	1378-1381	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-7	1381-1382	,	_
7-8	1383-1391	networks	_
7-9	1392-1402	subserving	_
7-10	1403-1419	autobiographical	_
7-11	1420-1422	or	_
7-12	1423-1431	semantic	_
7-13	1432-1438	memory	_
7-14	1438-1439	,	_
7-15	1440-1445	motor	_
7-16	1446-1455	execution	_
7-17	1455-1456	,	_
7-18	1457-1460	and	_
7-19	1461-1475	theory-of-mind	_
7-20	1476-1485	cognition	_
7-21	1486-1493	yielded	_
7-22	1494-1497	the	_
7-23	1498-1502	best	_
7-24	1503-1518	classifications	_
7-25	1518-1519	.	_

#Text=In contrast, young–old classification was excellent based on all networks and outperformed both clinical classifications.
8-1	1520-1522	In	_
8-2	1523-1531	contrast	_
8-3	1531-1532	,	_
8-4	1533-1542	young–old	_
8-5	1543-1557	classification	_
8-6	1558-1561	was	_
8-7	1562-1571	excellent	_
8-8	1572-1577	based	_
8-9	1578-1580	on	_
8-10	1581-1584	all	_
8-11	1585-1593	networks	_
8-12	1594-1597	and	_
8-13	1598-1610	outperformed	_
8-14	1611-1615	both	_
8-15	1616-1624	clinical	_
8-16	1625-1640	classifications	_
8-17	1640-1641	.	_

#Text=Our pattern-classification approach captured associations between clinical and developmental conditions and functional network integrity with a higher level of specificity than did previous whole-brain analyses.
9-1	1642-1645	Our	_
9-2	1646-1668	pattern-classification	_
9-3	1669-1677	approach	_
9-4	1678-1686	captured	_
9-5	1687-1699	associations	_
9-6	1700-1707	between	_
9-7	1708-1716	clinical	_
9-8	1717-1720	and	_
9-9	1721-1734	developmental	_
9-10	1735-1745	conditions	_
9-11	1746-1749	and	_
9-12	1750-1760	functional	_
9-13	1761-1768	network	_
9-14	1769-1778	integrity	_
9-15	1779-1783	with	_
9-16	1784-1785	a	_
9-17	1786-1792	higher	_
9-18	1793-1798	level	_
9-19	1799-1801	of	_
9-20	1802-1813	specificity	_
9-21	1814-1818	than	_
9-22	1819-1822	did	_
9-23	1823-1831	previous	_
9-24	1832-1843	whole-brain	_
9-25	1844-1852	analyses	_
9-26	1852-1853	.	_

#Text=Taken together, our results support resting-state connectivity as a marker of functional dysregulation in specific networks known to be affected by SCZ and PD, while suggesting that aging affects network integrity in a more global way.
#Text=1.
10-1	1854-1859	Taken	_
10-2	1860-1868	together	_
10-3	1868-1869	,	_
10-4	1870-1873	our	_
10-5	1874-1881	results	_
10-6	1882-1889	support	_
10-7	1890-1903	resting-state	_
10-8	1904-1916	connectivity	_
10-9	1917-1919	as	_
10-10	1920-1921	a	_
10-11	1922-1928	marker	_
10-12	1929-1931	of	_
10-13	1932-1942	functional	_
10-14	1943-1956	dysregulation	_
10-15	1957-1959	in	_
10-16	1960-1968	specific	_
10-17	1969-1977	networks	_
10-18	1978-1983	known	_
10-19	1984-1986	to	_
10-20	1987-1989	be	_
10-21	1990-1998	affected	_
10-22	1999-2001	by	_
10-23	2002-2005	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-24	2006-2009	and	_
10-25	2010-2012	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
10-26	2012-2013	,	_
10-27	2014-2019	while	_
10-28	2020-2030	suggesting	_
10-29	2031-2035	that	_
10-30	2036-2041	aging	_
10-31	2042-2049	affects	_
10-32	2050-2057	network	_
10-33	2058-2067	integrity	_
10-34	2068-2070	in	_
10-35	2071-2072	a	_
10-36	2073-2077	more	_
10-37	2078-2084	global	_
10-38	2085-2088	way	_
10-39	2088-2089	.	_
10-40	2090-2091	1	_
10-41	2091-2092	.	_

#Text=INTRODUCTION
#Text=Schizophrenia (SCZ) and Parkinson’s disease (PD) are two of the most prevalent and socio-economically relevant brain diseases.
11-1	2093-2105	INTRODUCTION	_
11-2	2106-2119	Schizophrenia	_
11-3	2120-2121	(	_
11-4	2121-2124	SCZ	_
11-5	2124-2125	)	_
11-6	2126-2129	and	_
11-7	2130-2139	Parkinson	_
11-8	2139-2140	’	_
11-9	2140-2141	s	_
11-10	2142-2149	disease	_
11-11	2150-2151	(	_
11-12	2151-2153	PD	_
11-13	2153-2154	)	_
11-14	2155-2158	are	_
11-15	2159-2162	two	_
11-16	2163-2165	of	_
11-17	2166-2169	the	_
11-18	2170-2174	most	_
11-19	2175-2184	prevalent	_
11-20	2185-2188	and	_
11-21	2189-2207	socio-economically	_
11-22	2208-2216	relevant	_
11-23	2217-2222	brain	_
11-24	2223-2231	diseases	_
11-25	2231-2232	.	_

#Text=While SCZ onset typically emerges during adolescence and early adulthood, PD is characterized by an onset during late adulthood and has been associated with premature aging, that is, earlier and more rapid neurodegeneration as compared to the course of normal aging.
12-1	2233-2238	While	_
12-2	2239-2242	SCZ	_
12-3	2243-2248	onset	_
12-4	2249-2258	typically	_
12-5	2259-2266	emerges	_
12-6	2267-2273	during	_
12-7	2274-2285	adolescence	_
12-8	2286-2289	and	_
12-9	2290-2295	early	_
12-10	2296-2305	adulthood	_
12-11	2305-2306	,	_
12-12	2307-2309	PD	_
12-13	2310-2312	is	_
12-14	2313-2326	characterized	_
12-15	2327-2329	by	_
12-16	2330-2332	an	_
12-17	2333-2338	onset	_
12-18	2339-2345	during	_
12-19	2346-2350	late	_
12-20	2351-2360	adulthood	_
12-21	2361-2364	and	_
12-22	2365-2368	has	_
12-23	2369-2373	been	_
12-24	2374-2384	associated	_
12-25	2385-2389	with	_
12-26	2390-2399	premature	_
12-27	2400-2405	aging	_
12-28	2405-2406	,	_
12-29	2407-2411	that	_
12-30	2412-2414	is	_
12-31	2414-2415	,	_
12-32	2416-2423	earlier	_
12-33	2424-2427	and	_
12-34	2428-2432	more	_
12-35	2433-2438	rapid	_
12-36	2439-2456	neurodegeneration	_
12-37	2457-2459	as	_
12-38	2460-2468	compared	_
12-39	2469-2471	to	_
12-40	2472-2475	the	_
12-41	2476-2482	course	_
12-42	2483-2485	of	_
12-43	2486-2492	normal	_
12-44	2493-2498	aging	_
12-45	2498-2499	.	_

#Text=Both SCZ and PD are characterized by disease-specific pathophysiological changes of the dopaminergic system, contrasting with a more global dopamine decline in normal aging (NA).
13-1	2500-2504	Both	_
13-2	2505-2508	SCZ	_
13-3	2509-2512	and	_
13-4	2513-2515	PD	_
13-5	2516-2519	are	_
13-6	2520-2533	characterized	_
13-7	2534-2536	by	_
13-8	2537-2553	disease-specific	_
13-9	2554-2572	pathophysiological	_
13-10	2573-2580	changes	_
13-11	2581-2583	of	_
13-12	2584-2587	the	_
13-13	2588-2600	dopaminergic	_
13-14	2601-2607	system	_
13-15	2607-2608	,	_
13-16	2609-2620	contrasting	_
13-17	2621-2625	with	_
13-18	2626-2627	a	_
13-19	2628-2632	more	_
13-20	2633-2639	global	_
13-21	2640-2648	dopamine	_
13-22	2649-2656	decline	_
13-23	2657-2659	in	_
13-24	2660-2666	normal	_
13-25	2667-2672	aging	_
13-26	2673-2674	(	_
13-27	2674-2676	NA	_
13-28	2676-2677	)	_
13-29	2677-2678	.	_

#Text=However, it has been proposed that dopaminergic dysfunction in SCZ arises as a secondary effect due to alterations of the glutaminergic system.
14-1	2679-2686	However	_
14-2	2686-2687	,	_
14-3	2688-2690	it	_
14-4	2691-2694	has	_
14-5	2695-2699	been	_
14-6	2700-2708	proposed	_
14-7	2709-2713	that	_
14-8	2714-2726	dopaminergic	_
14-9	2727-2738	dysfunction	_
14-10	2739-2741	in	_
14-11	2742-2745	SCZ	_
14-12	2746-2752	arises	_
14-13	2753-2755	as	_
14-14	2756-2757	a	_
14-15	2758-2767	secondary	_
14-16	2768-2774	effect	_
14-17	2775-2778	due	_
14-18	2779-2781	to	_
14-19	2782-2793	alterations	_
14-20	2794-2796	of	_
14-21	2797-2800	the	_
14-22	2801-2814	glutaminergic	_
14-23	2815-2821	system	_
14-24	2821-2822	.	_

#Text=In contrast, in PD dopaminergic deficiency represents the primary cause leading to pathophysiological upstream dysregulations of different neural systems.
15-1	2823-2825	In	_
15-2	2826-2834	contrast	_
15-3	2834-2835	,	_
15-4	2836-2838	in	_
15-5	2839-2841	PD	_
15-6	2842-2854	dopaminergic	_
15-7	2855-2865	deficiency	_
15-8	2866-2876	represents	_
15-9	2877-2880	the	_
15-10	2881-2888	primary	_
15-11	2889-2894	cause	_
15-12	2895-2902	leading	_
15-13	2903-2905	to	_
15-14	2906-2924	pathophysiological	_
15-15	2925-2933	upstream	_
15-16	2934-2948	dysregulations	_
15-17	2949-2951	of	_
15-18	2952-2961	different	_
15-19	2962-2968	neural	_
15-20	2969-2976	systems	_
15-21	2976-2977	.	_

#Text=These neurobiological features of SCZ, PD and NA may manifest themselves in functional connectivity alterations at the level of large-scale brain networks.
16-1	2978-2983	These	_
16-2	2984-2999	neurobiological	_
16-3	3000-3008	features	_
16-4	3009-3011	of	_
16-5	3012-3015	SCZ	_
16-6	3015-3016	,	_
16-7	3017-3019	PD	_
16-8	3020-3023	and	_
16-9	3024-3026	NA	_
16-10	3027-3030	may	_
16-11	3031-3039	manifest	_
16-12	3040-3050	themselves	_
16-13	3051-3053	in	_
16-14	3054-3064	functional	_
16-15	3065-3077	connectivity	_
16-16	3078-3089	alterations	_
16-17	3090-3092	at	_
16-18	3093-3096	the	_
16-19	3097-3102	level	_
16-20	3103-3105	of	_
16-21	3106-3117	large-scale	_
16-22	3118-3123	brain	_
16-23	3124-3132	networks	_
16-24	3132-3133	.	_

#Text=However, some putative commonalities (neurodegeneration, dopaminergic dysregulations, and altered connectivity) need to be juxtaposed with the prominent phenotypical differences between SCZ, PD, and NA and the fact that the clinical presentations of SCZ and PD are very different, raising the question whether various functional systems are differentially affected in the three conditions.
17-1	3134-3141	However	_
17-2	3141-3142	,	_
17-3	3143-3147	some	_
17-4	3148-3156	putative	_
17-5	3157-3170	commonalities	_
17-6	3171-3172	(	_
17-7	3172-3189	neurodegeneration	_
17-8	3189-3190	,	_
17-9	3191-3203	dopaminergic	_
17-10	3204-3218	dysregulations	_
17-11	3218-3219	,	_
17-12	3220-3223	and	_
17-13	3224-3231	altered	_
17-14	3232-3244	connectivity	_
17-15	3244-3245	)	_
17-16	3246-3250	need	_
17-17	3251-3253	to	_
17-18	3254-3256	be	_
17-19	3257-3267	juxtaposed	_
17-20	3268-3272	with	_
17-21	3273-3276	the	_
17-22	3277-3286	prominent	_
17-23	3287-3299	phenotypical	_
17-24	3300-3311	differences	_
17-25	3312-3319	between	_
17-26	3320-3323	SCZ	_
17-27	3323-3324	,	_
17-28	3325-3327	PD	_
17-29	3327-3328	,	_
17-30	3329-3332	and	_
17-31	3333-3335	NA	_
17-32	3336-3339	and	_
17-33	3340-3343	the	_
17-34	3344-3348	fact	_
17-35	3349-3353	that	_
17-36	3354-3357	the	_
17-37	3358-3366	clinical	_
17-38	3367-3380	presentations	_
17-39	3381-3383	of	_
17-40	3384-3387	SCZ	_
17-41	3388-3391	and	_
17-42	3392-3394	PD	_
17-43	3395-3398	are	_
17-44	3399-3403	very	_
17-45	3404-3413	different	_
17-46	3413-3414	,	_
17-47	3415-3422	raising	_
17-48	3423-3426	the	_
17-49	3427-3435	question	_
17-50	3436-3443	whether	_
17-51	3444-3451	various	_
17-52	3452-3462	functional	_
17-53	3463-3470	systems	_
17-54	3471-3474	are	_
17-55	3475-3489	differentially	_
17-56	3490-3498	affected	_
17-57	3499-3501	in	_
17-58	3502-3505	the	_
17-59	3506-3511	three	_
17-60	3512-3522	conditions	_
17-61	3522-3523	.	_

#Text=Rather than assessing altered activations in different functional systems by conducting task-fMRI studies, we examined altered functional connectivity within various functional networks robustly defined by meta-analyses of task-based neuroimaging studies in a comparative fashion (cf.).
18-1	3524-3530	Rather	_
18-2	3531-3535	than	_
18-3	3536-3545	assessing	_
18-4	3546-3553	altered	_
18-5	3554-3565	activations	_
18-6	3566-3568	in	_
18-7	3569-3578	different	_
18-8	3579-3589	functional	_
18-9	3590-3597	systems	_
18-10	3598-3600	by	_
18-11	3601-3611	conducting	_
18-12	3612-3621	task-fMRI	_
18-13	3622-3629	studies	_
18-14	3629-3630	,	_
18-15	3631-3633	we	_
18-16	3634-3642	examined	_
18-17	3643-3650	altered	_
18-18	3651-3661	functional	_
18-19	3662-3674	connectivity	_
18-20	3675-3681	within	_
18-21	3682-3689	various	_
18-22	3690-3700	functional	_
18-23	3701-3709	networks	_
18-24	3710-3718	robustly	_
18-25	3719-3726	defined	_
18-26	3727-3729	by	_
18-27	3730-3743	meta-analyses	_
18-28	3744-3746	of	_
18-29	3747-3757	task-based	_
18-30	3758-3770	neuroimaging	_
18-31	3771-3778	studies	_
18-32	3779-3781	in	_
18-33	3782-3783	a	_
18-34	3784-3795	comparative	_
18-35	3796-3803	fashion	_
18-36	3804-3805	(	_
18-37	3805-3807	cf	_
18-38	3807-3808	.	_
18-39	3808-3809	)	_
18-40	3809-3810	.	_

#Text=This has the practicable advantage of using easily accessible, short and standardized resting-state data while at the same time incorporating the consolidated knowledge based on task-based imaging into the analysis.
19-1	3811-3815	This	_
19-2	3816-3819	has	_
19-3	3820-3823	the	_
19-4	3824-3835	practicable	_
19-5	3836-3845	advantage	_
19-6	3846-3848	of	_
19-7	3849-3854	using	_
19-8	3855-3861	easily	_
19-9	3862-3872	accessible	_
19-10	3872-3873	,	_
19-11	3874-3879	short	_
19-12	3880-3883	and	_
19-13	3884-3896	standardized	_
19-14	3897-3910	resting-state	_
19-15	3911-3915	data	_
19-16	3916-3921	while	_
19-17	3922-3924	at	_
19-18	3925-3928	the	_
19-19	3929-3933	same	_
19-20	3934-3938	time	_
19-21	3939-3952	incorporating	_
19-22	3953-3956	the	_
19-23	3957-3969	consolidated	_
19-24	3970-3979	knowledge	_
19-25	3980-3985	based	_
19-26	3986-3988	on	_
19-27	3989-3999	task-based	_
19-28	4000-4007	imaging	_
19-29	4008-4012	into	_
19-30	4013-4016	the	_
19-31	4017-4025	analysis	_
19-32	4025-4026	.	_

#Text=We argue that such an approach is particularly relevant given that in contrast to resting-state imaging, task-based assessments will rarely be feasible in a routine clinical setting.
20-1	4027-4029	We	_
20-2	4030-4035	argue	_
20-3	4036-4040	that	_
20-4	4041-4045	such	_
20-5	4046-4048	an	_
20-6	4049-4057	approach	_
20-7	4058-4060	is	_
20-8	4061-4073	particularly	_
20-9	4074-4082	relevant	_
20-10	4083-4088	given	_
20-11	4089-4093	that	_
20-12	4094-4096	in	_
20-13	4097-4105	contrast	_
20-14	4106-4108	to	_
20-15	4109-4122	resting-state	_
20-16	4123-4130	imaging	_
20-17	4130-4131	,	_
20-18	4132-4142	task-based	_
20-19	4143-4154	assessments	_
20-20	4155-4159	will	_
20-21	4160-4166	rarely	_
20-22	4167-4169	be	_
20-23	4170-4178	feasible	_
20-24	4179-4181	in	_
20-25	4182-4183	a	_
20-26	4184-4191	routine	_
20-27	4192-4200	clinical	_
20-28	4201-4208	setting	_
20-29	4208-4209	.	_

#Text=Alterations in functional network integrity patterns in SCZ, PD or older adults (compared to respective healthy/young controls) can be captured by using machine learning-based classification.
21-1	4210-4221	Alterations	_
21-2	4222-4224	in	_
21-3	4225-4235	functional	_
21-4	4236-4243	network	_
21-5	4244-4253	integrity	_
21-6	4254-4262	patterns	_
21-7	4263-4265	in	_
21-8	4266-4269	SCZ	_
21-9	4269-4270	,	_
21-10	4271-4273	PD	_
21-11	4274-4276	or	_
21-12	4277-4282	older	_
21-13	4283-4289	adults	_
21-14	4290-4291	(	_
21-15	4291-4299	compared	_
21-16	4300-4302	to	_
21-17	4303-4313	respective	_
21-18	4314-4321	healthy	_
21-19	4321-4322	/	_
21-20	4322-4327	young	_
21-21	4328-4336	controls	_
21-22	4336-4337	)	_
21-23	4338-4341	can	_
21-24	4342-4344	be	_
21-25	4345-4353	captured	_
21-26	4354-4356	by	_
21-27	4357-4362	using	_
21-28	4363-4370	machine	_
21-29	4371-4385	learning-based	_
21-30	4386-4400	classification	_
21-31	4400-4401	.	_

#Text=For extracting a diagnostically relevant marker that allows the classification of individual subjects based on the connectivity in functional brain networks, multivariate decoding algorithms like support vector machine (SVM) should provide the most appropriate approach for this endeavor.
22-1	4402-4405	For	_
22-2	4406-4416	extracting	_
22-3	4417-4418	a	_
22-4	4419-4433	diagnostically	_
22-5	4434-4442	relevant	_
22-6	4443-4449	marker	_
22-7	4450-4454	that	_
22-8	4455-4461	allows	_
22-9	4462-4465	the	_
22-10	4466-4480	classification	_
22-11	4481-4483	of	_
22-12	4484-4494	individual	_
22-13	4495-4503	subjects	_
22-14	4504-4509	based	_
22-15	4510-4512	on	_
22-16	4513-4516	the	_
22-17	4517-4529	connectivity	_
22-18	4530-4532	in	_
22-19	4533-4543	functional	_
22-20	4544-4549	brain	_
22-21	4550-4558	networks	_
22-22	4558-4559	,	_
22-23	4560-4572	multivariate	_
22-24	4573-4581	decoding	_
22-25	4582-4592	algorithms	_
22-26	4593-4597	like	_
22-27	4598-4605	support	_
22-28	4606-4612	vector	_
22-29	4613-4620	machine	_
22-30	4621-4622	(	_
22-31	4622-4625	SVM	_
22-32	4625-4626	)	_
22-33	4627-4633	should	_
22-34	4634-4641	provide	_
22-35	4642-4645	the	_
22-36	4646-4650	most	_
22-37	4651-4662	appropriate	_
22-38	4663-4671	approach	_
22-39	4672-4675	for	_
22-40	4676-4680	this	_
22-41	4681-4689	endeavor	_
22-42	4689-4690	.	_

#Text=Rather than testing each connection independently for group differences, SVMs are trained on part of the data by weighting all connections in order to separate the known clinical status from healthy controls (HC).
23-1	4691-4697	Rather	_
23-2	4698-4702	than	_
23-3	4703-4710	testing	_
23-4	4711-4715	each	_
23-5	4716-4726	connection	_
23-6	4727-4740	independently	_
23-7	4741-4744	for	_
23-8	4745-4750	group	_
23-9	4751-4762	differences	_
23-10	4762-4763	,	_
23-11	4764-4768	SVMs	_
23-12	4769-4772	are	_
23-13	4773-4780	trained	_
23-14	4781-4783	on	_
23-15	4784-4788	part	_
23-16	4789-4791	of	_
23-17	4792-4795	the	_
23-18	4796-4800	data	_
23-19	4801-4803	by	_
23-20	4804-4813	weighting	_
23-21	4814-4817	all	_
23-22	4818-4829	connections	_
23-23	4830-4832	in	_
23-24	4833-4838	order	_
23-25	4839-4841	to	_
23-26	4842-4850	separate	_
23-27	4851-4854	the	_
23-28	4855-4860	known	_
23-29	4861-4869	clinical	_
23-30	4870-4876	status	_
23-31	4877-4881	from	_
23-32	4882-4889	healthy	_
23-33	4890-4898	controls	_
23-34	4899-4900	(	_
23-35	4900-4902	HC	_
23-36	4902-4903	)	_
23-37	4903-4904	.	_

#Text=Classification accuracy can then be determined by assessing the ability to predict group membership of previously unseen subjects.
24-1	4905-4919	Classification	_
24-2	4920-4928	accuracy	_
24-3	4929-4932	can	_
24-4	4933-4937	then	_
24-5	4938-4940	be	_
24-6	4941-4951	determined	_
24-7	4952-4954	by	_
24-8	4955-4964	assessing	_
24-9	4965-4968	the	_
24-10	4969-4976	ability	_
24-11	4977-4979	to	_
24-12	4980-4987	predict	_
24-13	4988-4993	group	_
24-14	4994-5004	membership	_
24-15	5005-5007	of	_
24-16	5008-5018	previously	_
24-17	5019-5025	unseen	_
24-18	5026-5034	subjects	_
24-19	5034-5035	.	_

#Text=Applied to (whole-brain) connectivity data, this approach has previously been found to distinguish SCZ patients (cf.) or PD patients (cf.) from healthy controls (HC), as well as aged from young subjects (NA) (cf.).
25-1	5036-5043	Applied	_
25-2	5044-5046	to	_
25-3	5047-5048	(	_
25-4	5048-5059	whole-brain	_
25-5	5059-5060	)	_
25-6	5061-5073	connectivity	_
25-7	5074-5078	data	_
25-8	5078-5079	,	_
25-9	5080-5084	this	_
25-10	5085-5093	approach	_
25-11	5094-5097	has	_
25-12	5098-5108	previously	_
25-13	5109-5113	been	_
25-14	5114-5119	found	_
25-15	5120-5122	to	_
25-16	5123-5134	distinguish	_
25-17	5135-5138	SCZ	_
25-18	5139-5147	patients	_
25-19	5148-5149	(	_
25-20	5149-5151	cf	_
25-21	5151-5152	.	_
25-22	5152-5153	)	_
25-23	5154-5156	or	_
25-24	5157-5159	PD	_
25-25	5160-5168	patients	_
25-26	5169-5170	(	_
25-27	5170-5172	cf	_
25-28	5172-5173	.	_
25-29	5173-5174	)	_
25-30	5175-5179	from	_
25-31	5180-5187	healthy	_
25-32	5188-5196	controls	_
25-33	5197-5198	(	_
25-34	5198-5200	HC	_
25-35	5200-5201	)	_
25-36	5201-5202	,	_
25-37	5203-5205	as	_
25-38	5206-5210	well	_
25-39	5211-5213	as	_
25-40	5214-5218	aged	_
25-41	5219-5223	from	_
25-42	5224-5229	young	_
25-43	5230-5238	subjects	_
25-44	5239-5240	(	_
25-45	5240-5242	NA	_
25-46	5242-5243	)	_
25-47	5244-5245	(	_
25-48	5245-5247	cf	_
25-49	5247-5248	.	_
25-50	5248-5249	)	_
25-51	5249-5250	.	_

#Text=Previous pattern-classification studies aimed at providing the best possible classification performance on whole-brain connectivity.
26-1	5251-5259	Previous	_
26-2	5260-5282	pattern-classification	_
26-3	5283-5290	studies	_
26-4	5291-5296	aimed	_
26-5	5297-5299	at	_
26-6	5300-5309	providing	_
26-7	5310-5313	the	_
26-8	5314-5318	best	_
26-9	5319-5327	possible	_
26-10	5328-5342	classification	_
26-11	5343-5354	performance	_
26-12	5355-5357	on	_
26-13	5358-5369	whole-brain	_
26-14	5370-5382	connectivity	_
26-15	5382-5383	.	_

#Text=In contrast, the aim of the current work was to assess whether specific functionally defined networks are altered in SCZ, PD, and NA.
27-1	5384-5386	In	_
27-2	5387-5395	contrast	_
27-3	5395-5396	,	_
27-4	5397-5400	the	_
27-5	5401-5404	aim	_
27-6	5405-5407	of	_
27-7	5408-5411	the	_
27-8	5412-5419	current	_
27-9	5420-5424	work	_
27-10	5425-5428	was	_
27-11	5429-5431	to	_
27-12	5432-5438	assess	_
27-13	5439-5446	whether	_
27-14	5447-5455	specific	_
27-15	5456-5468	functionally	_
27-16	5469-5476	defined	_
27-17	5477-5485	networks	_
27-18	5486-5489	are	_
27-19	5490-5497	altered	_
27-20	5498-5500	in	_
27-21	5501-5504	SCZ	_
27-22	5504-5505	,	_
27-23	5506-5508	PD	_
27-24	5508-5509	,	_
27-25	5510-5513	and	_
27-26	5514-5516	NA	_
27-27	5516-5517	.	_

#Text=While previous studies mainly used Independent Component Analysis (ICA) based data-driven methods to extract major resting-state networks, our work is based on a priori meta-analytically defined networks associated with specific sets of behavioral functions such as working memory or emotional processing.
28-1	5518-5523	While	_
28-2	5524-5532	previous	_
28-3	5533-5540	studies	_
28-4	5541-5547	mainly	_
28-5	5548-5552	used	_
28-6	5553-5564	Independent	_
28-7	5565-5574	Component	_
28-8	5575-5583	Analysis	_
28-9	5584-5585	(	_
28-10	5585-5588	ICA	_
28-11	5588-5589	)	_
28-12	5590-5595	based	_
28-13	5596-5607	data-driven	_
28-14	5608-5615	methods	_
28-15	5616-5618	to	_
28-16	5619-5626	extract	_
28-17	5627-5632	major	_
28-18	5633-5646	resting-state	_
28-19	5647-5655	networks	_
28-20	5655-5656	,	_
28-21	5657-5660	our	_
28-22	5661-5665	work	_
28-23	5666-5668	is	_
28-24	5669-5674	based	_
28-25	5675-5677	on	_
28-26	5678-5679	a	_
28-27	5680-5686	priori	_
28-28	5687-5704	meta-analytically	_
28-29	5705-5712	defined	_
28-30	5713-5721	networks	_
28-31	5722-5732	associated	_
28-32	5733-5737	with	_
28-33	5738-5746	specific	_
28-34	5747-5751	sets	_
28-35	5752-5754	of	_
28-36	5755-5765	behavioral	_
28-37	5766-5775	functions	_
28-38	5776-5780	such	_
28-39	5781-5783	as	_
28-40	5784-5791	working	_
28-41	5792-5798	memory	_
28-42	5799-5801	or	_
28-43	5802-5811	emotional	_
28-44	5812-5822	processing	_
28-45	5822-5823	.	_

#Text=In contrast to well-established resting-state networks, these networks represent the consolidated information from hundreds of task-based fMRI studies and hence those locations in the brain that are reliably activated when subjects perform tasks pertaining to a particular mental function.
29-1	5824-5826	In	_
29-2	5827-5835	contrast	_
29-3	5836-5838	to	_
29-4	5839-5855	well-established	_
29-5	5856-5869	resting-state	_
29-6	5870-5878	networks	_
29-7	5878-5879	,	_
29-8	5880-5885	these	_
29-9	5886-5894	networks	_
29-10	5895-5904	represent	_
29-11	5905-5908	the	_
29-12	5909-5921	consolidated	_
29-13	5922-5933	information	_
29-14	5934-5938	from	_
29-15	5939-5947	hundreds	_
29-16	5948-5950	of	_
29-17	5951-5961	task-based	_
29-18	5962-5966	fMRI	_
29-19	5967-5974	studies	_
29-20	5975-5978	and	_
29-21	5979-5984	hence	_
29-22	5985-5990	those	_
29-23	5991-6000	locations	_
29-24	6001-6003	in	_
29-25	6004-6007	the	_
29-26	6008-6013	brain	_
29-27	6014-6018	that	_
29-28	6019-6022	are	_
29-29	6023-6031	reliably	_
29-30	6032-6041	activated	_
29-31	6042-6046	when	_
29-32	6047-6055	subjects	_
29-33	6056-6063	perform	_
29-34	6064-6069	tasks	_
29-35	6070-6080	pertaining	_
29-36	6081-6083	to	_
29-37	6084-6085	a	_
29-38	6086-6096	particular	_
29-39	6097-6103	mental	_
29-40	6104-6112	function	_
29-41	6112-6113	.	_

#Text=We thus argue that these nodes define robust functional networks in the brain related to specific mental domains.
30-1	6114-6116	We	_
30-2	6117-6121	thus	_
30-3	6122-6127	argue	_
30-4	6128-6132	that	_
30-5	6133-6138	these	_
30-6	6139-6144	nodes	_
30-7	6145-6151	define	_
30-8	6152-6158	robust	_
30-9	6159-6169	functional	_
30-10	6170-6178	networks	_
30-11	6179-6181	in	_
30-12	6182-6185	the	_
30-13	6186-6191	brain	_
30-14	6192-6199	related	_
30-15	6200-6202	to	_
30-16	6203-6211	specific	_
30-17	6212-6218	mental	_
30-18	6219-6226	domains	_
30-19	6226-6227	.	_

#Text=In turn, the functions associated with resting-state networks are usually derived from a reverse inference approach, as these lack any direct relationship to mental functions.
31-1	6228-6230	In	_
31-2	6231-6235	turn	_
31-3	6235-6236	,	_
31-4	6237-6240	the	_
31-5	6241-6250	functions	_
31-6	6251-6261	associated	_
31-7	6262-6266	with	_
31-8	6267-6280	resting-state	_
31-9	6281-6289	networks	_
31-10	6290-6293	are	_
31-11	6294-6301	usually	_
31-12	6302-6309	derived	_
31-13	6310-6314	from	_
31-14	6315-6316	a	_
31-15	6317-6324	reverse	_
31-16	6325-6334	inference	_
31-17	6335-6343	approach	_
31-18	6343-6344	,	_
31-19	6345-6347	as	_
31-20	6348-6353	these	_
31-21	6354-6358	lack	_
31-22	6359-6362	any	_
31-23	6363-6369	direct	_
31-24	6370-6382	relationship	_
31-25	6383-6385	to	_
31-26	6386-6392	mental	_
31-27	6393-6402	functions	_
31-28	6402-6403	.	_

#Text=We suggest that this more direct relationship between the network-nodes and actual task-demands is an important advantage of our approach.
32-1	6404-6406	We	_
32-2	6407-6414	suggest	_
32-3	6415-6419	that	_
32-4	6420-6424	this	_
32-5	6425-6429	more	_
32-6	6430-6436	direct	_
32-7	6437-6449	relationship	_
32-8	6450-6457	between	_
32-9	6458-6461	the	_
32-10	6462-6475	network-nodes	_
32-11	6476-6479	and	_
32-12	6480-6486	actual	_
32-13	6487-6499	task-demands	_
32-14	6500-6502	is	_
32-15	6503-6505	an	_
32-16	6506-6515	important	_
32-17	6516-6525	advantage	_
32-18	6526-6528	of	_
32-19	6529-6532	our	_
32-20	6533-6541	approach	_
32-21	6541-6542	.	_

#Text=Moreover, the employed strategy results in an a priori, unbiased definition of the respective networks, whereas ICA-based networks are usually defined from the current data.
33-1	6543-6551	Moreover	_
33-2	6551-6552	,	_
33-3	6553-6556	the	_
33-4	6557-6565	employed	_
33-5	6566-6574	strategy	_
33-6	6575-6582	results	_
33-7	6583-6585	in	_
33-8	6586-6588	an	_
33-9	6589-6590	a	_
33-10	6591-6597	priori	_
33-11	6597-6598	,	_
33-12	6599-6607	unbiased	_
33-13	6608-6618	definition	_
33-14	6619-6621	of	_
33-15	6622-6625	the	_
33-16	6626-6636	respective	_
33-17	6637-6645	networks	_
33-18	6645-6646	,	_
33-19	6647-6654	whereas	_
33-20	6655-6664	ICA-based	_
33-21	6665-6673	networks	_
33-22	6674-6677	are	_
33-23	6678-6685	usually	_
33-24	6686-6693	defined	_
33-25	6694-6698	from	_
33-26	6699-6702	the	_
33-27	6703-6710	current	_
33-28	6711-6715	data	_
33-29	6715-6716	.	_

#Text=Our meta-analytically derived network model approach thus offers the potential to investigate functional connectivity within robust a priori brain networks that are implicated in processing a specific mental process.
34-1	6717-6720	Our	_
34-2	6721-6738	meta-analytically	_
34-3	6739-6746	derived	_
34-4	6747-6754	network	_
34-5	6755-6760	model	_
34-6	6761-6769	approach	_
34-7	6770-6774	thus	_
34-8	6775-6781	offers	_
34-9	6782-6785	the	_
34-10	6786-6795	potential	_
34-11	6796-6798	to	_
34-12	6799-6810	investigate	_
34-13	6811-6821	functional	_
34-14	6822-6834	connectivity	_
34-15	6835-6841	within	_
34-16	6842-6848	robust	_
34-17	6849-6850	a	_
34-18	6851-6857	priori	_
34-19	6858-6863	brain	_
34-20	6864-6872	networks	_
34-21	6873-6877	that	_
34-22	6878-6881	are	_
34-23	6882-6892	implicated	_
34-24	6893-6895	in	_
34-25	6896-6906	processing	_
34-26	6907-6908	a	_
34-27	6909-6917	specific	_
34-28	6918-6924	mental	_
34-29	6925-6932	process	_
34-30	6932-6933	.	_

#Text=Therefore, the present study aimed to examine whether the known impairment of different functions in SCZ, PD, or aging, respectively, would equally translate into a high classification accuracy for a given network in the respective group, based on the connectivity pattern within this network.
35-1	6934-6943	Therefore	_
35-2	6943-6944	,	_
35-3	6945-6948	the	_
35-4	6949-6956	present	_
35-5	6957-6962	study	_
35-6	6963-6968	aimed	_
35-7	6969-6971	to	_
35-8	6972-6979	examine	_
35-9	6980-6987	whether	_
35-10	6988-6991	the	_
35-11	6992-6997	known	_
35-12	6998-7008	impairment	_
35-13	7009-7011	of	_
35-14	7012-7021	different	_
35-15	7022-7031	functions	_
35-16	7032-7034	in	_
35-17	7035-7038	SCZ	_
35-18	7038-7039	,	_
35-19	7040-7042	PD	_
35-20	7042-7043	,	_
35-21	7044-7046	or	_
35-22	7047-7052	aging	_
35-23	7052-7053	,	_
35-24	7054-7066	respectively	_
35-25	7066-7067	,	_
35-26	7068-7073	would	_
35-27	7074-7081	equally	_
35-28	7082-7091	translate	_
35-29	7092-7096	into	_
35-30	7097-7098	a	_
35-31	7099-7103	high	_
35-32	7104-7118	classification	_
35-33	7119-7127	accuracy	_
35-34	7128-7131	for	_
35-35	7132-7133	a	_
35-36	7134-7139	given	_
35-37	7140-7147	network	_
35-38	7148-7150	in	_
35-39	7151-7154	the	_
35-40	7155-7165	respective	_
35-41	7166-7171	group	_
35-42	7171-7172	,	_
35-43	7173-7178	based	_
35-44	7179-7181	on	_
35-45	7182-7185	the	_
35-46	7186-7198	connectivity	_
35-47	7199-7206	pattern	_
35-48	7207-7213	within	_
35-49	7214-7218	this	_
35-50	7219-7226	network	_
35-51	7226-7227	.	_

#Text=As a “proof-of-principle” approach we therefore intended to investigate whether various a priori networks based on task-activation findings carry differential disease-related information assessable by resting-state imaging.
36-1	7228-7230	As	_
36-2	7231-7232	a	_
36-3	7233-7234	“	_
36-4	7234-7252	proof-of-principle	_
36-5	7252-7253	”	_
36-6	7254-7262	approach	_
36-7	7263-7265	we	_
36-8	7266-7275	therefore	_
36-9	7276-7284	intended	_
36-10	7285-7287	to	_
36-11	7288-7299	investigate	_
36-12	7300-7307	whether	_
36-13	7308-7315	various	_
36-14	7316-7317	a	_
36-15	7318-7324	priori	_
36-16	7325-7333	networks	_
36-17	7334-7339	based	_
36-18	7340-7342	on	_
36-19	7343-7358	task-activation	_
36-20	7359-7367	findings	_
36-21	7368-7373	carry	_
36-22	7374-7386	differential	_
36-23	7387-7402	disease-related	_
36-24	7403-7414	information	_
36-25	7415-7425	assessable	_
36-26	7426-7428	by	_
36-27	7429-7442	resting-state	_
36-28	7443-7450	imaging	_
36-29	7450-7451	.	_

#Text=To this end, we examined two diseases which are clinically very disparate but well studied in the previous neuroimaging literature.
37-1	7452-7454	To	_
37-2	7455-7459	this	_
37-3	7460-7463	end	_
37-4	7463-7464	,	_
37-5	7465-7467	we	_
37-6	7468-7476	examined	_
37-7	7477-7480	two	_
37-8	7481-7489	diseases	_
37-9	7490-7495	which	_
37-10	7496-7499	are	_
37-11	7500-7510	clinically	_
37-12	7511-7515	very	_
37-13	7516-7525	disparate	_
37-14	7526-7529	but	_
37-15	7530-7534	well	_
37-16	7535-7542	studied	_
37-17	7543-7545	in	_
37-18	7546-7549	the	_
37-19	7550-7558	previous	_
37-20	7559-7571	neuroimaging	_
37-21	7572-7582	literature	_
37-22	7582-7583	.	_

#Text=The findings were then juxtaposed to findings on age-related effects in the same networks.
38-1	7584-7587	The	_
38-2	7588-7596	findings	_
38-3	7597-7601	were	_
38-4	7602-7606	then	_
38-5	7607-7617	juxtaposed	_
38-6	7618-7620	to	_
38-7	7621-7629	findings	_
38-8	7630-7632	on	_
38-9	7633-7644	age-related	_
38-10	7645-7652	effects	_
38-11	7653-7655	in	_
38-12	7656-7659	the	_
38-13	7660-7664	same	_
38-14	7665-7673	networks	_
38-15	7673-7674	.	_

#Text=Thereby, we could evaluate whether the respective networks carry differential information related to the different conditions or, conversely, whether the different networks carry differential information related to a particular condition.
39-1	7675-7682	Thereby	_
39-2	7682-7683	,	_
39-3	7684-7686	we	_
39-4	7687-7692	could	_
39-5	7693-7701	evaluate	_
39-6	7702-7709	whether	_
39-7	7710-7713	the	_
39-8	7714-7724	respective	_
39-9	7725-7733	networks	_
39-10	7734-7739	carry	_
39-11	7740-7752	differential	_
39-12	7753-7764	information	_
39-13	7765-7772	related	_
39-14	7773-7775	to	_
39-15	7776-7779	the	_
39-16	7780-7789	different	_
39-17	7790-7800	conditions	_
39-18	7801-7803	or	_
39-19	7803-7804	,	_
39-20	7805-7815	conversely	_
39-21	7815-7816	,	_
39-22	7817-7824	whether	_
39-23	7825-7828	the	_
39-24	7829-7838	different	_
39-25	7839-7847	networks	_
39-26	7848-7853	carry	_
39-27	7854-7866	differential	_
39-28	7867-7878	information	_
39-29	7879-7886	related	_
39-30	7887-7889	to	_
39-31	7890-7891	a	_
39-32	7892-7902	particular	_
39-33	7903-7912	condition	_
39-34	7912-7913	.	_

#Text=Given some putative commonalities and especially phenotypical differences, the aim was to examine the possibility for differential classification of SCZ, PD und age, rather than to primarily study the specific diseases and their clinical separation from each other or aging per se.
40-1	7914-7919	Given	_
40-2	7920-7924	some	_
40-3	7925-7933	putative	_
40-4	7934-7947	commonalities	_
40-5	7948-7951	and	_
40-6	7952-7962	especially	_
40-7	7963-7975	phenotypical	_
40-8	7976-7987	differences	_
40-9	7987-7988	,	_
40-10	7989-7992	the	_
40-11	7993-7996	aim	_
40-12	7997-8000	was	_
40-13	8001-8003	to	_
40-14	8004-8011	examine	_
40-15	8012-8015	the	_
40-16	8016-8027	possibility	_
40-17	8028-8031	for	_
40-18	8032-8044	differential	_
40-19	8045-8059	classification	_
40-20	8060-8062	of	_
40-21	8063-8066	SCZ	_
40-22	8066-8067	,	_
40-23	8068-8070	PD	_
40-24	8071-8074	und	_
40-25	8075-8078	age	_
40-26	8078-8079	,	_
40-27	8080-8086	rather	_
40-28	8087-8091	than	_
40-29	8092-8094	to	_
40-30	8095-8104	primarily	_
40-31	8105-8110	study	_
40-32	8111-8114	the	_
40-33	8115-8123	specific	_
40-34	8124-8132	diseases	_
40-35	8133-8136	and	_
40-36	8137-8142	their	_
40-37	8143-8151	clinical	_
40-38	8152-8162	separation	_
40-39	8163-8167	from	_
40-40	8168-8172	each	_
40-41	8173-8178	other	_
40-42	8179-8181	or	_
40-43	8182-8187	aging	_
40-44	8188-8191	per	_
40-45	8192-8194	se	_
40-46	8194-8195	.	_

#Text=In our investigation, these three groups thereby serve as examples to evaluate this approach.
41-1	8196-8198	In	_
41-2	8199-8202	our	_
41-3	8203-8216	investigation	_
41-4	8216-8217	,	_
41-5	8218-8223	these	_
41-6	8224-8229	three	_
41-7	8230-8236	groups	_
41-8	8237-8244	thereby	_
41-9	8245-8250	serve	_
41-10	8251-8253	as	_
41-11	8254-8262	examples	_
41-12	8263-8265	to	_
41-13	8266-8274	evaluate	_
41-14	8275-8279	this	_
41-15	8280-8288	approach	_
41-16	8288-8289	.	_

#Text=For example, we assume that connectivity in the reward network will be potent in differentiating SCZ patiens from matched HCs, as several studies have shown impairments related to reward learning in SCZ, and the neurobiology of this network has been linked to psychosis.
42-1	8290-8293	For	_
42-2	8294-8301	example	_
42-3	8301-8302	,	_
42-4	8303-8305	we	_
42-5	8306-8312	assume	_
42-6	8313-8317	that	_
42-7	8318-8330	connectivity	_
42-8	8331-8333	in	_
42-9	8334-8337	the	_
42-10	8338-8344	reward	_
42-11	8345-8352	network	_
42-12	8353-8357	will	_
42-13	8358-8360	be	_
42-14	8361-8367	potent	_
42-15	8368-8370	in	_
42-16	8371-8386	differentiating	_
42-17	8387-8390	SCZ	_
42-18	8391-8398	patiens	_
42-19	8399-8403	from	_
42-20	8404-8411	matched	_
42-21	8412-8415	HCs	_
42-22	8415-8416	,	_
42-23	8417-8419	as	_
42-24	8420-8427	several	_
42-25	8428-8435	studies	_
42-26	8436-8440	have	_
42-27	8441-8446	shown	_
42-28	8447-8458	impairments	_
42-29	8459-8466	related	_
42-30	8467-8469	to	_
42-31	8470-8476	reward	_
42-32	8477-8485	learning	_
42-33	8486-8488	in	_
42-34	8489-8492	SCZ	_
42-35	8492-8493	,	_
42-36	8494-8497	and	_
42-37	8498-8501	the	_
42-38	8502-8514	neurobiology	_
42-39	8515-8517	of	_
42-40	8518-8522	this	_
42-41	8523-8530	network	_
42-42	8531-8534	has	_
42-43	8535-8539	been	_
42-44	8540-8546	linked	_
42-45	8547-8549	to	_
42-46	8550-8559	psychosis	_
42-47	8559-8560	.	_

#Text=Likewise, we would expect a good classification accuracy for PD patients based on FC in the motor network, given that motor impairments represent the core feature of this disease, and motor circuits in the brains of PD patients are altered during motor tasks and at rest.
43-1	8561-8569	Likewise	_
43-2	8569-8570	,	_
43-3	8571-8573	we	_
43-4	8574-8579	would	_
43-5	8580-8586	expect	_
43-6	8587-8588	a	_
43-7	8589-8593	good	_
43-8	8594-8608	classification	_
43-9	8609-8617	accuracy	_
43-10	8618-8621	for	_
43-11	8622-8624	PD	_
43-12	8625-8633	patients	_
43-13	8634-8639	based	_
43-14	8640-8642	on	_
43-15	8643-8645	FC	_
43-16	8646-8648	in	_
43-17	8649-8652	the	_
43-18	8653-8658	motor	_
43-19	8659-8666	network	_
43-20	8666-8667	,	_
43-21	8668-8673	given	_
43-22	8674-8678	that	_
43-23	8679-8684	motor	_
43-24	8685-8696	impairments	_
43-25	8697-8706	represent	_
43-26	8707-8710	the	_
43-27	8711-8715	core	_
43-28	8716-8723	feature	_
43-29	8724-8726	of	_
43-30	8727-8731	this	_
43-31	8732-8739	disease	_
43-32	8739-8740	,	_
43-33	8741-8744	and	_
43-34	8745-8750	motor	_
43-35	8751-8759	circuits	_
43-36	8760-8762	in	_
43-37	8763-8766	the	_
43-38	8767-8773	brains	_
43-39	8774-8776	of	_
43-40	8777-8779	PD	_
43-41	8780-8788	patients	_
43-42	8789-8792	are	_
43-43	8793-8800	altered	_
43-44	8801-8807	during	_
43-45	8808-8813	motor	_
43-46	8814-8819	tasks	_
43-47	8820-8823	and	_
43-48	8824-8826	at	_
43-49	8827-8831	rest	_
43-50	8831-8832	.	_

#Text=Finally, NA is accompanied by cognitive decline in various domains, such as deterioration in working-memory function.
44-1	8833-8840	Finally	_
44-2	8840-8841	,	_
44-3	8842-8844	NA	_
44-4	8845-8847	is	_
44-5	8848-8859	accompanied	_
44-6	8860-8862	by	_
44-7	8863-8872	cognitive	_
44-8	8873-8880	decline	_
44-9	8881-8883	in	_
44-10	8884-8891	various	_
44-11	8892-8899	domains	_
44-12	8899-8900	,	_
44-13	8901-8905	such	_
44-14	8906-8908	as	_
44-15	8909-8922	deterioration	_
44-16	8923-8925	in	_
44-17	8926-8940	working-memory	_
44-18	8941-8949	function	_
44-19	8949-8950	.	_

#Text=For the latter, age-related neural changes have repeatedly been shown at task and rest.
45-1	8951-8954	For	_
45-2	8955-8958	the	_
45-3	8959-8965	latter	_
45-4	8965-8966	,	_
45-5	8967-8978	age-related	_
45-6	8979-8985	neural	_
45-7	8986-8993	changes	_
45-8	8994-8998	have	_
45-9	8999-9009	repeatedly	_
45-10	9010-9014	been	_
45-11	9015-9020	shown	_
45-12	9021-9023	at	_
45-13	9024-9028	task	_
45-14	9029-9032	and	_
45-15	9033-9037	rest	_
45-16	9037-9038	.	_

#Text=Accordingly, we assume that the working-memory network allows a clear distinction between old and young adults.
46-1	9039-9050	Accordingly	_
46-2	9050-9051	,	_
46-3	9052-9054	we	_
46-4	9055-9061	assume	_
46-5	9062-9066	that	_
46-6	9067-9070	the	_
46-7	9071-9085	working-memory	_
46-8	9086-9093	network	_
46-9	9094-9100	allows	_
46-10	9101-9102	a	_
46-11	9103-9108	clear	_
46-12	9109-9120	distinction	_
46-13	9121-9128	between	_
46-14	9129-9132	old	_
46-15	9133-9136	and	_
46-16	9137-9142	young	_
46-17	9143-9149	adults	_
46-18	9149-9150	.	_

#Text=In an explorative manner, we furthermore assessed a broad set of networks associated with different behavioural domains (cognitive, social-affective, motivational and motor-related) since all three conditions (PD, SCZ, and NA) show alterations in various functional domains on the behavioral and neural level.
47-1	9151-9153	In	_
47-2	9154-9156	an	_
47-3	9157-9168	explorative	_
47-4	9169-9175	manner	_
47-5	9175-9176	,	_
47-6	9177-9179	we	_
47-7	9180-9191	furthermore	_
47-8	9192-9200	assessed	_
47-9	9201-9202	a	_
47-10	9203-9208	broad	_
47-11	9209-9212	set	_
47-12	9213-9215	of	_
47-13	9216-9224	networks	_
47-14	9225-9235	associated	_
47-15	9236-9240	with	_
47-16	9241-9250	different	_
47-17	9251-9262	behavioural	_
47-18	9263-9270	domains	_
47-19	9271-9272	(	_
47-20	9272-9281	cognitive	_
47-21	9281-9282	,	_
47-22	9283-9299	social-affective	_
47-23	9299-9300	,	_
47-24	9301-9313	motivational	_
47-25	9314-9317	and	_
47-26	9318-9331	motor-related	_
47-27	9331-9332	)	_
47-28	9333-9338	since	_
47-29	9339-9342	all	_
47-30	9343-9348	three	_
47-31	9349-9359	conditions	_
47-32	9360-9361	(	_
47-33	9361-9363	PD	_
47-34	9363-9364	,	_
47-35	9365-9368	SCZ	_
47-36	9368-9369	,	_
47-37	9370-9373	and	_
47-38	9374-9376	NA	_
47-39	9376-9377	)	_
47-40	9378-9382	show	_
47-41	9383-9394	alterations	_
47-42	9395-9397	in	_
47-43	9398-9405	various	_
47-44	9406-9416	functional	_
47-45	9417-9424	domains	_
47-46	9425-9427	on	_
47-47	9428-9431	the	_
47-48	9432-9442	behavioral	_
47-49	9443-9446	and	_
47-50	9447-9453	neural	_
47-51	9454-9459	level	_
47-52	9459-9460	.	_

#Text=Importantly, in our approach, we reasoned that classification performance may be interpreted as an indication for the amount of information contained in a given network regarding a particular disease or age status, and thus of the degree of change observed in the integrity of particular networks under these conditions.
48-1	9461-9472	Importantly	_
48-2	9472-9473	,	_
48-3	9474-9476	in	_
48-4	9477-9480	our	_
48-5	9481-9489	approach	_
48-6	9489-9490	,	_
48-7	9491-9493	we	_
48-8	9494-9502	reasoned	_
48-9	9503-9507	that	_
48-10	9508-9522	classification	_
48-11	9523-9534	performance	_
48-12	9535-9538	may	_
48-13	9539-9541	be	_
48-14	9542-9553	interpreted	_
48-15	9554-9556	as	_
48-16	9557-9559	an	_
48-17	9560-9570	indication	_
48-18	9571-9574	for	_
48-19	9575-9578	the	_
48-20	9579-9585	amount	_
48-21	9586-9588	of	_
48-22	9589-9600	information	_
48-23	9601-9610	contained	_
48-24	9611-9613	in	_
48-25	9614-9615	a	_
48-26	9616-9621	given	_
48-27	9622-9629	network	_
48-28	9630-9639	regarding	_
48-29	9640-9641	a	_
48-30	9642-9652	particular	_
48-31	9653-9660	disease	_
48-32	9661-9663	or	_
48-33	9664-9667	age	_
48-34	9668-9674	status	_
48-35	9674-9675	,	_
48-36	9676-9679	and	_
48-37	9680-9684	thus	_
48-38	9685-9687	of	_
48-39	9688-9691	the	_
48-40	9692-9698	degree	_
48-41	9699-9701	of	_
48-42	9702-9708	change	_
48-43	9709-9717	observed	_
48-44	9718-9720	in	_
48-45	9721-9724	the	_
48-46	9725-9734	integrity	_
48-47	9735-9737	of	_
48-48	9738-9748	particular	_
48-49	9749-9757	networks	_
48-50	9758-9763	under	_
48-51	9764-9769	these	_
48-52	9770-9780	conditions	_
48-53	9780-9781	.	_

#Text=We assume that classification performance will be best for connectivity in those networks that subserve mental functions known to be affected in SCZ and PD.
49-1	9782-9784	We	_
49-2	9785-9791	assume	_
49-3	9792-9796	that	_
49-4	9797-9811	classification	_
49-5	9812-9823	performance	_
49-6	9824-9828	will	_
49-7	9829-9831	be	_
49-8	9832-9836	best	_
49-9	9837-9840	for	_
49-10	9841-9853	connectivity	_
49-11	9854-9856	in	_
49-12	9857-9862	those	_
49-13	9863-9871	networks	_
49-14	9872-9876	that	_
49-15	9877-9885	subserve	_
49-16	9886-9892	mental	_
49-17	9893-9902	functions	_
49-18	9903-9908	known	_
49-19	9909-9911	to	_
49-20	9912-9914	be	_
49-21	9915-9923	affected	_
49-22	9924-9926	in	_
49-23	9927-9930	SCZ	_
49-24	9931-9934	and	_
49-25	9935-9937	PD	_
49-26	9937-9938	.	_

#Text=SCZ is characterized by prominent social-affective/motivational alterations, whereas in PD motor impairments are most affected.
50-1	9939-9942	SCZ	_
50-2	9943-9945	is	_
50-3	9946-9959	characterized	_
50-4	9960-9962	by	_
50-5	9963-9972	prominent	_
50-6	9973-9989	social-affective	_
50-7	9989-9990	/	_
50-8	9990-10002	motivational	_
50-9	10003-10014	alterations	_
50-10	10014-10015	,	_
50-11	10016-10023	whereas	_
50-12	10024-10026	in	_
50-13	10027-10029	PD	_
50-14	10030-10035	motor	_
50-15	10036-10047	impairments	_
50-16	10048-10051	are	_
50-17	10052-10056	most	_
50-18	10057-10065	affected	_
50-19	10065-10066	.	_

#Text=We, therefore, hypothesized that social-affective/motivational and motor-related networks provide a superior classification of SCZ and PD patients, respectively.
51-1	10067-10069	We	_
51-2	10069-10070	,	_
51-3	10071-10080	therefore	_
51-4	10080-10081	,	_
51-5	10082-10094	hypothesized	_
51-6	10095-10099	that	_
51-7	10100-10116	social-affective	_
51-8	10116-10117	/	_
51-9	10117-10129	motivational	_
51-10	10130-10133	and	_
51-11	10134-10147	motor-related	_
51-12	10148-10156	networks	_
51-13	10157-10164	provide	_
51-14	10165-10166	a	_
51-15	10167-10175	superior	_
51-16	10176-10190	classification	_
51-17	10191-10193	of	_
51-18	10194-10197	SCZ	_
51-19	10198-10201	and	_
51-20	10202-10204	PD	_
51-21	10205-10213	patients	_
51-22	10213-10214	,	_
51-23	10215-10227	respectively	_
51-24	10227-10228	.	_

#Text=As both diseases are accompanied by cognitive impairments as well, we assumed that cognitive networks may also be predictive to some degree.
52-1	10229-10231	As	_
52-2	10232-10236	both	_
52-3	10237-10245	diseases	_
52-4	10246-10249	are	_
52-5	10250-10261	accompanied	_
52-6	10262-10264	by	_
52-7	10265-10274	cognitive	_
52-8	10275-10286	impairments	_
52-9	10287-10289	as	_
52-10	10290-10294	well	_
52-11	10294-10295	,	_
52-12	10296-10298	we	_
52-13	10299-10306	assumed	_
52-14	10307-10311	that	_
52-15	10312-10321	cognitive	_
52-16	10322-10330	networks	_
52-17	10331-10334	may	_
52-18	10335-10339	also	_
52-19	10340-10342	be	_
52-20	10343-10353	predictive	_
52-21	10354-10356	to	_
52-22	10357-10361	some	_
52-23	10362-10368	degree	_
52-24	10368-10369	.	_

#Text=As NA is associated with a broad spectrum of decline affecting various functional systems (albeit to a varying degree), we expected that most networks allowed for an accurate discrimination of old from young adults.
#Text=2.
53-1	10370-10372	As	_
53-2	10373-10375	NA	_
53-3	10376-10378	is	_
53-4	10379-10389	associated	_
53-5	10390-10394	with	_
53-6	10395-10396	a	_
53-7	10397-10402	broad	_
53-8	10403-10411	spectrum	_
53-9	10412-10414	of	_
53-10	10415-10422	decline	_
53-11	10423-10432	affecting	_
53-12	10433-10440	various	_
53-13	10441-10451	functional	_
53-14	10452-10459	systems	_
53-15	10460-10461	(	_
53-16	10461-10467	albeit	_
53-17	10468-10470	to	_
53-18	10471-10472	a	_
53-19	10473-10480	varying	_
53-20	10481-10487	degree	_
53-21	10487-10488	)	_
53-22	10488-10489	,	_
53-23	10490-10492	we	_
53-24	10493-10501	expected	_
53-25	10502-10506	that	_
53-26	10507-10511	most	_
53-27	10512-10520	networks	_
53-28	10521-10528	allowed	_
53-29	10529-10532	for	_
53-30	10533-10535	an	_
53-31	10536-10544	accurate	_
53-32	10545-10559	discrimination	_
53-33	10560-10562	of	_
53-34	10563-10566	old	_
53-35	10567-10571	from	_
53-36	10572-10577	young	_
53-37	10578-10584	adults	_
53-38	10584-10585	.	_
53-39	10586-10587	2	_
53-40	10587-10588	.	_

#Text=MATERIALS AND METHODS
#Text=2.1 Samples
#Text=Schizophrenia
#Text=Resting-state (RS) functional magnetic resonance imaging (fMRI) data and phenotypical information of 86 SCZ patients and 84 HCs obtained from the COBRE sample (http://fcon_1000.projects.nitrc.org/indi/retro/cobre.html) and the University Hospital of Göttingen, Germany, were included in the analysis.
54-1	10589-10598	MATERIALS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
54-2	10599-10602	AND	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
54-3	10603-10610	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
54-4	10611-10614	2.1	_
54-5	10615-10622	Samples	_
54-6	10623-10636	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]
54-7	10637-10650	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
54-8	10651-10652	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
54-9	10652-10654	RS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
54-10	10654-10655	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
54-11	10656-10666	functional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
54-12	10667-10675	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
54-13	10676-10685	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
54-14	10686-10693	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
54-15	10694-10695	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
54-16	10695-10699	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
54-17	10699-10700	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-18	10701-10705	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-19	10706-10709	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-20	10710-10722	phenotypical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-21	10723-10734	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-22	10735-10737	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-23	10738-10740	86	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-24	10741-10744	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]
54-25	10745-10753	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-26	10754-10757	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-27	10758-10760	84	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-28	10761-10764	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
54-29	10765-10773	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-30	10774-10778	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-31	10779-10782	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-32	10783-10788	COBRE	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-33	10789-10795	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-34	10796-10797	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-35	10797-10801	http	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-36	10801-10802	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-37	10802-10803	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-38	10803-10804	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-39	10804-10808	fcon	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-40	10808-10809	_	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-41	10809-10813	1000	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-42	10813-10814	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-43	10814-10832	projects.nitrc.org	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-44	10832-10833	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-45	10833-10837	indi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-46	10837-10838	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-47	10838-10843	retro	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-48	10843-10844	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-49	10844-10854	cobre.html	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-50	10854-10855	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-51	10856-10859	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-52	10860-10863	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-53	10864-10874	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-54	10875-10883	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-55	10884-10886	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-56	10887-10896	Göttingen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-57	10896-10897	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-58	10898-10905	Germany	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-59	10905-10906	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-60	10907-10911	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-61	10912-10920	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-62	10921-10923	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-63	10924-10927	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-64	10928-10936	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
54-65	10936-10937	.	_

#Text=SCZ diagnosis was assigned as assessed by the DSM-IV-TR based on the structured clinical interview (SCID-P) and the International Classification of Diseases (ICD-10), respectively.
55-1	10938-10941	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[12]
55-2	10942-10951	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-3	10952-10955	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-4	10956-10964	assigned	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-5	10965-10967	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-6	10968-10976	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-7	10977-10979	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-8	10980-10983	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-9	10984-10993	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[13]
55-10	10994-10999	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[13]
55-11	11000-11002	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[13]
55-12	11003-11006	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[13]
55-13	11007-11017	structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[13]
55-14	11018-11026	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[13]
55-15	11027-11036	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[13]
55-16	11037-11038	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[13]
55-17	11038-11044	SCID-P	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[13]
55-18	11044-11045	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[13]
55-19	11046-11049	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-20	11050-11053	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-21	11054-11067	International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-22	11068-11082	Classification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-23	11083-11085	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-24	11086-11094	Diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-25	11095-11096	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-26	11096-11099	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-27	11099-11100	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-28	11100-11102	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-29	11102-11103	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-30	11103-11104	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-31	11105-11117	respectively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
55-32	11117-11118	.	_

#Text=SCZ symptom severity was assed using the Positive and Negative Symptom Scale (PANSS) evaluating the severity of positive and negative symptoms as well as the general psychopathology.
56-1	11119-11122	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
56-2	11123-11130	symptom	_
56-3	11131-11139	severity	_
56-4	11140-11143	was	_
56-5	11144-11149	assed	_
56-6	11150-11155	using	_
56-7	11156-11159	the	_
56-8	11160-11168	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[14]
56-9	11169-11172	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[14]
56-10	11173-11181	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[14]
56-11	11182-11189	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[14]
56-12	11190-11195	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[14]
56-13	11196-11197	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[14]
56-14	11197-11202	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[14]
56-15	11202-11203	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[14]
56-16	11204-11214	evaluating	_
56-17	11215-11218	the	_
56-18	11219-11227	severity	_
56-19	11228-11230	of	_
56-20	11231-11239	positive	_
56-21	11240-11243	and	_
56-22	11244-11252	negative	_
56-23	11253-11261	symptoms	_
56-24	11262-11264	as	_
56-25	11265-11269	well	_
56-26	11270-11272	as	_
56-27	11273-11276	the	_
56-28	11277-11284	general	_
56-29	11285-11300	psychopathology	_
56-30	11300-11301	.	_

#Text=Patients received their regular medication therapy with considerable variability in the exact compounds used and a high prevalence of combination drug therapy (medicated patients but exact medication and dose unknown for Olanzapine equivalent dose: COBRE: 50,9%; Göttingen: 25,8%; medication status unknown: COBRE: 1 SCZ patient; Göttingen: 2 SCZ patients).
57-1	11302-11310	Patients	_
57-2	11311-11319	received	_
57-3	11320-11325	their	_
57-4	11326-11333	regular	_
57-5	11334-11344	medication	_
57-6	11345-11352	therapy	_
57-7	11353-11357	with	_
57-8	11358-11370	considerable	_
57-9	11371-11382	variability	_
57-10	11383-11385	in	_
57-11	11386-11389	the	_
57-12	11390-11395	exact	_
57-13	11396-11405	compounds	_
57-14	11406-11410	used	_
57-15	11411-11414	and	_
57-16	11415-11416	a	_
57-17	11417-11421	high	_
57-18	11422-11432	prevalence	_
57-19	11433-11435	of	_
57-20	11436-11447	combination	_
57-21	11448-11452	drug	_
57-22	11453-11460	therapy	_
57-23	11461-11462	(	_
57-24	11462-11471	medicated	_
57-25	11472-11480	patients	_
57-26	11481-11484	but	_
57-27	11485-11490	exact	_
57-28	11491-11501	medication	_
57-29	11502-11505	and	_
57-30	11506-11510	dose	_
57-31	11511-11518	unknown	_
57-32	11519-11522	for	_
57-33	11523-11533	Olanzapine	_
57-34	11534-11544	equivalent	_
57-35	11545-11549	dose	_
57-36	11549-11550	:	_
57-37	11551-11556	COBRE	_
57-38	11556-11557	:	_
57-39	11558-11563	50,9%	_
57-40	11563-11564	;	_
57-41	11565-11574	Göttingen	_
57-42	11574-11575	:	_
57-43	11576-11581	25,8%	_
57-44	11581-11582	;	_
57-45	11583-11593	medication	_
57-46	11594-11600	status	_
57-47	11601-11608	unknown	_
57-48	11608-11609	:	_
57-49	11610-11615	COBRE	_
57-50	11615-11616	:	_
57-51	11617-11618	1	_
57-52	11619-11622	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
57-53	11623-11630	patient	_
57-54	11630-11631	;	_
57-55	11632-11641	Göttingen	_
57-56	11641-11642	:	_
57-57	11643-11644	2	_
57-58	11645-11648	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
57-59	11649-11657	patients	_
57-60	11657-11658	)	_
57-61	11658-11659	.	_

#Text=Parkinson’s disease
#Text=RS fMRI data of 80 PD patients and 84 HCs obtained from the RWTH Aachen University Hospital and the University Hospital Düsseldorf, Germany, were included in the analysis.
58-1	11660-11669	Parkinson	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[16]
58-2	11669-11670	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[16]
58-3	11670-11671	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[16]
58-4	11672-11679	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[16]
58-5	11680-11682	RS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[17]
58-6	11683-11687	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[17]
58-7	11688-11692	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-8	11693-11695	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-9	11696-11698	80	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-10	11699-11701	PD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[18]
58-11	11702-11710	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-12	11711-11714	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-13	11715-11717	84	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-14	11718-11721	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[19]
58-15	11722-11730	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-16	11731-11735	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-17	11736-11739	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-18	11740-11744	RWTH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-19	11745-11751	Aachen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-20	11752-11762	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-21	11763-11771	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-22	11772-11775	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-23	11776-11779	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-24	11780-11790	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-25	11791-11799	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-26	11800-11810	Düsseldorf	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-27	11810-11811	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-28	11812-11819	Germany	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-29	11819-11820	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-30	11821-11825	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-31	11826-11834	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-32	11835-11837	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-33	11838-11841	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-34	11842-11850	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
58-35	11850-11851	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=Diagnosis of PD was assigned by consultant neurologists with longstanding expertise in movement disorders based on clinical examination and review of the medical history.
59-1	11852-11861	Diagnosis	_
59-2	11862-11864	of	_
59-3	11865-11867	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
59-4	11868-11871	was	_
59-5	11872-11880	assigned	_
59-6	11881-11883	by	_
59-7	11884-11894	consultant	_
59-8	11895-11907	neurologists	_
59-9	11908-11912	with	_
59-10	11913-11925	longstanding	_
59-11	11926-11935	expertise	_
59-12	11936-11938	in	_
59-13	11939-11947	movement	_
59-14	11948-11957	disorders	_
59-15	11958-11963	based	_
59-16	11964-11966	on	_
59-17	11967-11975	clinical	_
59-18	11976-11987	examination	_
59-19	11988-11991	and	_
59-20	11992-11998	review	_
59-21	11999-12001	of	_
59-22	12002-12005	the	_
59-23	12006-12013	medical	_
59-24	12014-12021	history	_
59-25	12021-12022	.	_

#Text=Included PD patients fulfilled the standard UK Brain Bank criteria for PD and had on average a mild cognitive impairment as confirmed by the Montreal Cognitive Assessment (MoCA) but no major depression symptoms.
60-1	12023-12031	Included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-2	12032-12034	PD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[21]
60-3	12035-12043	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-4	12044-12053	fulfilled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-5	12054-12057	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-6	12058-12066	standard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-7	12067-12069	UK	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-8	12070-12075	Brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-9	12076-12080	Bank	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-10	12081-12089	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-11	12090-12093	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-12	12094-12096	PD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism[22]
60-13	12097-12100	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-14	12101-12104	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-15	12105-12107	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-16	12108-12115	average	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-17	12116-12117	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-18	12118-12122	mild	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-19	12123-12132	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-20	12133-12143	impairment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-21	12144-12146	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-22	12147-12156	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-23	12157-12159	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-24	12160-12163	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-25	12164-12172	Montreal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[23]
60-26	12173-12182	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[23]
60-27	12183-12193	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[23]
60-28	12194-12195	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[23]
60-29	12195-12199	MoCA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[23]
60-30	12199-12200	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment[23]
60-31	12201-12204	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-32	12205-12207	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-33	12208-12213	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-34	12214-12224	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-35	12225-12233	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
60-36	12233-12234	.	_

#Text=To assess PD symptom severity and evaluate motor impairments the Unified Parkinson’s disease Rating Scale Part III (UPDRS) and Hoehn and Yahr Scale (H & Y Scale) were applied.
61-1	12235-12237	To	_
61-2	12238-12244	assess	_
61-3	12245-12247	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
61-4	12248-12255	symptom	_
61-5	12256-12264	severity	_
61-6	12265-12268	and	_
61-7	12269-12277	evaluate	_
61-8	12278-12283	motor	_
61-9	12284-12295	impairments	_
61-10	12296-12299	the	_
61-11	12300-12307	Unified	_
61-12	12308-12317	Parkinson	_
61-13	12317-12318	’	_
61-14	12318-12319	s	_
61-15	12320-12327	disease	_
61-16	12328-12334	Rating	_
61-17	12335-12340	Scale	_
61-18	12341-12345	Part	_
61-19	12346-12349	III	_
61-20	12350-12351	(	_
61-21	12351-12356	UPDRS	_
61-22	12356-12357	)	_
61-23	12358-12361	and	_
61-24	12362-12367	Hoehn	_
61-25	12368-12371	and	_
61-26	12372-12376	Yahr	_
61-27	12377-12382	Scale	_
61-28	12383-12384	(	_
61-29	12384-12385	H	_
61-30	12386-12387	&	_
61-31	12388-12389	Y	_
61-32	12390-12395	Scale	_
61-33	12395-12396	)	_
61-34	12397-12401	were	_
61-35	12402-12409	applied	_
61-36	12409-12410	.	_

#Text=All patients were medicated with their regular individual PD-related treatment (medication and dose unknown for Levodopa equivalent daily dose: RWTH Aachen: 28,1%; HHU Düsseldorf: 12,5%).
62-1	12411-12414	All	_
62-2	12415-12423	patients	_
62-3	12424-12428	were	_
62-4	12429-12438	medicated	_
62-5	12439-12443	with	_
62-6	12444-12449	their	_
62-7	12450-12457	regular	_
62-8	12458-12468	individual	_
62-9	12469-12479	PD-related	_
62-10	12480-12489	treatment	_
62-11	12490-12491	(	_
62-12	12491-12501	medication	_
62-13	12502-12505	and	_
62-14	12506-12510	dose	_
62-15	12511-12518	unknown	_
62-16	12519-12522	for	_
62-17	12523-12531	Levodopa	_
62-18	12532-12542	equivalent	_
62-19	12543-12548	daily	_
62-20	12549-12553	dose	_
62-21	12553-12554	:	_
62-22	12555-12559	RWTH	_
62-23	12560-12566	Aachen	_
62-24	12566-12567	:	_
62-25	12568-12573	28,1%	_
62-26	12573-12574	;	_
62-27	12575-12578	HHU	_
62-28	12579-12589	Düsseldorf	_
62-29	12589-12590	:	_
62-30	12591-12596	12,5%	_
62-31	12596-12597	)	_
62-32	12597-12598	.	_

#Text=Healthy controls (HC)
#Text=RS fMRI data of HC (HCSCZ and HCPD) were obtained from the four different sites as respective clinical subjects (SCZ and PD), and were without any record of neurological or psychiatric disorders as confirmed via structured clinical screening (SCID).
63-1	12599-12606	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]
63-2	12607-12615	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]
63-3	12616-12617	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]
63-4	12617-12619	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]
63-5	12619-12620	)	_
63-6	12621-12623	RS	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[25]
63-7	12624-12628	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[25]
63-8	12629-12633	data	_
63-9	12634-12636	of	_
63-10	12637-12639	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
63-11	12640-12641	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
63-12	12641-12646	HCSCZ	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
63-13	12647-12650	and	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
63-14	12651-12655	HCPD	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
63-15	12655-12656	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
63-16	12657-12661	were	_
63-17	12662-12670	obtained	_
63-18	12671-12675	from	_
63-19	12676-12679	the	_
63-20	12680-12684	four	_
63-21	12685-12694	different	_
63-22	12695-12700	sites	_
63-23	12701-12703	as	_
63-24	12704-12714	respective	_
63-25	12715-12723	clinical	_
63-26	12724-12732	subjects	_
63-27	12733-12734	(	_
63-28	12734-12737	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
63-29	12738-12741	and	_
63-30	12742-12744	PD	*
63-31	12744-12745	)	_
63-32	12745-12746	,	_
63-33	12747-12750	and	_
63-34	12751-12755	were	_
63-35	12756-12763	without	_
63-36	12764-12767	any	_
63-37	12768-12774	record	_
63-38	12775-12777	of	_
63-39	12778-12790	neurological	_
63-40	12791-12793	or	_
63-41	12794-12805	psychiatric	_
63-42	12806-12815	disorders	_
63-43	12816-12818	as	_
63-44	12819-12828	confirmed	_
63-45	12829-12832	via	_
63-46	12833-12843	structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
63-47	12844-12852	clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
63-48	12853-12862	screening	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
63-49	12863-12864	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
63-50	12864-12868	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
63-51	12868-12869	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[27]
63-52	12869-12870	.	_

#Text=Normal Aging
#Text=RS fMRI data of 95 old (age range: 55 – 70 years) and 93 young (age range: 20 – 35 years) participants with an age range of 15 years in each group were obtained from the population-based 1000BRAINS study and another separate study at the Research Centre Jülich, Germany.
64-1	12871-12877	Normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-2	12878-12883	Aging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-3	12884-12886	RS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[29]
64-4	12887-12891	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[29]
64-5	12892-12896	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-6	12897-12899	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-7	12900-12902	95	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-8	12903-12906	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-9	12907-12908	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-10	12908-12911	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-11	12912-12917	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-12	12917-12918	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-13	12919-12921	55	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-14	12922-12923	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-15	12924-12926	70	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-16	12927-12932	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-17	12932-12933	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-18	12934-12937	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-19	12938-12940	93	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-20	12941-12946	young	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-21	12947-12948	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-22	12948-12951	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-23	12952-12957	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-24	12957-12958	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-25	12959-12961	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-26	12962-12963	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-27	12964-12966	35	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-28	12967-12972	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-29	12972-12973	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-30	12974-12986	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-31	12987-12991	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-32	12992-12994	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-33	12995-12998	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-34	12999-13004	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-35	13005-13007	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-36	13008-13010	15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-37	13011-13016	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-38	13017-13019	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-39	13020-13024	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-40	13025-13030	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-41	13031-13035	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-42	13036-13044	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-43	13045-13049	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-44	13050-13053	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-45	13054-13070	population-based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-46	13071-13081	1000BRAINS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-47	13082-13087	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-48	13088-13091	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-49	13092-13099	another	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-50	13100-13108	separate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-51	13109-13114	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-52	13115-13117	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-53	13118-13121	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-54	13122-13130	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-55	13131-13137	Centre	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-56	13138-13144	Jülich	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-57	13144-13145	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-58	13146-13153	Germany	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]
64-59	13153-13154	.	_

#Text=This relative small age-range aims to enhance the subsample homogeneity.
65-1	13155-13159	This	_
65-2	13160-13168	relative	_
65-3	13169-13174	small	_
65-4	13175-13184	age-range	_
65-5	13185-13189	aims	_
65-6	13190-13192	to	_
65-7	13193-13200	enhance	_
65-8	13201-13204	the	_
65-9	13205-13214	subsample	_
65-10	13215-13226	homogeneity	_
65-11	13226-13227	.	_

#Text=“Normal aging” in old participants refers to the absence of neurodegenerative diseases.
66-1	13228-13229	“	_
66-2	13229-13235	Normal	_
66-3	13236-13241	aging	_
66-4	13241-13242	”	_
66-5	13243-13245	in	_
66-6	13246-13249	old	_
66-7	13250-13262	participants	_
66-8	13263-13269	refers	_
66-9	13270-13272	to	_
66-10	13273-13276	the	_
66-11	13277-13284	absence	_
66-12	13285-13287	of	_
66-13	13288-13305	neurodegenerative	_
66-14	13306-13314	diseases	_
66-15	13314-13315	.	_

#Text=Older adults showed cognitive performance adequate for their age (DemTect > 13) as assessed by the Mild Cognitive Impairment and Early Dementia Detection (DemTect) assessment and all participants did not exhibit clinically relevant symptoms for depression (BDI-II < 13) as evaluated via the Beck Depression Inventory-II.
67-1	13316-13321	Older	_
67-2	13322-13328	adults	_
67-3	13329-13335	showed	_
67-4	13336-13345	cognitive	_
67-5	13346-13357	performance	_
67-6	13358-13366	adequate	_
67-7	13367-13370	for	_
67-8	13371-13376	their	_
67-9	13377-13380	age	_
67-10	13381-13382	(	_
67-11	13382-13389	DemTect	_
67-12	13390-13391	>	_
67-13	13392-13394	13	_
67-14	13394-13395	)	_
67-15	13396-13398	as	_
67-16	13399-13407	assessed	_
67-17	13408-13410	by	_
67-18	13411-13414	the	_
67-19	13415-13419	Mild	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]
67-20	13420-13429	Cognitive	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]
67-21	13430-13440	Impairment	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]
67-22	13441-13444	and	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]
67-23	13445-13450	Early	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]
67-24	13451-13459	Dementia	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]
67-25	13460-13469	Detection	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]
67-26	13470-13471	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]
67-27	13471-13478	DemTect	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]
67-28	13478-13479	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[30]
67-29	13480-13490	assessment	_
67-30	13491-13494	and	_
67-31	13495-13498	all	_
67-32	13499-13511	participants	_
67-33	13512-13515	did	_
67-34	13516-13519	not	_
67-35	13520-13527	exhibit	_
67-36	13528-13538	clinically	_
67-37	13539-13547	relevant	_
67-38	13548-13556	symptoms	_
67-39	13557-13560	for	_
67-40	13561-13571	depression	_
67-41	13572-13573	(	_
67-42	13573-13579	BDI-II	_
67-43	13580-13581	<	_
67-44	13582-13584	13	_
67-45	13584-13585	)	_
67-46	13586-13588	as	_
67-47	13589-13598	evaluated	_
67-48	13599-13602	via	_
67-49	13603-13606	the	_
67-50	13607-13611	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[31]
67-51	13612-13622	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[31]
67-52	13623-13635	Inventory-II	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[31]
67-53	13635-13636	.	_

#Text=Importantly, target and control groups (i.e., patients vs. healthy controls, old vs. young adults) of all three samples (PD, SCZ, NA) represent subsamples from larger samples that were post-hoc matched for gender, within-scanner movement and (only for the clinical samples) age (cf.
68-1	13637-13648	Importantly	_
68-2	13648-13649	,	_
68-3	13650-13656	target	_
68-4	13657-13660	and	_
68-5	13661-13668	control	_
68-6	13669-13675	groups	_
68-7	13676-13677	(	_
68-8	13677-13680	i.e	_
68-9	13680-13681	.	_
68-10	13681-13682	,	_
68-11	13683-13691	patients	_
68-12	13692-13694	vs	_
68-13	13694-13695	.	_
68-14	13696-13703	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[32]
68-15	13704-13712	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[32]
68-16	13712-13713	,	_
68-17	13714-13717	old	_
68-18	13718-13720	vs	_
68-19	13720-13721	.	_
68-20	13722-13727	young	_
68-21	13728-13734	adults	_
68-22	13734-13735	)	_
68-23	13736-13738	of	_
68-24	13739-13742	all	_
68-25	13743-13748	three	_
68-26	13749-13756	samples	_
68-27	13757-13758	(	_
68-28	13758-13760	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
68-29	13760-13761	,	_
68-30	13762-13765	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
68-31	13765-13766	,	_
68-32	13767-13769	NA	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
68-33	13769-13770	)	_
68-34	13771-13780	represent	_
68-35	13781-13791	subsamples	_
68-36	13792-13796	from	_
68-37	13797-13803	larger	_
68-38	13804-13811	samples	_
68-39	13812-13816	that	_
68-40	13817-13821	were	_
68-41	13822-13830	post-hoc	_
68-42	13831-13838	matched	_
68-43	13839-13842	for	_
68-44	13843-13849	gender	_
68-45	13849-13850	,	_
68-46	13851-13865	within-scanner	_
68-47	13866-13874	movement	_
68-48	13875-13878	and	_
68-49	13879-13880	(	_
68-50	13880-13884	only	_
68-51	13885-13888	for	_
68-52	13889-13892	the	_
68-53	13893-13901	clinical	_
68-54	13902-13909	samples	_
68-55	13909-13910	)	_
68-56	13911-13914	age	_
68-57	13915-13916	(	_
68-58	13916-13918	cf	_
68-59	13918-13919	.	_

#Text=Table I for sample and group matching characteristics).
69-1	13920-13925	Table	_
69-2	13926-13927	I	_
69-3	13928-13931	for	_
69-4	13932-13938	sample	_
69-5	13939-13942	and	_
69-6	13943-13948	group	_
69-7	13949-13957	matching	_
69-8	13958-13973	characteristics	_
69-9	13973-13974	)	_
69-10	13974-13975	.	_

#Text=Written informed consent from all subjects and approval by the local ethics committees was obtained from all sites.
70-1	13976-13983	Written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-2	13984-13992	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-3	13993-14000	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-4	14001-14005	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-5	14006-14009	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-6	14010-14018	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-7	14019-14022	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-8	14023-14031	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-9	14032-14034	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-10	14035-14038	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-11	14039-14044	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-12	14045-14051	ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-13	14052-14062	committees	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-14	14063-14066	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-15	14067-14075	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-16	14076-14080	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-17	14081-14084	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-18	14085-14090	sites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
70-19	14090-14091	.	_

#Text=Joint reanalysis of the anonymized data was approved by the ethics committee of the HHU Düsseldorf.
#Text=2.2 Resting-state fMRI data acquisition, preprocessing, and analysis
#Text=During image acquisition (see Table SI for fMRI parameters), participants were instructed to lie still, let their mind wander and not fall asleep (confirmed at debriefing).
71-1	14092-14097	Joint	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-2	14098-14108	reanalysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-3	14109-14111	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-4	14112-14115	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-5	14116-14126	anonymized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-6	14127-14131	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-7	14132-14135	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-8	14136-14144	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-9	14145-14147	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-10	14148-14151	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-11	14152-14158	ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-12	14159-14168	committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-13	14169-14171	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-14	14172-14175	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-15	14176-14179	HHU	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-16	14180-14190	Düsseldorf	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
71-17	14190-14191	.	_
71-18	14192-14195	2.2	_
71-19	14196-14209	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]
71-20	14210-14214	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[35]
71-21	14215-14219	data	_
71-22	14220-14231	acquisition	_
71-23	14231-14232	,	_
71-24	14233-14246	preprocessing	_
71-25	14246-14247	,	_
71-26	14248-14251	and	_
71-27	14252-14260	analysis	_
71-28	14261-14267	During	_
71-29	14268-14273	image	_
71-30	14274-14285	acquisition	_
71-31	14286-14287	(	_
71-32	14287-14290	see	_
71-33	14291-14296	Table	_
71-34	14297-14299	SI	_
71-35	14300-14303	for	_
71-36	14304-14308	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
71-37	14309-14319	parameters	_
71-38	14319-14320	)	_
71-39	14320-14321	,	_
71-40	14322-14334	participants	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-41	14335-14339	were	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-42	14340-14350	instructed	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-43	14351-14353	to	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-44	14354-14357	lie	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-45	14358-14363	still	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-46	14363-14364	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-47	14365-14368	let	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-48	14369-14374	their	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-49	14375-14379	mind	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-50	14380-14386	wander	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-51	14387-14390	and	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-52	14391-14394	not	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-53	14395-14399	fall	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-54	14400-14406	asleep	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImagingProtocol[36]
71-55	14407-14408	(	_
71-56	14408-14417	confirmed	_
71-57	14418-14420	at	_
71-58	14421-14431	debriefing	_
71-59	14431-14432	)	_
71-60	14432-14433	.	_

#Text=SPM8 (www.fil.ion.ucl.ac.uk/spm) was used for image realignment, spatial normalization to the MNI-152 template using the unified segmentation approach, and smoothing (5-mm full width at half maximum Gaussian).
72-1	14434-14438	SPM8	_
72-2	14439-14440	(	_
72-3	14440-14461	www.fil.ion.ucl.ac.uk	_
72-4	14461-14462	/	_
72-5	14462-14465	spm	_
72-6	14465-14466	)	_
72-7	14467-14470	was	_
72-8	14471-14475	used	_
72-9	14476-14479	for	_
72-10	14480-14485	image	_
72-11	14486-14497	realignment	_
72-12	14497-14498	,	_
72-13	14499-14506	spatial	_
72-14	14507-14520	normalization	_
72-15	14521-14523	to	_
72-16	14524-14527	the	_
72-17	14528-14531	MNI	_
72-18	14531-14532	-	_
72-19	14532-14535	152	_
72-20	14536-14544	template	_
72-21	14545-14550	using	_
72-22	14551-14554	the	_
72-23	14555-14562	unified	_
72-24	14563-14575	segmentation	_
72-25	14576-14584	approach	_
72-26	14584-14585	,	_
72-27	14586-14589	and	_
72-28	14590-14599	smoothing	_
72-29	14600-14601	(	_
72-30	14601-14602	5	_
72-31	14602-14603	-	_
72-32	14603-14605	mm	_
72-33	14606-14610	full	_
72-34	14611-14616	width	_
72-35	14617-14619	at	_
72-36	14620-14624	half	_
72-37	14625-14632	maximum	_
72-38	14633-14641	Gaussian	_
72-39	14641-14642	)	_
72-40	14642-14643	.	_

#Text=We investigated 12 functional networks, robustly defined by previous quantitative meta-analyses, to reflect neural correlates of a broad set of cognitive, social-affective/motivational and motor functions (see Table II for an overview and Table SII for detailed network coordinates and corresponding brain regions).
73-1	14644-14646	We	_
73-2	14647-14659	investigated	_
73-3	14660-14662	12	_
73-4	14663-14673	functional	_
73-5	14674-14682	networks	_
73-6	14682-14683	,	_
73-7	14684-14692	robustly	_
73-8	14693-14700	defined	_
73-9	14701-14703	by	_
73-10	14704-14712	previous	_
73-11	14713-14725	quantitative	_
73-12	14726-14739	meta-analyses	_
73-13	14739-14740	,	_
73-14	14741-14743	to	_
73-15	14744-14751	reflect	_
73-16	14752-14758	neural	_
73-17	14759-14769	correlates	_
73-18	14770-14772	of	_
73-19	14773-14774	a	_
73-20	14775-14780	broad	_
73-21	14781-14784	set	_
73-22	14785-14787	of	_
73-23	14788-14797	cognitive	_
73-24	14797-14798	,	_
73-25	14799-14815	social-affective	_
73-26	14815-14816	/	_
73-27	14816-14828	motivational	_
73-28	14829-14832	and	_
73-29	14833-14838	motor	_
73-30	14839-14848	functions	_
73-31	14849-14850	(	_
73-32	14850-14853	see	_
73-33	14854-14859	Table	_
73-34	14860-14862	II	_
73-35	14863-14866	for	_
73-36	14867-14869	an	_
73-37	14870-14878	overview	_
73-38	14879-14882	and	_
73-39	14883-14888	Table	_
73-40	14889-14892	SII	_
73-41	14893-14896	for	_
73-42	14897-14905	detailed	_
73-43	14906-14913	network	_
73-44	14914-14925	coordinates	_
73-45	14926-14929	and	_
73-46	14930-14943	corresponding	_
73-47	14944-14949	brain	_
73-48	14950-14957	regions	_
73-49	14957-14958	)	_
73-50	14958-14959	.	_

#Text=Only meta-analytic networks with a minimum of 10 nodes were included, since a lower number of features are uninformative for robust classification.
74-1	14960-14964	Only	_
74-2	14965-14978	meta-analytic	_
74-3	14979-14987	networks	_
74-4	14988-14992	with	_
74-5	14993-14994	a	_
74-6	14995-15002	minimum	_
74-7	15003-15005	of	_
74-8	15006-15008	10	_
74-9	15009-15014	nodes	_
74-10	15015-15019	were	_
74-11	15020-15028	included	_
74-12	15028-15029	,	_
74-13	15030-15035	since	_
74-14	15036-15037	a	_
74-15	15038-15043	lower	_
74-16	15044-15050	number	_
74-17	15051-15053	of	_
74-18	15054-15062	features	_
74-19	15063-15066	are	_
74-20	15067-15080	uninformative	_
74-21	15081-15084	for	_
74-22	15085-15091	robust	_
74-23	15092-15106	classification	_
74-24	15106-15107	.	_

#Text=Resting-state functional connectivity (RSFC) within each network was computed per subject by first extracting the time-series for each node within 6 mm of the meta-analytic peaks.
75-1	15108-15121	Resting-state	_
75-2	15122-15132	functional	_
75-3	15133-15145	connectivity	_
75-4	15146-15147	(	_
75-5	15147-15151	RSFC	_
75-6	15151-15152	)	_
75-7	15153-15159	within	_
75-8	15160-15164	each	_
75-9	15165-15172	network	_
75-10	15173-15176	was	_
75-11	15177-15185	computed	_
75-12	15186-15189	per	_
75-13	15190-15197	subject	_
75-14	15198-15200	by	_
75-15	15201-15206	first	_
75-16	15207-15217	extracting	_
75-17	15218-15221	the	_
75-18	15222-15233	time-series	_
75-19	15234-15237	for	_
75-20	15238-15242	each	_
75-21	15243-15247	node	_
75-22	15248-15254	within	_
75-23	15255-15256	6	_
75-24	15257-15259	mm	_
75-25	15260-15262	of	_
75-26	15263-15266	the	_
75-27	15267-15280	meta-analytic	_
75-28	15281-15286	peaks	_
75-29	15286-15287	.	_

#Text=To reduce spurious correlations, variance explained by the 6 movement parameters and their derivatives (modeled as 1st and 2nd order effects) as well as the mean white-matter and Cerebrospinal fluid signal time-courses was removed from the time series.
76-1	15288-15290	To	_
76-2	15291-15297	reduce	_
76-3	15298-15306	spurious	_
76-4	15307-15319	correlations	_
76-5	15319-15320	,	_
76-6	15321-15329	variance	_
76-7	15330-15339	explained	_
76-8	15340-15342	by	_
76-9	15343-15346	the	_
76-10	15347-15348	6	_
76-11	15349-15357	movement	_
76-12	15358-15368	parameters	_
76-13	15369-15372	and	_
76-14	15373-15378	their	_
76-15	15379-15390	derivatives	_
76-16	15391-15392	(	_
76-17	15392-15399	modeled	_
76-18	15400-15402	as	_
76-19	15403-15406	1st	_
76-20	15407-15410	and	_
76-21	15411-15414	2nd	_
76-22	15415-15420	order	_
76-23	15421-15428	effects	_
76-24	15428-15429	)	_
76-25	15430-15432	as	_
76-26	15433-15437	well	_
76-27	15438-15440	as	_
76-28	15441-15444	the	_
76-29	15445-15449	mean	_
76-30	15450-15462	white-matter	_
76-31	15463-15466	and	_
76-32	15467-15480	Cerebrospinal	_
76-33	15481-15486	fluid	_
76-34	15487-15493	signal	_
76-35	15494-15506	time-courses	_
76-36	15507-15510	was	_
76-37	15511-15518	removed	_
76-38	15519-15523	from	_
76-39	15524-15527	the	_
76-40	15528-15532	time	_
76-41	15533-15539	series	_
76-42	15539-15540	.	_

#Text=Subsequently, time series were high-pass filtered retaining frequencies above 0.01 Hz.
77-1	15541-15553	Subsequently	_
77-2	15553-15554	,	_
77-3	15555-15559	time	_
77-4	15560-15566	series	_
77-5	15567-15571	were	_
77-6	15572-15581	high-pass	_
77-7	15582-15590	filtered	_
77-8	15591-15600	retaining	_
77-9	15601-15612	frequencies	_
77-10	15613-15618	above	_
77-11	15619-15623	0.01	_
77-12	15624-15626	Hz	_
77-13	15626-15627	.	_

#Text=Connectivity was computed as the Fisher’s Z-transformed Pearson correlation between the time series of each network’s nodes; connectivity values were adjusted for effects of acquisition site, gender, movement, total brain volume, and (only for the clinical samples) age (cf.) to avoid classification based on spurious between-subject effects.
#Text=2.3 Support Vector Machine Features and Classification
#Text=To examine whether the RSFC pattern of a network contains predictive information on the respective groups (SCZ vs.
78-1	15628-15640	Connectivity	_
78-2	15641-15644	was	_
78-3	15645-15653	computed	_
78-4	15654-15656	as	_
78-5	15657-15660	the	_
78-6	15661-15667	Fisher	_
78-7	15667-15668	’	_
78-8	15668-15669	s	_
78-9	15670-15683	Z-transformed	_
78-10	15684-15691	Pearson	_
78-11	15692-15703	correlation	_
78-12	15704-15711	between	_
78-13	15712-15715	the	_
78-14	15716-15720	time	_
78-15	15721-15727	series	_
78-16	15728-15730	of	_
78-17	15731-15735	each	_
78-18	15736-15743	network	_
78-19	15743-15744	’	_
78-20	15744-15745	s	_
78-21	15746-15751	nodes	_
78-22	15751-15752	;	_
78-23	15753-15765	connectivity	_
78-24	15766-15772	values	_
78-25	15773-15777	were	_
78-26	15778-15786	adjusted	_
78-27	15787-15790	for	_
78-28	15791-15798	effects	_
78-29	15799-15801	of	_
78-30	15802-15813	acquisition	_
78-31	15814-15818	site	_
78-32	15818-15819	,	_
78-33	15820-15826	gender	_
78-34	15826-15827	,	_
78-35	15828-15836	movement	_
78-36	15836-15837	,	_
78-37	15838-15843	total	_
78-38	15844-15849	brain	_
78-39	15850-15856	volume	_
78-40	15856-15857	,	_
78-41	15858-15861	and	_
78-42	15862-15863	(	_
78-43	15863-15867	only	_
78-44	15868-15871	for	_
78-45	15872-15875	the	_
78-46	15876-15884	clinical	_
78-47	15885-15892	samples	_
78-48	15892-15893	)	_
78-49	15894-15897	age	_
78-50	15898-15899	(	_
78-51	15899-15901	cf	_
78-52	15901-15902	.	_
78-53	15902-15903	)	_
78-54	15904-15906	to	_
78-55	15907-15912	avoid	_
78-56	15913-15927	classification	_
78-57	15928-15933	based	_
78-58	15934-15936	on	_
78-59	15937-15945	spurious	_
78-60	15946-15961	between-subject	_
78-61	15962-15969	effects	_
78-62	15969-15970	.	_
78-63	15971-15974	2.3	_
78-64	15975-15982	Support	_
78-65	15983-15989	Vector	_
78-66	15990-15997	Machine	_
78-67	15998-16006	Features	_
78-68	16007-16010	and	_
78-69	16011-16025	Classification	_
78-70	16026-16028	To	_
78-71	16029-16036	examine	_
78-72	16037-16044	whether	_
78-73	16045-16048	the	_
78-74	16049-16053	RSFC	_
78-75	16054-16061	pattern	_
78-76	16062-16064	of	_
78-77	16065-16066	a	_
78-78	16067-16074	network	_
78-79	16075-16083	contains	_
78-80	16084-16094	predictive	_
78-81	16095-16106	information	_
78-82	16107-16109	on	_
78-83	16110-16113	the	_
78-84	16114-16124	respective	_
78-85	16125-16131	groups	_
78-86	16132-16133	(	_
78-87	16133-16136	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
78-88	16137-16139	vs	_
78-89	16139-16140	.	_

#Text=HCSCZ, PD vs.
79-1	16141-16146	HCSCZ	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
79-2	16146-16147	,	_
79-3	16148-16150	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
79-4	16151-16153	vs	_
79-5	16153-16154	.	_

#Text=HCPD, old vs. young) non-sparse linear two-class SVMs were computed using LibSVM (https://www.csie.ntu.edu.tw/~cjlin/libsvm).
80-1	16155-16159	HCPD	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
80-2	16159-16160	,	_
80-3	16161-16164	old	_
80-4	16165-16167	vs	_
80-5	16167-16168	.	_
80-6	16169-16174	young	_
80-7	16174-16175	)	_
80-8	16176-16186	non-sparse	_
80-9	16187-16193	linear	_
80-10	16194-16203	two-class	_
80-11	16204-16208	SVMs	_
80-12	16209-16213	were	_
80-13	16214-16222	computed	_
80-14	16223-16228	using	_
80-15	16229-16235	LibSVM	_
80-16	16236-16237	(	_
80-17	16237-16242	https	_
80-18	16242-16243	:	_
80-19	16243-16244	/	_
80-20	16244-16245	/	_
80-21	16245-16264	www.csie.ntu.edu.tw	_
80-22	16264-16265	/	_
80-23	16265-16266	~	_
80-24	16266-16271	cjlin	_
80-25	16271-16272	/	_
80-26	16272-16278	libsvm	_
80-27	16278-16279	)	_
80-28	16279-16280	.	_

#Text=SVMs’ were trained separately for each of all three analyses (PD, SCZ, NA) and each of the functional networks.
81-1	16281-16285	SVMs	_
81-2	16285-16286	’	_
81-3	16287-16291	were	_
81-4	16292-16299	trained	_
81-5	16300-16310	separately	_
81-6	16311-16314	for	_
81-7	16315-16319	each	_
81-8	16320-16322	of	_
81-9	16323-16326	all	_
81-10	16327-16332	three	_
81-11	16333-16341	analyses	_
81-12	16342-16343	(	_
81-13	16343-16345	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
81-14	16345-16346	,	_
81-15	16347-16350	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
81-16	16350-16351	,	_
81-17	16352-16354	NA	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
81-18	16354-16355	)	_
81-19	16356-16359	and	_
81-20	16360-16364	each	_
81-21	16365-16367	of	_
81-22	16368-16371	the	_
81-23	16372-16382	functional	_
81-24	16383-16391	networks	_
81-25	16391-16392	.	_

#Text=Of note, we did not attempt between-patient classification (i.e., PD vs.
82-1	16393-16395	Of	_
82-2	16396-16400	note	_
82-3	16400-16401	,	_
82-4	16402-16404	we	_
82-5	16405-16408	did	_
82-6	16409-16412	not	_
82-7	16413-16420	attempt	_
82-8	16421-16436	between-patient	_
82-9	16437-16451	classification	_
82-10	16452-16453	(	_
82-11	16453-16456	i.e	_
82-12	16456-16457	.	_
82-13	16457-16458	,	_
82-14	16459-16461	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
82-15	16462-16464	vs	_
82-16	16464-16465	.	_

#Text=SCZ), as the different groups were closely matched to their respective controls but substantially different from each other with respect to age, gender, and movement.
83-1	16466-16469	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
83-2	16469-16470	)	_
83-3	16470-16471	,	_
83-4	16472-16474	as	_
83-5	16475-16478	the	_
83-6	16479-16488	different	_
83-7	16489-16495	groups	_
83-8	16496-16500	were	_
83-9	16501-16508	closely	_
83-10	16509-16516	matched	_
83-11	16517-16519	to	_
83-12	16520-16525	their	_
83-13	16526-16536	respective	_
83-14	16537-16545	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
83-15	16546-16549	but	_
83-16	16550-16563	substantially	_
83-17	16564-16573	different	_
83-18	16574-16578	from	_
83-19	16579-16583	each	_
83-20	16584-16589	other	_
83-21	16590-16594	with	_
83-22	16595-16602	respect	_
83-23	16603-16605	to	_
83-24	16606-16609	age	_
83-25	16609-16610	,	_
83-26	16611-16617	gender	_
83-27	16617-16618	,	_
83-28	16619-16622	and	_
83-29	16623-16631	movement	_
83-30	16631-16632	.	_

#Text=The input variables (features) to the SVM consisted of edge-wise RSFC between all nodes of a given network.
84-1	16633-16636	The	_
84-2	16637-16642	input	_
84-3	16643-16652	variables	_
84-4	16653-16654	(	_
84-5	16654-16662	features	_
84-6	16662-16663	)	_
84-7	16664-16666	to	_
84-8	16667-16670	the	_
84-9	16671-16674	SVM	_
84-10	16675-16684	consisted	_
84-11	16685-16687	of	_
84-12	16688-16697	edge-wise	_
84-13	16698-16702	RSFC	_
84-14	16703-16710	between	_
84-15	16711-16714	all	_
84-16	16715-16720	nodes	_
84-17	16721-16723	of	_
84-18	16724-16725	a	_
84-19	16726-16731	given	_
84-20	16732-16739	network	_
84-21	16739-16740	.	_

#Text=Each SVM was trained and tested by a nested 10-fold cross validation scheme for each individual group (see example Figure 1) (cf.).
85-1	16741-16745	Each	_
85-2	16746-16749	SVM	_
85-3	16750-16753	was	_
85-4	16754-16761	trained	_
85-5	16762-16765	and	_
85-6	16766-16772	tested	_
85-7	16773-16775	by	_
85-8	16776-16777	a	_
85-9	16778-16784	nested	_
85-10	16785-16787	10	_
85-11	16787-16788	-	_
85-12	16788-16792	fold	_
85-13	16793-16798	cross	_
85-14	16799-16809	validation	_
85-15	16810-16816	scheme	_
85-16	16817-16820	for	_
85-17	16821-16825	each	_
85-18	16826-16836	individual	_
85-19	16837-16842	group	_
85-20	16843-16844	(	_
85-21	16844-16847	see	_
85-22	16848-16855	example	_
85-23	16856-16862	Figure	_
85-24	16863-16864	1	_
85-25	16864-16865	)	_
85-26	16866-16867	(	_
85-27	16867-16869	cf	_
85-28	16869-16870	.	_
85-29	16870-16871	)	_
85-30	16871-16872	.	_

#Text=The inner loop used a 10-fold cross-validation within the training group to optimize the soft-margin slack parameter.
86-1	16873-16876	The	_
86-2	16877-16882	inner	_
86-3	16883-16887	loop	_
86-4	16888-16892	used	_
86-5	16893-16894	a	_
86-6	16895-16897	10	_
86-7	16897-16898	-	_
86-8	16898-16902	fold	_
86-9	16903-16919	cross-validation	_
86-10	16920-16926	within	_
86-11	16927-16930	the	_
86-12	16931-16939	training	_
86-13	16940-16945	group	_
86-14	16946-16948	to	_
86-15	16949-16957	optimize	_
86-16	16958-16961	the	_
86-17	16962-16973	soft-margin	_
86-18	16974-16979	slack	_
86-19	16980-16989	parameter	_
86-20	16989-16990	.	_

#Text=For each fold of the outer loop, the left-out (unseen) 10% were then classified using the SVM trained on the (entire) training-set using the optimized parameter.
87-1	16991-16994	For	_
87-2	16995-16999	each	_
87-3	17000-17004	fold	_
87-4	17005-17007	of	_
87-5	17008-17011	the	_
87-6	17012-17017	outer	_
87-7	17018-17022	loop	_
87-8	17022-17023	,	_
87-9	17024-17027	the	_
87-10	17028-17036	left-out	_
87-11	17037-17038	(	_
87-12	17038-17044	unseen	_
87-13	17044-17045	)	_
87-14	17046-17049	10%	_
87-15	17050-17054	were	_
87-16	17055-17059	then	_
87-17	17060-17070	classified	_
87-18	17071-17076	using	_
87-19	17077-17080	the	_
87-20	17081-17084	SVM	_
87-21	17085-17092	trained	_
87-22	17093-17095	on	_
87-23	17096-17099	the	_
87-24	17100-17101	(	_
87-25	17101-17107	entire	_
87-26	17107-17108	)	_
87-27	17109-17121	training-set	_
87-28	17122-17127	using	_
87-29	17128-17131	the	_
87-30	17132-17141	optimized	_
87-31	17142-17151	parameter	_
87-32	17151-17152	.	_

#Text=This nested scheme ensured that classifier optimization and evaluation was performed independent of each other.
88-1	17153-17157	This	_
88-2	17158-17164	nested	_
88-3	17165-17171	scheme	_
88-4	17172-17179	ensured	_
88-5	17180-17184	that	_
88-6	17185-17195	classifier	_
88-7	17196-17208	optimization	_
88-8	17209-17212	and	_
88-9	17213-17223	evaluation	_
88-10	17224-17227	was	_
88-11	17228-17237	performed	_
88-12	17238-17249	independent	_
88-13	17250-17252	of	_
88-14	17253-17257	each	_
88-15	17258-17263	other	_
88-16	17263-17264	.	_

#Text=Classification performance was evaluated based on accuracy (Acc.), balanced accuracy (bAcc.), sensitivity (Sens.), and specificity (Spec.) as well as two measures derived from signal-detection theory: the area under the receiver operating characteristics curve (AUC) and d’.
89-1	17265-17279	Classification	_
89-2	17280-17291	performance	_
89-3	17292-17295	was	_
89-4	17296-17305	evaluated	_
89-5	17306-17311	based	_
89-6	17312-17314	on	_
89-7	17315-17323	accuracy	_
89-8	17324-17325	(	_
89-9	17325-17328	Acc	_
89-10	17328-17329	.	_
89-11	17329-17330	)	_
89-12	17330-17331	,	_
89-13	17332-17340	balanced	_
89-14	17341-17349	accuracy	_
89-15	17350-17351	(	_
89-16	17351-17355	bAcc	_
89-17	17355-17356	.	_
89-18	17356-17357	)	_
89-19	17357-17358	,	_
89-20	17359-17370	sensitivity	_
89-21	17371-17372	(	_
89-22	17372-17376	Sens	_
89-23	17376-17377	.	_
89-24	17377-17378	)	_
89-25	17378-17379	,	_
89-26	17380-17383	and	_
89-27	17384-17395	specificity	_
89-28	17396-17397	(	_
89-29	17397-17401	Spec	_
89-30	17401-17402	.	_
89-31	17402-17403	)	_
89-32	17404-17406	as	_
89-33	17407-17411	well	_
89-34	17412-17414	as	_
89-35	17415-17418	two	_
89-36	17419-17427	measures	_
89-37	17428-17435	derived	_
89-38	17436-17440	from	_
89-39	17441-17457	signal-detection	_
89-40	17458-17464	theory	_
89-41	17464-17465	:	_
89-42	17466-17469	the	_
89-43	17470-17474	area	_
89-44	17475-17480	under	_
89-45	17481-17484	the	_
89-46	17485-17493	receiver	_
89-47	17494-17503	operating	_
89-48	17504-17519	characteristics	_
89-49	17520-17525	curve	_
89-50	17526-17527	(	_
89-51	17527-17530	AUC	_
89-52	17530-17531	)	_
89-53	17532-17535	and	_
89-54	17536-17537	d	_
89-55	17537-17538	’	_
89-56	17538-17539	.	_

#Text=Acc. denotes the overall proportion of subjects correctly classified as patients (PD, SCZ) or advanced age versus healthy or younger age, respectively.
90-1	17540-17543	Acc	_
90-2	17543-17544	.	_
90-3	17545-17552	denotes	_
90-4	17553-17556	the	_
90-5	17557-17564	overall	_
90-6	17565-17575	proportion	_
90-7	17576-17578	of	_
90-8	17579-17587	subjects	_
90-9	17588-17597	correctly	_
90-10	17598-17608	classified	_
90-11	17609-17611	as	_
90-12	17612-17620	patients	_
90-13	17621-17622	(	_
90-14	17622-17624	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
90-15	17624-17625	,	_
90-16	17626-17629	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
90-17	17629-17630	)	_
90-18	17631-17633	or	_
90-19	17634-17642	advanced	_
90-20	17643-17646	age	_
90-21	17647-17653	versus	_
90-22	17654-17661	healthy	_
90-23	17662-17664	or	_
90-24	17665-17672	younger	_
90-25	17673-17676	age	_
90-26	17676-17677	,	_
90-27	17678-17690	respectively	_
90-28	17690-17691	.	_

#Text=The bAcc. is calculated as the average proportion of subjects correctly classified as patients (PD, SCZ) or advanced age versus healthy or younger age, respectively.
91-1	17692-17695	The	_
91-2	17696-17700	bAcc	_
91-3	17700-17701	.	_
91-4	17702-17704	is	_
91-5	17705-17715	calculated	_
91-6	17716-17718	as	_
91-7	17719-17722	the	_
91-8	17723-17730	average	_
91-9	17731-17741	proportion	_
91-10	17742-17744	of	_
91-11	17745-17753	subjects	_
91-12	17754-17763	correctly	_
91-13	17764-17774	classified	_
91-14	17775-17777	as	_
91-15	17778-17786	patients	_
91-16	17787-17788	(	_
91-17	17788-17790	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
91-18	17790-17791	,	_
91-19	17792-17795	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
91-20	17795-17796	)	_
91-21	17797-17799	or	_
91-22	17800-17808	advanced	_
91-23	17809-17812	age	_
91-24	17813-17819	versus	_
91-25	17820-17827	healthy	_
91-26	17828-17830	or	_
91-27	17831-17838	younger	_
91-28	17839-17842	age	_
91-29	17842-17843	,	_
91-30	17844-17856	respectively	_
91-31	17856-17857	.	_

#Text=Sens. indicates the percentage of patients (SCZ or PD) correctly classified as ill or subjects correctly classified as old in the aging sample (true positives).
92-1	17858-17862	Sens	_
92-2	17862-17863	.	_
92-3	17864-17873	indicates	_
92-4	17874-17877	the	_
92-5	17878-17888	percentage	_
92-6	17889-17891	of	_
92-7	17892-17900	patients	_
92-8	17901-17902	(	_
92-9	17902-17905	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
92-10	17906-17908	or	_
92-11	17909-17911	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
92-12	17911-17912	)	_
92-13	17913-17922	correctly	_
92-14	17923-17933	classified	_
92-15	17934-17936	as	_
92-16	17937-17940	ill	_
92-17	17941-17943	or	_
92-18	17944-17952	subjects	_
92-19	17953-17962	correctly	_
92-20	17963-17973	classified	_
92-21	17974-17976	as	_
92-22	17977-17980	old	_
92-23	17981-17983	in	_
92-24	17984-17987	the	_
92-25	17988-17993	aging	_
92-26	17994-18000	sample	_
92-27	18001-18002	(	_
92-28	18002-18006	true	_
92-29	18007-18016	positives	_
92-30	18016-18017	)	_
92-31	18017-18018	.	_

#Text=Spec. in turn represents the fraction of HCs correctly classified as healthy or subjects correctly identified as young in the aging sample (true negatives).
93-1	18019-18023	Spec	_
93-2	18023-18024	.	_
93-3	18025-18027	in	_
93-4	18028-18032	turn	_
93-5	18033-18043	represents	_
93-6	18044-18047	the	_
93-7	18048-18056	fraction	_
93-8	18057-18059	of	_
93-9	18060-18063	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
93-10	18064-18073	correctly	_
93-11	18074-18084	classified	_
93-12	18085-18087	as	_
93-13	18088-18095	healthy	_
93-14	18096-18098	or	_
93-15	18099-18107	subjects	_
93-16	18108-18117	correctly	_
93-17	18118-18128	identified	_
93-18	18129-18131	as	_
93-19	18132-18137	young	_
93-20	18138-18140	in	_
93-21	18141-18144	the	_
93-22	18145-18150	aging	_
93-23	18151-18157	sample	_
93-24	18158-18159	(	_
93-25	18159-18163	true	_
93-26	18164-18173	negatives	_
93-27	18173-18174	)	_
93-28	18174-18175	.	_

#Text=AUC refers to the area under the receiver operating characteristics (ROC) curve.
94-1	18176-18179	AUC	_
94-2	18180-18186	refers	_
94-3	18187-18189	to	_
94-4	18190-18193	the	_
94-5	18194-18198	area	_
94-6	18199-18204	under	_
94-7	18205-18208	the	_
94-8	18209-18217	receiver	_
94-9	18218-18227	operating	_
94-10	18228-18243	characteristics	_
94-11	18244-18245	(	_
94-12	18245-18248	ROC	_
94-13	18248-18249	)	_
94-14	18250-18255	curve	_
94-15	18255-18256	.	_

#Text=An ROC curve depicts the relationship between true positive rate and false positive rate, and its AUC value indicates the sensitivity of the diagnostic process independent of any specific decision criterion.
95-1	18257-18259	An	_
95-2	18260-18263	ROC	_
95-3	18264-18269	curve	_
95-4	18270-18277	depicts	_
95-5	18278-18281	the	_
95-6	18282-18294	relationship	_
95-7	18295-18302	between	_
95-8	18303-18307	true	_
95-9	18308-18316	positive	_
95-10	18317-18321	rate	_
95-11	18322-18325	and	_
95-12	18326-18331	false	_
95-13	18332-18340	positive	_
95-14	18341-18345	rate	_
95-15	18345-18346	,	_
95-16	18347-18350	and	_
95-17	18351-18354	its	_
95-18	18355-18358	AUC	_
95-19	18359-18364	value	_
95-20	18365-18374	indicates	_
95-21	18375-18378	the	_
95-22	18379-18390	sensitivity	_
95-23	18391-18393	of	_
95-24	18394-18397	the	_
95-25	18398-18408	diagnostic	_
95-26	18409-18416	process	_
95-27	18417-18428	independent	_
95-28	18429-18431	of	_
95-29	18432-18435	any	_
95-30	18436-18444	specific	_
95-31	18445-18453	decision	_
95-32	18454-18463	criterion	_
95-33	18463-18464	.	_

#Text=Finally, we assessed d’, an alternative index of diagnostic sensitivity independent of the decision criterion, calculated as z(true positive rate) – z(false positive rate).
96-1	18465-18472	Finally	_
96-2	18472-18473	,	_
96-3	18474-18476	we	_
96-4	18477-18485	assessed	_
96-5	18486-18487	d	_
96-6	18487-18488	’	_
96-7	18488-18489	,	_
96-8	18490-18492	an	_
96-9	18493-18504	alternative	_
96-10	18505-18510	index	_
96-11	18511-18513	of	_
96-12	18514-18524	diagnostic	_
96-13	18525-18536	sensitivity	_
96-14	18537-18548	independent	_
96-15	18549-18551	of	_
96-16	18552-18555	the	_
96-17	18556-18564	decision	_
96-18	18565-18574	criterion	_
96-19	18574-18575	,	_
96-20	18576-18586	calculated	_
96-21	18587-18589	as	_
96-22	18590-18591	z	_
96-23	18591-18592	(	_
96-24	18592-18596	true	_
96-25	18597-18605	positive	_
96-26	18606-18610	rate	_
96-27	18610-18611	)	_
96-28	18612-18613	–	_
96-29	18614-18615	z	_
96-30	18615-18616	(	_
96-31	18616-18621	false	_
96-32	18622-18630	positive	_
96-33	18631-18635	rate	_
96-34	18635-18636	)	_
96-35	18636-18637	.	_

#Text=To increase robustness, the entire procedure was repeated 25 times, and each performance measures was averaged across repetitions.
97-1	18638-18640	To	_
97-2	18641-18649	increase	_
97-3	18650-18660	robustness	_
97-4	18660-18661	,	_
97-5	18662-18665	the	_
97-6	18666-18672	entire	_
97-7	18673-18682	procedure	_
97-8	18683-18686	was	_
97-9	18687-18695	repeated	_
97-10	18696-18698	25	_
97-11	18699-18704	times	_
97-12	18704-18705	,	_
97-13	18706-18709	and	_
97-14	18710-18714	each	_
97-15	18715-18726	performance	_
97-16	18727-18735	measures	_
97-17	18736-18739	was	_
97-18	18740-18748	averaged	_
97-19	18749-18755	across	_
97-20	18756-18767	repetitions	_
97-21	18767-18768	.	_

#Text=To examine significant differences in classification performance between networks within each group, pairwise t-tests were performed for each of the 12 networks based on the accuracies obtained from the 25 cross-validation outer-loop replications of the separate SVMs (significance threshold of p < 0.05, Bonferroni-corrected for the number of pairwise network comparisons).
98-1	18769-18771	To	_
98-2	18772-18779	examine	_
98-3	18780-18791	significant	_
98-4	18792-18803	differences	_
98-5	18804-18806	in	_
98-6	18807-18821	classification	_
98-7	18822-18833	performance	_
98-8	18834-18841	between	_
98-9	18842-18850	networks	_
98-10	18851-18857	within	_
98-11	18858-18862	each	_
98-12	18863-18868	group	_
98-13	18868-18869	,	_
98-14	18870-18878	pairwise	_
98-15	18879-18886	t-tests	_
98-16	18887-18891	were	_
98-17	18892-18901	performed	_
98-18	18902-18905	for	_
98-19	18906-18910	each	_
98-20	18911-18913	of	_
98-21	18914-18917	the	_
98-22	18918-18920	12	_
98-23	18921-18929	networks	_
98-24	18930-18935	based	_
98-25	18936-18938	on	_
98-26	18939-18942	the	_
98-27	18943-18953	accuracies	_
98-28	18954-18962	obtained	_
98-29	18963-18967	from	_
98-30	18968-18971	the	_
98-31	18972-18974	25	_
98-32	18975-18991	cross-validation	_
98-33	18992-19002	outer-loop	_
98-34	19003-19015	replications	_
98-35	19016-19018	of	_
98-36	19019-19022	the	_
98-37	19023-19031	separate	_
98-38	19032-19036	SVMs	_
98-39	19037-19038	(	_
98-40	19038-19050	significance	_
98-41	19051-19060	threshold	_
98-42	19061-19063	of	_
98-43	19064-19065	p	_
98-44	19066-19067	<	_
98-45	19068-19072	0.05	_
98-46	19072-19073	,	_
98-47	19074-19094	Bonferroni-corrected	_
98-48	19095-19098	for	_
98-49	19099-19102	the	_
98-50	19103-19109	number	_
98-51	19110-19112	of	_
98-52	19113-19121	pairwise	_
98-53	19122-19129	network	_
98-54	19130-19141	comparisons	_
98-55	19141-19142	)	_
98-56	19142-19143	.	_

#Text=To compare the separately conducted classifications for SCZ vs.
99-1	19144-19146	To	_
99-2	19147-19154	compare	_
99-3	19155-19158	the	_
99-4	19159-19169	separately	_
99-5	19170-19179	conducted	_
99-6	19180-19195	classifications	_
99-7	19196-19199	for	_
99-8	19200-19203	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
99-9	19204-19206	vs	_
99-10	19206-19207	.	_

#Text=HCSCZ and PD vs.
100-1	19208-19213	HCSCZ	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
100-2	19214-19217	and	_
100-3	19218-19220	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
100-4	19221-19223	vs	_
100-5	19223-19224	.	_

#Text=HCPD subgroups, accuracies obtained for each individual analysis for every network were converted to standardized z-scores by reference to the binomial distribution reflecting chance level and corrected for multiple comparisons by the amount of networks-based classifications.
101-1	19225-19229	HCPD	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
101-2	19230-19239	subgroups	_
101-3	19239-19240	,	_
101-4	19241-19251	accuracies	_
101-5	19252-19260	obtained	_
101-6	19261-19264	for	_
101-7	19265-19269	each	_
101-8	19270-19280	individual	_
101-9	19281-19289	analysis	_
101-10	19290-19293	for	_
101-11	19294-19299	every	_
101-12	19300-19307	network	_
101-13	19308-19312	were	_
101-14	19313-19322	converted	_
101-15	19323-19325	to	_
101-16	19326-19338	standardized	_
101-17	19339-19347	z-scores	_
101-18	19348-19350	by	_
101-19	19351-19360	reference	_
101-20	19361-19363	to	_
101-21	19364-19367	the	_
101-22	19368-19376	binomial	_
101-23	19377-19389	distribution	_
101-24	19390-19400	reflecting	_
101-25	19401-19407	chance	_
101-26	19408-19413	level	_
101-27	19414-19417	and	_
101-28	19418-19427	corrected	_
101-29	19428-19431	for	_
101-30	19432-19440	multiple	_
101-31	19441-19452	comparisons	_
101-32	19453-19455	by	_
101-33	19456-19459	the	_
101-34	19460-19466	amount	_
101-35	19467-19469	of	_
101-36	19470-19484	networks-based	_
101-37	19485-19500	classifications	_
101-38	19500-19501	.	_

#Text=Log-likelihood ratios (LLRs) were estimated to identify networks showing better classification performance for one patient group than the other.
102-1	19502-19516	Log-likelihood	_
102-2	19517-19523	ratios	_
102-3	19524-19525	(	_
102-4	19525-19529	LLRs	_
102-5	19529-19530	)	_
102-6	19531-19535	were	_
102-7	19536-19545	estimated	_
102-8	19546-19548	to	_
102-9	19549-19557	identify	_
102-10	19558-19566	networks	_
102-11	19567-19574	showing	_
102-12	19575-19581	better	_
102-13	19582-19596	classification	_
102-14	19597-19608	performance	_
102-15	19609-19612	for	_
102-16	19613-19616	one	_
102-17	19617-19624	patient	_
102-18	19625-19630	group	_
102-19	19631-19635	than	_
102-20	19636-19639	the	_
102-21	19640-19645	other	_
102-22	19645-19646	.	_

#Text=To investigate significant differences in classification performance between the groups, t-tests were calculated based on the 25 accuracies obtained from the cross-validation outer-loop replications of the separate SVMs performed in each group (SCZ, PD, NA) for each of the 12 networks (significance threshold of p < 0.05, Bonferroni-corrected for the number of groups and networks).
#Text=3.
103-1	19647-19649	To	_
103-2	19650-19661	investigate	_
103-3	19662-19673	significant	_
103-4	19674-19685	differences	_
103-5	19686-19688	in	_
103-6	19689-19703	classification	_
103-7	19704-19715	performance	_
103-8	19716-19723	between	_
103-9	19724-19727	the	_
103-10	19728-19734	groups	_
103-11	19734-19735	,	_
103-12	19736-19743	t-tests	_
103-13	19744-19748	were	_
103-14	19749-19759	calculated	_
103-15	19760-19765	based	_
103-16	19766-19768	on	_
103-17	19769-19772	the	_
103-18	19773-19775	25	_
103-19	19776-19786	accuracies	_
103-20	19787-19795	obtained	_
103-21	19796-19800	from	_
103-22	19801-19804	the	_
103-23	19805-19821	cross-validation	_
103-24	19822-19832	outer-loop	_
103-25	19833-19845	replications	_
103-26	19846-19848	of	_
103-27	19849-19852	the	_
103-28	19853-19861	separate	_
103-29	19862-19866	SVMs	_
103-30	19867-19876	performed	_
103-31	19877-19879	in	_
103-32	19880-19884	each	_
103-33	19885-19890	group	_
103-34	19891-19892	(	_
103-35	19892-19895	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
103-36	19895-19896	,	_
103-37	19897-19899	PD	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
103-38	19899-19900	,	_
103-39	19901-19903	NA	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
103-40	19903-19904	)	_
103-41	19905-19908	for	_
103-42	19909-19913	each	_
103-43	19914-19916	of	_
103-44	19917-19920	the	_
103-45	19921-19923	12	_
103-46	19924-19932	networks	_
103-47	19933-19934	(	_
103-48	19934-19946	significance	_
103-49	19947-19956	threshold	_
103-50	19957-19959	of	_
103-51	19960-19961	p	_
103-52	19962-19963	<	_
103-53	19964-19968	0.05	_
103-54	19968-19969	,	_
103-55	19970-19990	Bonferroni-corrected	_
103-56	19991-19994	for	_
103-57	19995-19998	the	_
103-58	19999-20005	number	_
103-59	20006-20008	of	_
103-60	20009-20015	groups	_
103-61	20016-20019	and	_
103-62	20020-20028	networks	_
103-63	20028-20029	)	_
103-64	20029-20030	.	_
103-65	20031-20032	3	_
103-66	20032-20033	.	_

#Text=Results
#Text=As expected, SCZ patients could be distinguished above chance from matched HCs based on RSFC in the reward network (Rew; Acc. = 68%; AUC =0.73).
104-1	20034-20041	Results	_
104-2	20042-20044	As	_
104-3	20045-20053	expected	_
104-4	20053-20054	,	_
104-5	20055-20058	SCZ	_
104-6	20059-20067	patients	_
104-7	20068-20073	could	_
104-8	20074-20076	be	_
104-9	20077-20090	distinguished	_
104-10	20091-20096	above	_
104-11	20097-20103	chance	_
104-12	20104-20108	from	_
104-13	20109-20116	matched	_
104-14	20117-20120	HCs	_
104-15	20121-20126	based	_
104-16	20127-20129	on	_
104-17	20130-20134	RSFC	_
104-18	20135-20137	in	_
104-19	20138-20141	the	_
104-20	20142-20148	reward	_
104-21	20149-20156	network	_
104-22	20157-20158	(	_
104-23	20158-20161	Rew	_
104-24	20161-20162	;	_
104-25	20163-20166	Acc	_
104-26	20166-20167	.	_
104-27	20168-20169	=	_
104-28	20170-20173	68%	_
104-29	20173-20174	;	_
104-30	20175-20178	AUC	_
104-31	20179-20180	=	_
104-32	20180-20184	0.73	_
104-33	20184-20185	)	_
104-34	20185-20186	.	_

#Text=In turn, PD patients were distinguished above chance from their matched HCs based on RSFC in the motor network (Motor; Acc. = 70%; AUC = 0.77).
105-1	20187-20189	In	_
105-2	20190-20194	turn	_
105-3	20194-20195	,	_
105-4	20196-20198	PD	_
105-5	20199-20207	patients	_
105-6	20208-20212	were	_
105-7	20213-20226	distinguished	_
105-8	20227-20232	above	_
105-9	20233-20239	chance	_
105-10	20240-20244	from	_
105-11	20245-20250	their	_
105-12	20251-20258	matched	_
105-13	20259-20262	HCs	_
105-14	20263-20268	based	_
105-15	20269-20271	on	_
105-16	20272-20276	RSFC	_
105-17	20277-20279	in	_
105-18	20280-20283	the	_
105-19	20284-20289	motor	_
105-20	20290-20297	network	_
105-21	20298-20299	(	_
105-22	20299-20304	Motor	_
105-23	20304-20305	;	_
105-24	20306-20309	Acc	_
105-25	20309-20310	.	_
105-26	20311-20312	=	_
105-27	20313-20316	70%	_
105-28	20316-20317	;	_
105-29	20318-20321	AUC	_
105-30	20322-20323	=	_
105-31	20324-20328	0.77	_
105-32	20328-20329	)	_
105-33	20329-20330	.	_

#Text=Finally, old and young subjects were differentiated very well from each other based on RSFC in the working-memory network (WM; Acc. = 79%; AUC = 0.84).
106-1	20331-20338	Finally	_
106-2	20338-20339	,	_
106-3	20340-20343	old	_
106-4	20344-20347	and	_
106-5	20348-20353	young	_
106-6	20354-20362	subjects	_
106-7	20363-20367	were	_
106-8	20368-20382	differentiated	_
106-9	20383-20387	very	_
106-10	20388-20392	well	_
106-11	20393-20397	from	_
106-12	20398-20402	each	_
106-13	20403-20408	other	_
106-14	20409-20414	based	_
106-15	20415-20417	on	_
106-16	20418-20422	RSFC	_
106-17	20423-20425	in	_
106-18	20426-20429	the	_
106-19	20430-20444	working-memory	_
106-20	20445-20452	network	_
106-21	20453-20454	(	_
106-22	20454-20456	WM	_
106-23	20456-20457	;	_
106-24	20458-20461	Acc	_
106-25	20461-20462	.	_
106-26	20463-20464	=	_
106-27	20465-20468	79%	_
106-28	20468-20469	;	_
106-29	20470-20473	AUC	_
106-30	20474-20475	=	_
106-31	20476-20480	0.84	_
106-32	20480-20481	)	_
106-33	20481-20482	.	_

#Text=Results are summarized as follows: Figure 2A for polar plot of group classification accuracies, Table III for Acc., Sens., Spec. and AUC, Table SIII for bACC., Table SIV for d’, Figure S1 for z-standardized accuracies of all groups and Figure S2 for variance of accuracies.
107-1	20483-20490	Results	_
107-2	20491-20494	are	_
107-3	20495-20505	summarized	_
107-4	20506-20508	as	_
107-5	20509-20516	follows	_
107-6	20516-20517	:	_
107-7	20518-20524	Figure	_
107-8	20525-20527	2A	_
107-9	20528-20531	for	_
107-10	20532-20537	polar	_
107-11	20538-20542	plot	_
107-12	20543-20545	of	_
107-13	20546-20551	group	_
107-14	20552-20566	classification	_
107-15	20567-20577	accuracies	_
107-16	20577-20578	,	_
107-17	20579-20584	Table	_
107-18	20585-20588	III	_
107-19	20589-20592	for	_
107-20	20593-20596	Acc	_
107-21	20596-20597	.	_
107-22	20597-20598	,	_
107-23	20599-20603	Sens	_
107-24	20603-20604	.	_
107-25	20604-20605	,	_
107-26	20606-20610	Spec	_
107-27	20610-20611	.	_
107-28	20612-20615	and	_
107-29	20616-20619	AUC	_
107-30	20619-20620	,	_
107-31	20621-20626	Table	_
107-32	20627-20631	SIII	_
107-33	20632-20635	for	_
107-34	20636-20640	bACC	_
107-35	20640-20641	.	_
107-36	20641-20642	,	_
107-37	20643-20648	Table	_
107-38	20649-20652	SIV	_
107-39	20653-20656	for	_
107-40	20657-20658	d	_
107-41	20658-20659	’	_
107-42	20659-20660	,	_
107-43	20661-20667	Figure	_
107-44	20668-20670	S1	_
107-45	20671-20674	for	_
107-46	20675-20689	z-standardized	_
107-47	20690-20700	accuracies	_
107-48	20701-20703	of	_
107-49	20704-20707	all	_
107-50	20708-20714	groups	_
107-51	20715-20718	and	_
107-52	20719-20725	Figure	_
107-53	20726-20728	S2	_
107-54	20729-20732	for	_
107-55	20733-20741	variance	_
107-56	20742-20744	of	_
107-57	20745-20755	accuracies	_
107-58	20755-20756	.	_

#Text=Considering the performance of all functional networks in distinguishing SCZ and PD patients from their respective HCs, a clear differentiation between networks becomes evident, even though only 2 (SCZ) and 1 (PD) out of 12 networks, respectively, did not significantly exceed chance accuracy (Figure 2B).
108-1	20757-20768	Considering	_
108-2	20769-20772	the	_
108-3	20773-20784	performance	_
108-4	20785-20787	of	_
108-5	20788-20791	all	_
108-6	20792-20802	functional	_
108-7	20803-20811	networks	_
108-8	20812-20814	in	_
108-9	20815-20829	distinguishing	_
108-10	20830-20833	SCZ	_
108-11	20834-20837	and	_
108-12	20838-20840	PD	_
108-13	20841-20849	patients	_
108-14	20850-20854	from	_
108-15	20855-20860	their	_
108-16	20861-20871	respective	_
108-17	20872-20875	HCs	_
108-18	20875-20876	,	_
108-19	20877-20878	a	_
108-20	20879-20884	clear	_
108-21	20885-20900	differentiation	_
108-22	20901-20908	between	_
108-23	20909-20917	networks	_
108-24	20918-20925	becomes	_
108-25	20926-20933	evident	_
108-26	20933-20934	,	_
108-27	20935-20939	even	_
108-28	20940-20946	though	_
108-29	20947-20951	only	_
108-30	20952-20953	2	_
108-31	20954-20955	(	_
108-32	20955-20958	SCZ	_
108-33	20958-20959	)	_
108-34	20960-20963	and	_
108-35	20964-20965	1	_
108-36	20966-20967	(	_
108-37	20967-20969	PD	_
108-38	20969-20970	)	_
108-39	20971-20974	out	_
108-40	20975-20977	of	_
108-41	20978-20980	12	_
108-42	20981-20989	networks	_
108-43	20989-20990	,	_
108-44	20991-21003	respectively	_
108-45	21003-21004	,	_
108-46	21005-21008	did	_
108-47	21009-21012	not	_
108-48	21013-21026	significantly	_
108-49	21027-21033	exceed	_
108-50	21034-21040	chance	_
108-51	21041-21049	accuracy	_
108-52	21050-21051	(	_
108-53	21051-21057	Figure	_
108-54	21058-21060	2B	_
108-55	21060-21061	)	_
108-56	21061-21062	.	_

#Text=The following results and discussion are focused on networks with superior classification performance for the respective disorders.
109-1	21063-21066	The	_
109-2	21067-21076	following	_
109-3	21077-21084	results	_
109-4	21085-21088	and	_
109-5	21089-21099	discussion	_
109-6	21100-21103	are	_
109-7	21104-21111	focused	_
109-8	21112-21114	on	_
109-9	21115-21123	networks	_
109-10	21124-21128	with	_
109-11	21129-21137	superior	_
109-12	21138-21152	classification	_
109-13	21153-21164	performance	_
109-14	21165-21168	for	_
109-15	21169-21172	the	_
109-16	21173-21183	respective	_
109-17	21184-21193	disorders	_
109-18	21193-21194	.	_

#Text=In this context, we would like to re-iterate that we did not attempt to train any classifier to distinguish SCZ from PD patients, since the two samples differed substantially from each other in various confounding factors such as age, gender distribution, and within-scanner movement.
110-1	21195-21197	In	_
110-2	21198-21202	this	_
110-3	21203-21210	context	_
110-4	21210-21211	,	_
110-5	21212-21214	we	_
110-6	21215-21220	would	_
110-7	21221-21225	like	_
110-8	21226-21228	to	_
110-9	21229-21239	re-iterate	_
110-10	21240-21244	that	_
110-11	21245-21247	we	_
110-12	21248-21251	did	_
110-13	21252-21255	not	_
110-14	21256-21263	attempt	_
110-15	21264-21266	to	_
110-16	21267-21272	train	_
110-17	21273-21276	any	_
110-18	21277-21287	classifier	_
110-19	21288-21290	to	_
110-20	21291-21302	distinguish	_
110-21	21303-21306	SCZ	_
110-22	21307-21311	from	_
110-23	21312-21314	PD	_
110-24	21315-21323	patients	_
110-25	21323-21324	,	_
110-26	21325-21330	since	_
110-27	21331-21334	the	_
110-28	21335-21338	two	_
110-29	21339-21346	samples	_
110-30	21347-21355	differed	_
110-31	21356-21369	substantially	_
110-32	21370-21374	from	_
110-33	21375-21379	each	_
110-34	21380-21385	other	_
110-35	21386-21388	in	_
110-36	21389-21396	various	_
110-37	21397-21408	confounding	_
110-38	21409-21416	factors	_
110-39	21417-21421	such	_
110-40	21422-21424	as	_
110-41	21425-21428	age	_
110-42	21428-21429	,	_
110-43	21430-21436	gender	_
110-44	21437-21449	distribution	_
110-45	21449-21450	,	_
110-46	21451-21454	and	_
110-47	21455-21469	within-scanner	_
110-48	21470-21478	movement	_
110-49	21478-21479	.	_

#Text=For SCZ, the emotional scene and face processing network (EmoSF; Acc. = 72%; AUC = 0.79) as well as the networks for empathic processing (Empathy; Acc. = 71%; AUC = 0.78) and cognitive action-control (CogAC; Acc. = 68%; AUC = 0.69) distinguished patients most accurately from their HCs.
111-1	21480-21483	For	_
111-2	21484-21487	SCZ	_
111-3	21487-21488	,	_
111-4	21489-21492	the	_
111-5	21493-21502	emotional	_
111-6	21503-21508	scene	_
111-7	21509-21512	and	_
111-8	21513-21517	face	_
111-9	21518-21528	processing	_
111-10	21529-21536	network	_
111-11	21537-21538	(	_
111-12	21538-21543	EmoSF	_
111-13	21543-21544	;	_
111-14	21545-21548	Acc	_
111-15	21548-21549	.	_
111-16	21550-21551	=	_
111-17	21552-21555	72%	_
111-18	21555-21556	;	_
111-19	21557-21560	AUC	_
111-20	21561-21562	=	_
111-21	21563-21567	0.79	_
111-22	21567-21568	)	_
111-23	21569-21571	as	_
111-24	21572-21576	well	_
111-25	21577-21579	as	_
111-26	21580-21583	the	_
111-27	21584-21592	networks	_
111-28	21593-21596	for	_
111-29	21597-21605	empathic	_
111-30	21606-21616	processing	_
111-31	21617-21618	(	_
111-32	21618-21625	Empathy	_
111-33	21625-21626	;	_
111-34	21627-21630	Acc	_
111-35	21630-21631	.	_
111-36	21632-21633	=	_
111-37	21634-21637	71%	_
111-38	21637-21638	;	_
111-39	21639-21642	AUC	_
111-40	21643-21644	=	_
111-41	21645-21649	0.78	_
111-42	21649-21650	)	_
111-43	21651-21654	and	_
111-44	21655-21664	cognitive	_
111-45	21665-21679	action-control	_
111-46	21680-21681	(	_
111-47	21681-21686	CogAC	_
111-48	21686-21687	;	_
111-49	21688-21691	Acc	_
111-50	21691-21692	.	_
111-51	21693-21694	=	_
111-52	21695-21698	68%	_
111-53	21698-21699	;	_
111-54	21700-21703	AUC	_
111-55	21704-21705	=	_
111-56	21706-21710	0.69	_
111-57	21710-21711	)	_
111-58	21712-21725	distinguished	_
111-59	21726-21734	patients	_
111-60	21735-21739	most	_
111-61	21740-21750	accurately	_
111-62	21751-21755	from	_
111-63	21756-21761	their	_
111-64	21762-21765	HCs	_
111-65	21765-21766	.	_

#Text=Hence these networks’ connectivity patterns may be considered to contain the highest level of information with respect to SCZ.
112-1	21767-21772	Hence	_
112-2	21773-21778	these	_
112-3	21779-21787	networks	_
112-4	21787-21788	’	_
112-5	21789-21801	connectivity	_
112-6	21802-21810	patterns	_
112-7	21811-21814	may	_
112-8	21815-21817	be	_
112-9	21818-21828	considered	_
112-10	21829-21831	to	_
112-11	21832-21839	contain	_
112-12	21840-21843	the	_
112-13	21844-21851	highest	_
112-14	21852-21857	level	_
112-15	21858-21860	of	_
112-16	21861-21872	information	_
112-17	21873-21877	with	_
112-18	21878-21885	respect	_
112-19	21886-21888	to	_
112-20	21889-21892	SCZ	_
112-21	21892-21893	.	_

#Text=The EmoSF network was significantly better in the SCZ classification compared to all other networks (p< 0.001).
113-1	21894-21897	The	_
113-2	21898-21903	EmoSF	_
113-3	21904-21911	network	_
113-4	21912-21915	was	_
113-5	21916-21929	significantly	_
113-6	21930-21936	better	_
113-7	21937-21939	in	_
113-8	21940-21943	the	_
113-9	21944-21947	SCZ	_
113-10	21948-21962	classification	_
113-11	21963-21971	compared	_
113-12	21972-21974	to	_
113-13	21975-21978	all	_
113-14	21979-21984	other	_
113-15	21985-21993	networks	_
113-16	21994-21995	(	_
113-17	21995-21996	p	_
113-18	21996-21997	<	_
113-19	21998-22003	0.001	_
113-20	22003-22004	)	_
113-21	22004-22005	.	_

#Text=For PD, the networks subserving autobiographical memory (AM; Acc. = 75%; AUC = 0.76), motor execution (Motor; Acc. = 70%; AUC = 0.77), semantic memory (SM; Acc. = 69%; AUC = 0.75), and theory-of-mind cognition (ToM; Acc. = 67%; AUC = 0.71) yielded the highest classification accuracies, that is, contained the most informative PD-related differences in RSFC.
114-1	22006-22009	For	_
114-2	22010-22012	PD	_
114-3	22012-22013	,	_
114-4	22014-22017	the	_
114-5	22018-22026	networks	_
114-6	22027-22037	subserving	_
114-7	22038-22054	autobiographical	_
114-8	22055-22061	memory	_
114-9	22062-22063	(	_
114-10	22063-22065	AM	_
114-11	22065-22066	;	_
114-12	22067-22070	Acc	_
114-13	22070-22071	.	_
114-14	22072-22073	=	_
114-15	22074-22077	75%	_
114-16	22077-22078	;	_
114-17	22079-22082	AUC	_
114-18	22083-22084	=	_
114-19	22085-22089	0.76	_
114-20	22089-22090	)	_
114-21	22090-22091	,	_
114-22	22092-22097	motor	_
114-23	22098-22107	execution	_
114-24	22108-22109	(	_
114-25	22109-22114	Motor	_
114-26	22114-22115	;	_
114-27	22116-22119	Acc	_
114-28	22119-22120	.	_
114-29	22121-22122	=	_
114-30	22123-22126	70%	_
114-31	22126-22127	;	_
114-32	22128-22131	AUC	_
114-33	22132-22133	=	_
114-34	22134-22138	0.77	_
114-35	22138-22139	)	_
114-36	22139-22140	,	_
114-37	22141-22149	semantic	_
114-38	22150-22156	memory	_
114-39	22157-22158	(	_
114-40	22158-22160	SM	_
114-41	22160-22161	;	_
114-42	22162-22165	Acc	_
114-43	22165-22166	.	_
114-44	22167-22168	=	_
114-45	22169-22172	69%	_
114-46	22172-22173	;	_
114-47	22174-22177	AUC	_
114-48	22178-22179	=	_
114-49	22180-22184	0.75	_
114-50	22184-22185	)	_
114-51	22185-22186	,	_
114-52	22187-22190	and	_
114-53	22191-22205	theory-of-mind	_
114-54	22206-22215	cognition	_
114-55	22216-22217	(	_
114-56	22217-22220	ToM	_
114-57	22220-22221	;	_
114-58	22222-22225	Acc	_
114-59	22225-22226	.	_
114-60	22227-22228	=	_
114-61	22229-22232	67%	_
114-62	22232-22233	;	_
114-63	22234-22237	AUC	_
114-64	22238-22239	=	_
114-65	22240-22244	0.71	_
114-66	22244-22245	)	_
114-67	22246-22253	yielded	_
114-68	22254-22257	the	_
114-69	22258-22265	highest	_
114-70	22266-22280	classification	_
114-71	22281-22291	accuracies	_
114-72	22291-22292	,	_
114-73	22293-22297	that	_
114-74	22298-22300	is	_
114-75	22300-22301	,	_
114-76	22302-22311	contained	_
114-77	22312-22315	the	_
114-78	22316-22320	most	_
114-79	22321-22332	informative	_
114-80	22333-22343	PD-related	_
114-81	22344-22355	differences	_
114-82	22356-22358	in	_
114-83	22359-22363	RSFC	_
114-84	22363-22364	.	_

#Text=The AM network was significantly better in the PD classification compared to all other networks (p< 0.001).
115-1	22365-22368	The	_
115-2	22369-22371	AM	_
115-3	22372-22379	network	_
115-4	22380-22383	was	_
115-5	22384-22397	significantly	_
115-6	22398-22404	better	_
115-7	22405-22407	in	_
115-8	22408-22411	the	_
115-9	22412-22414	PD	_
115-10	22415-22429	classification	_
115-11	22430-22438	compared	_
115-12	22439-22441	to	_
115-13	22442-22445	all	_
115-14	22446-22451	other	_
115-15	22452-22460	networks	_
115-16	22461-22462	(	_
115-17	22462-22463	p	_
115-18	22463-22464	<	_
115-19	22465-22470	0.001	_
115-20	22470-22471	)	_
115-21	22471-22472	.	_

#Text=All Network comparison results within the patient groups are summarized in Table SV and SVI.
116-1	22473-22476	All	_
116-2	22477-22484	Network	_
116-3	22485-22495	comparison	_
116-4	22496-22503	results	_
116-5	22504-22510	within	_
116-6	22511-22514	the	_
116-7	22515-22522	patient	_
116-8	22523-22529	groups	_
116-9	22530-22533	are	_
116-10	22534-22544	summarized	_
116-11	22545-22547	in	_
116-12	22548-22553	Table	_
116-13	22554-22556	SV	_
116-14	22557-22560	and	_
116-15	22561-22564	SVI	_
116-16	22564-22565	.	_

#Text=The between-network comparison of classification performance with respect to SCZ and PD revealed that the networks discriminating either disorder from their respective controls were highly specific (Figure 2B,C), indicating that these networks carry differential amounts of information regarding SCZ and PD, respectively.
117-1	22566-22569	The	_
117-2	22570-22585	between-network	_
117-3	22586-22596	comparison	_
117-4	22597-22599	of	_
117-5	22600-22614	classification	_
117-6	22615-22626	performance	_
117-7	22627-22631	with	_
117-8	22632-22639	respect	_
117-9	22640-22642	to	_
117-10	22643-22646	SCZ	_
117-11	22647-22650	and	_
117-12	22651-22653	PD	_
117-13	22654-22662	revealed	_
117-14	22663-22667	that	_
117-15	22668-22671	the	_
117-16	22672-22680	networks	_
117-17	22681-22695	discriminating	_
117-18	22696-22702	either	_
117-19	22703-22711	disorder	_
117-20	22712-22716	from	_
117-21	22717-22722	their	_
117-22	22723-22733	respective	_
117-23	22734-22742	controls	_
117-24	22743-22747	were	_
117-25	22748-22754	highly	_
117-26	22755-22763	specific	_
117-27	22764-22765	(	_
117-28	22765-22771	Figure	_
117-29	22772-22774	2B	_
117-30	22774-22775	,	_
117-31	22775-22776	C	_
117-32	22776-22777	)	_
117-33	22777-22778	,	_
117-34	22779-22789	indicating	_
117-35	22790-22794	that	_
117-36	22795-22800	these	_
117-37	22801-22809	networks	_
117-38	22810-22815	carry	_
117-39	22816-22828	differential	_
117-40	22829-22836	amounts	_
117-41	22837-22839	of	_
117-42	22840-22851	information	_
117-43	22852-22861	regarding	_
117-44	22862-22865	SCZ	_
117-45	22866-22869	and	_
117-46	22870-22872	PD	_
117-47	22872-22873	,	_
117-48	22874-22886	respectively	_
117-49	22886-22887	.	_

#Text=In particular, both EmoSF and Empathy networks showed the best performance at distinguishing SCZ patients from HCs (EmoSF: z = 5.9; Empathy: z = 5.5) but were notably worse at discriminating PD patients from their HCs (EmoSF: z = 3.2; Empathy: z = 3.2).
118-1	22888-22890	In	_
118-2	22891-22901	particular	_
118-3	22901-22902	,	_
118-4	22903-22907	both	_
118-5	22908-22913	EmoSF	_
118-6	22914-22917	and	_
118-7	22918-22925	Empathy	_
118-8	22926-22934	networks	_
118-9	22935-22941	showed	_
118-10	22942-22945	the	_
118-11	22946-22950	best	_
118-12	22951-22962	performance	_
118-13	22963-22965	at	_
118-14	22966-22980	distinguishing	_
118-15	22981-22984	SCZ	_
118-16	22985-22993	patients	_
118-17	22994-22998	from	_
118-18	22999-23002	HCs	_
118-19	23003-23004	(	_
118-20	23004-23009	EmoSF	_
118-21	23009-23010	:	_
118-22	23011-23012	z	_
118-23	23013-23014	=	_
118-24	23015-23018	5.9	_
118-25	23018-23019	;	_
118-26	23020-23027	Empathy	_
118-27	23027-23028	:	_
118-28	23029-23030	z	_
118-29	23031-23032	=	_
118-30	23033-23036	5.5	_
118-31	23036-23037	)	_
118-32	23038-23041	but	_
118-33	23042-23046	were	_
118-34	23047-23054	notably	_
118-35	23055-23060	worse	_
118-36	23061-23063	at	_
118-37	23064-23078	discriminating	_
118-38	23079-23081	PD	_
118-39	23082-23090	patients	_
118-40	23091-23095	from	_
118-41	23096-23101	their	_
118-42	23102-23105	HCs	_
118-43	23106-23107	(	_
118-44	23107-23112	EmoSF	_
118-45	23112-23113	:	_
118-46	23114-23115	z	_
118-47	23116-23117	=	_
118-48	23118-23121	3.2	_
118-49	23121-23122	;	_
118-50	23123-23130	Empathy	_
118-51	23130-23131	:	_
118-52	23132-23133	z	_
118-53	23134-23135	=	_
118-54	23136-23139	3.2	_
118-55	23139-23140	)	_
118-56	23140-23141	.	_

#Text=Similarly, the CogAC network exhibited high accuracy at classifying SCZ patients and their respective HCs (z = 4.7) but inferior performance at distinguishing PD patients from their HCs (z = 2.7).
119-1	23142-23151	Similarly	_
119-2	23151-23152	,	_
119-3	23153-23156	the	_
119-4	23157-23162	CogAC	_
119-5	23163-23170	network	_
119-6	23171-23180	exhibited	_
119-7	23181-23185	high	_
119-8	23186-23194	accuracy	_
119-9	23195-23197	at	_
119-10	23198-23209	classifying	_
119-11	23210-23213	SCZ	_
119-12	23214-23222	patients	_
119-13	23223-23226	and	_
119-14	23227-23232	their	_
119-15	23233-23243	respective	_
119-16	23244-23247	HCs	_
119-17	23248-23249	(	_
119-18	23249-23250	z	_
119-19	23251-23252	=	_
119-20	23253-23256	4.7	_
119-21	23256-23257	)	_
119-22	23258-23261	but	_
119-23	23262-23270	inferior	_
119-24	23271-23282	performance	_
119-25	23283-23285	at	_
119-26	23286-23300	distinguishing	_
119-27	23301-23303	PD	_
119-28	23304-23312	patients	_
119-29	23313-23317	from	_
119-30	23318-23323	their	_
119-31	23324-23327	HCs	_
119-32	23328-23329	(	_
119-33	23329-23330	z	_
119-34	23331-23332	=	_
119-35	23333-23336	2.7	_
119-36	23336-23337	)	_
119-37	23337-23338	.	_

#Text=In turn, the motor network very well classified PD patients and their HCs (z = 5) but was remarkably ineffective at classifying SCZ patients and their HCs (z = 2.9).
120-1	23339-23341	In	_
120-2	23342-23346	turn	_
120-3	23346-23347	,	_
120-4	23348-23351	the	_
120-5	23352-23357	motor	_
120-6	23358-23365	network	_
120-7	23366-23370	very	_
120-8	23371-23375	well	_
120-9	23376-23386	classified	_
120-10	23387-23389	PD	_
120-11	23390-23398	patients	_
120-12	23399-23402	and	_
120-13	23403-23408	their	_
120-14	23409-23412	HCs	_
120-15	23413-23414	(	_
120-16	23414-23415	z	_
120-17	23416-23417	=	_
120-18	23418-23419	5	_
120-19	23419-23420	)	_
120-20	23421-23424	but	_
120-21	23425-23428	was	_
120-22	23429-23439	remarkably	_
120-23	23440-23451	ineffective	_
120-24	23452-23454	at	_
120-25	23455-23466	classifying	_
120-26	23467-23470	SCZ	_
120-27	23471-23479	patients	_
120-28	23480-23483	and	_
120-29	23484-23489	their	_
120-30	23490-23493	HCs	_
120-31	23494-23495	(	_
120-32	23495-23496	z	_
120-33	23497-23498	=	_
120-34	23499-23502	2.9	_
120-35	23502-23503	)	_
120-36	23503-23504	.	_

#Text=Likewise, the AM and SM networks achieved high accuracies in classifying PD patients and controls (AM: z = 6.3; SM: z = 4.5) but performed much less well when classifying SCZ patients and controls (AM: z = 3.2; SM: z = 2.5).
121-1	23505-23513	Likewise	_
121-2	23513-23514	,	_
121-3	23515-23518	the	_
121-4	23519-23521	AM	_
121-5	23522-23525	and	_
121-6	23526-23528	SM	_
121-7	23529-23537	networks	_
121-8	23538-23546	achieved	_
121-9	23547-23551	high	_
121-10	23552-23562	accuracies	_
121-11	23563-23565	in	_
121-12	23566-23577	classifying	_
121-13	23578-23580	PD	_
121-14	23581-23589	patients	_
121-15	23590-23593	and	_
121-16	23594-23602	controls	_
121-17	23603-23604	(	_
121-18	23604-23606	AM	_
121-19	23606-23607	:	_
121-20	23608-23609	z	_
121-21	23610-23611	=	_
121-22	23612-23615	6.3	_
121-23	23615-23616	;	_
121-24	23617-23619	SM	_
121-25	23619-23620	:	_
121-26	23621-23622	z	_
121-27	23623-23624	=	_
121-28	23625-23628	4.5	_
121-29	23628-23629	)	_
121-30	23630-23633	but	_
121-31	23634-23643	performed	_
121-32	23644-23648	much	_
121-33	23649-23653	less	_
121-34	23654-23658	well	_
121-35	23659-23663	when	_
121-36	23664-23675	classifying	_
121-37	23676-23679	SCZ	_
121-38	23680-23688	patients	_
121-39	23689-23692	and	_
121-40	23693-23701	controls	_
121-41	23702-23703	(	_
121-42	23703-23705	AM	_
121-43	23705-23706	:	_
121-44	23707-23708	z	_
121-45	23709-23710	=	_
121-46	23711-23714	3.2	_
121-47	23714-23715	;	_
121-48	23716-23718	SM	_
121-49	23718-23719	:	_
121-50	23720-23721	z	_
121-51	23722-23723	=	_
121-52	23724-23727	2.5	_
121-53	23727-23728	)	_
121-54	23728-23729	.	_

#Text=Networks which were most accurate in distinguishing SCZ from HCs (EmoSF, Empathy and CogAC) exhibited significant better classification performance in the SCZ group compared to the PD group (EmoSF: p < 0.001; Empathy: p < 0.001; CogAC: p < 0.001; Table SVII).
122-1	23730-23738	Networks	_
122-2	23739-23744	which	_
122-3	23745-23749	were	_
122-4	23750-23754	most	_
122-5	23755-23763	accurate	_
122-6	23764-23766	in	_
122-7	23767-23781	distinguishing	_
122-8	23782-23785	SCZ	_
122-9	23786-23790	from	_
122-10	23791-23794	HCs	_
122-11	23795-23796	(	_
122-12	23796-23801	EmoSF	_
122-13	23801-23802	,	_
122-14	23803-23810	Empathy	_
122-15	23811-23814	and	_
122-16	23815-23820	CogAC	_
122-17	23820-23821	)	_
122-18	23822-23831	exhibited	_
122-19	23832-23843	significant	_
122-20	23844-23850	better	_
122-21	23851-23865	classification	_
122-22	23866-23877	performance	_
122-23	23878-23880	in	_
122-24	23881-23884	the	_
122-25	23885-23888	SCZ	_
122-26	23889-23894	group	_
122-27	23895-23903	compared	_
122-28	23904-23906	to	_
122-29	23907-23910	the	_
122-30	23911-23913	PD	_
122-31	23914-23919	group	_
122-32	23920-23921	(	_
122-33	23921-23926	EmoSF	_
122-34	23926-23927	:	_
122-35	23928-23929	p	_
122-36	23930-23931	<	_
122-37	23932-23937	0.001	_
122-38	23937-23938	;	_
122-39	23939-23946	Empathy	_
122-40	23946-23947	:	_
122-41	23948-23949	p	_
122-42	23950-23951	<	_
122-43	23952-23957	0.001	_
122-44	23957-23958	;	_
122-45	23959-23964	CogAC	_
122-46	23964-23965	:	_
122-47	23966-23967	p	_
122-48	23968-23969	<	_
122-49	23970-23975	0.001	_
122-50	23975-23976	;	_
122-51	23977-23982	Table	_
122-52	23983-23987	SVII	_
122-53	23987-23988	)	_
122-54	23988-23989	.	_

#Text=Likewise, networks which performed best at discriminating PD patients from HCs (AM, Motor, SM and ToM) showed significant better classification performance in the PD group compared to the SCZ group (AM: p < 0.001; Motor: p < 0.001; SM: p < 0.001; ToM: p < 0.001; Table SVII).
123-1	23990-23998	Likewise	_
123-2	23998-23999	,	_
123-3	24000-24008	networks	_
123-4	24009-24014	which	_
123-5	24015-24024	performed	_
123-6	24025-24029	best	_
123-7	24030-24032	at	_
123-8	24033-24047	discriminating	_
123-9	24048-24050	PD	_
123-10	24051-24059	patients	_
123-11	24060-24064	from	_
123-12	24065-24068	HCs	_
123-13	24069-24070	(	_
123-14	24070-24072	AM	_
123-15	24072-24073	,	_
123-16	24074-24079	Motor	_
123-17	24079-24080	,	_
123-18	24081-24083	SM	_
123-19	24084-24087	and	_
123-20	24088-24091	ToM	_
123-21	24091-24092	)	_
123-22	24093-24099	showed	_
123-23	24100-24111	significant	_
123-24	24112-24118	better	_
123-25	24119-24133	classification	_
123-26	24134-24145	performance	_
123-27	24146-24148	in	_
123-28	24149-24152	the	_
123-29	24153-24155	PD	_
123-30	24156-24161	group	_
123-31	24162-24170	compared	_
123-32	24171-24173	to	_
123-33	24174-24177	the	_
123-34	24178-24181	SCZ	_
123-35	24182-24187	group	_
123-36	24188-24189	(	_
123-37	24189-24191	AM	_
123-38	24191-24192	:	_
123-39	24193-24194	p	_
123-40	24195-24196	<	_
123-41	24197-24202	0.001	_
123-42	24202-24203	;	_
123-43	24204-24209	Motor	_
123-44	24209-24210	:	_
123-45	24211-24212	p	_
123-46	24213-24214	<	_
123-47	24215-24220	0.001	_
123-48	24220-24221	;	_
123-49	24222-24224	SM	_
123-50	24224-24225	:	_
123-51	24226-24227	p	_
123-52	24228-24229	<	_
123-53	24230-24235	0.001	_
123-54	24235-24236	;	_
123-55	24237-24240	ToM	_
123-56	24240-24241	:	_
123-57	24242-24243	p	_
123-58	24244-24245	<	_
123-59	24246-24251	0.001	_
123-60	24251-24252	;	_
123-61	24253-24258	Table	_
123-62	24259-24263	SVII	_
123-63	24263-24264	)	_
123-64	24264-24265	.	_

#Text=This differential picture markedly contrasted with the results obtained for the classification between old and young subjects.
124-1	24266-24270	This	_
124-2	24271-24283	differential	_
124-3	24284-24291	picture	_
124-4	24292-24300	markedly	_
124-5	24301-24311	contrasted	_
124-6	24312-24316	with	_
124-7	24317-24320	the	_
124-8	24321-24328	results	_
124-9	24329-24337	obtained	_
124-10	24338-24341	for	_
124-11	24342-24345	the	_
124-12	24346-24360	classification	_
124-13	24361-24368	between	_
124-14	24369-24372	old	_
124-15	24373-24376	and	_
124-16	24377-24382	young	_
124-17	24383-24391	subjects	_
124-18	24391-24392	.	_

#Text=In the aging sample, each network yielded accuracies ≥ 73% (see Table SVIII for network comparison results within NA), significantly outperforming every classification obtained in the SCZ or PD samples (p < 0.001; see Figure 2A, Figure S1, Table III, Table SIX and Table SX).
125-1	24393-24395	In	_
125-2	24396-24399	the	_
125-3	24400-24405	aging	_
125-4	24406-24412	sample	_
125-5	24412-24413	,	_
125-6	24414-24418	each	_
125-7	24419-24426	network	_
125-8	24427-24434	yielded	_
125-9	24435-24445	accuracies	_
125-10	24446-24447	≥	_
125-11	24448-24451	73%	_
125-12	24452-24453	(	_
125-13	24453-24456	see	_
125-14	24457-24462	Table	_
125-15	24463-24468	SVIII	_
125-16	24469-24472	for	_
125-17	24473-24480	network	_
125-18	24481-24491	comparison	_
125-19	24492-24499	results	_
125-20	24500-24506	within	_
125-21	24507-24509	NA	_
125-22	24509-24510	)	_
125-23	24510-24511	,	_
125-24	24512-24525	significantly	_
125-25	24526-24539	outperforming	_
125-26	24540-24545	every	_
125-27	24546-24560	classification	_
125-28	24561-24569	obtained	_
125-29	24570-24572	in	_
125-30	24573-24576	the	_
125-31	24577-24580	SCZ	_
125-32	24581-24583	or	_
125-33	24584-24586	PD	_
125-34	24587-24594	samples	_
125-35	24595-24596	(	_
125-36	24596-24597	p	_
125-37	24598-24599	<	_
125-38	24600-24605	0.001	_
125-39	24605-24606	;	_
125-40	24607-24610	see	_
125-41	24611-24617	Figure	_
125-42	24618-24620	2A	_
125-43	24620-24621	,	_
125-44	24622-24628	Figure	_
125-45	24629-24631	S1	_
125-46	24631-24632	,	_
125-47	24633-24638	Table	_
125-48	24639-24642	III	_
125-49	24642-24643	,	_
125-50	24644-24649	Table	_
125-51	24650-24653	SIX	_
125-52	24654-24657	and	_
125-53	24658-24663	Table	_
125-54	24664-24666	SX	_
125-55	24666-24667	)	_
125-56	24667-24668	.	_

#Text=In particular, for each network the accuracy for classifying a previously unseen participant as young or old was about 10% higher than any clinical classification based on the same network.
126-1	24669-24671	In	_
126-2	24672-24682	particular	_
126-3	24682-24683	,	_
126-4	24684-24687	for	_
126-5	24688-24692	each	_
126-6	24693-24700	network	_
126-7	24701-24704	the	_
126-8	24705-24713	accuracy	_
126-9	24714-24717	for	_
126-10	24718-24729	classifying	_
126-11	24730-24731	a	_
126-12	24732-24742	previously	_
126-13	24743-24749	unseen	_
126-14	24750-24761	participant	_
126-15	24762-24764	as	_
126-16	24765-24770	young	_
126-17	24771-24773	or	_
126-18	24774-24777	old	_
126-19	24778-24781	was	_
126-20	24782-24787	about	_
126-21	24788-24791	10%	_
126-22	24792-24798	higher	_
126-23	24799-24803	than	_
126-24	24804-24807	any	_
126-25	24808-24816	clinical	_
126-26	24817-24831	classification	_
126-27	24832-24837	based	_
126-28	24838-24840	on	_
126-29	24841-24844	the	_
126-30	24845-24849	same	_
126-31	24850-24857	network	_
126-32	24857-24858	.	_

#Text=Additionally, the comparison of all 3 separate group classifications revealed that the variance of the classification accuracies over the 25 replications of the outer loop was distinctively lower for the classification of age, as compared with classifying the clinical status.
127-1	24859-24871	Additionally	_
127-2	24871-24872	,	_
127-3	24873-24876	the	_
127-4	24877-24887	comparison	_
127-5	24888-24890	of	_
127-6	24891-24894	all	_
127-7	24895-24896	3	_
127-8	24897-24905	separate	_
127-9	24906-24911	group	_
127-10	24912-24927	classifications	_
127-11	24928-24936	revealed	_
127-12	24937-24941	that	_
127-13	24942-24945	the	_
127-14	24946-24954	variance	_
127-15	24955-24957	of	_
127-16	24958-24961	the	_
127-17	24962-24976	classification	_
127-18	24977-24987	accuracies	_
127-19	24988-24992	over	_
127-20	24993-24996	the	_
127-21	24997-24999	25	_
127-22	25000-25012	replications	_
127-23	25013-25015	of	_
127-24	25016-25019	the	_
127-25	25020-25025	outer	_
127-26	25026-25030	loop	_
127-27	25031-25034	was	_
127-28	25035-25048	distinctively	_
127-29	25049-25054	lower	_
127-30	25055-25058	for	_
127-31	25059-25062	the	_
127-32	25063-25077	classification	_
127-33	25078-25080	of	_
127-34	25081-25084	age	_
127-35	25084-25085	,	_
127-36	25086-25088	as	_
127-37	25089-25097	compared	_
127-38	25098-25102	with	_
127-39	25103-25114	classifying	_
127-40	25115-25118	the	_
127-41	25119-25127	clinical	_
127-42	25128-25134	status	_
127-43	25134-25135	.	_

#Text=(Figure S2).
#Text=4.
128-1	25136-25137	(	_
128-2	25137-25143	Figure	_
128-3	25144-25146	S2	_
128-4	25146-25147	)	_
128-5	25147-25148	.	_
128-6	25149-25150	4	_
128-7	25150-25151	.	_

#Text=DISCUSSION
#Text=We assessed whether RSFC patterns in a diverse set of functionally defined brain networks allowed for a classification of patients with SCZ or PD or healthy older adults on the one hand, and their respective healthy or young controls on the other.
129-1	25152-25162	DISCUSSION	_
129-2	25163-25165	We	_
129-3	25166-25174	assessed	_
129-4	25175-25182	whether	_
129-5	25183-25187	RSFC	_
129-6	25188-25196	patterns	_
129-7	25197-25199	in	_
129-8	25200-25201	a	_
129-9	25202-25209	diverse	_
129-10	25210-25213	set	_
129-11	25214-25216	of	_
129-12	25217-25229	functionally	_
129-13	25230-25237	defined	_
129-14	25238-25243	brain	_
129-15	25244-25252	networks	_
129-16	25253-25260	allowed	_
129-17	25261-25264	for	_
129-18	25265-25266	a	_
129-19	25267-25281	classification	_
129-20	25282-25284	of	_
129-21	25285-25293	patients	_
129-22	25294-25298	with	_
129-23	25299-25302	SCZ	_
129-24	25303-25305	or	_
129-25	25306-25308	PD	_
129-26	25309-25311	or	_
129-27	25312-25319	healthy	_
129-28	25320-25325	older	_
129-29	25326-25332	adults	_
129-30	25333-25335	on	_
129-31	25336-25339	the	_
129-32	25340-25343	one	_
129-33	25344-25348	hand	_
129-34	25348-25349	,	_
129-35	25350-25353	and	_
129-36	25354-25359	their	_
129-37	25360-25370	respective	_
129-38	25371-25378	healthy	_
129-39	25379-25381	or	_
129-40	25382-25387	young	_
129-41	25388-25396	controls	_
129-42	25397-25399	on	_
129-43	25400-25403	the	_
129-44	25404-25409	other	_
129-45	25409-25410	.	_

#Text=Thereby, we evaluated which functional system was most informative for a given condition (i.e., SCZ, PD, or higher age).
130-1	25411-25418	Thereby	_
130-2	25418-25419	,	_
130-3	25420-25422	we	_
130-4	25423-25432	evaluated	_
130-5	25433-25438	which	_
130-6	25439-25449	functional	_
130-7	25450-25456	system	_
130-8	25457-25460	was	_
130-9	25461-25465	most	_
130-10	25466-25477	informative	_
130-11	25478-25481	for	_
130-12	25482-25483	a	_
130-13	25484-25489	given	_
130-14	25490-25499	condition	_
130-15	25500-25501	(	_
130-16	25501-25504	i.e	_
130-17	25504-25505	.	_
130-18	25505-25506	,	_
130-19	25507-25510	SCZ	_
130-20	25510-25511	,	_
130-21	25512-25514	PD	_
130-22	25514-25515	,	_
130-23	25516-25518	or	_
130-24	25519-25525	higher	_
130-25	25526-25529	age	_
130-26	25529-25530	)	_
130-27	25530-25531	.	_

#Text=Conversely, our analysis also assessed the amount of information on each condition found in a given network.
131-1	25532-25542	Conversely	_
131-2	25542-25543	,	_
131-3	25544-25547	our	_
131-4	25548-25556	analysis	_
131-5	25557-25561	also	_
131-6	25562-25570	assessed	_
131-7	25571-25574	the	_
131-8	25575-25581	amount	_
131-9	25582-25584	of	_
131-10	25585-25596	information	_
131-11	25597-25599	on	_
131-12	25600-25604	each	_
131-13	25605-25614	condition	_
131-14	25615-25620	found	_
131-15	25621-25623	in	_
131-16	25624-25625	a	_
131-17	25626-25631	given	_
131-18	25632-25639	network	_
131-19	25639-25640	.	_

#Text=Our results show in a proof-of-principle manner that networks pertaining to functions known to be affected by SCZ, PD, or aging indeed exhibited good classification performance for the respective condition.
132-1	25641-25644	Our	_
132-2	25645-25652	results	_
132-3	25653-25657	show	_
132-4	25658-25660	in	_
132-5	25661-25662	a	_
132-6	25663-25681	proof-of-principle	_
132-7	25682-25688	manner	_
132-8	25689-25693	that	_
132-9	25694-25702	networks	_
132-10	25703-25713	pertaining	_
132-11	25714-25716	to	_
132-12	25717-25726	functions	_
132-13	25727-25732	known	_
132-14	25733-25735	to	_
132-15	25736-25738	be	_
132-16	25739-25747	affected	_
132-17	25748-25750	by	_
132-18	25751-25754	SCZ	_
132-19	25754-25755	,	_
132-20	25756-25758	PD	_
132-21	25758-25759	,	_
132-22	25760-25762	or	_
132-23	25763-25768	aging	_
132-24	25769-25775	indeed	_
132-25	25776-25785	exhibited	_
132-26	25786-25790	good	_
132-27	25791-25805	classification	_
132-28	25806-25817	performance	_
132-29	25818-25821	for	_
132-30	25822-25825	the	_
132-31	25826-25836	respective	_
132-32	25837-25846	condition	_
132-33	25846-25847	.	_

#Text=Furthermore, each network’s young–old classification outperformed any disease-related classification.
133-1	25848-25859	Furthermore	_
133-2	25859-25860	,	_
133-3	25861-25865	each	_
133-4	25866-25873	network	_
133-5	25873-25874	’	_
133-6	25874-25875	s	_
133-7	25876-25885	young–old	_
133-8	25886-25900	classification	_
133-9	25901-25913	outperformed	_
133-10	25914-25917	any	_
133-11	25918-25933	disease-related	_
133-12	25934-25948	classification	_
133-13	25948-25949	.	_

#Text=This indicates that specific networks are affected by and associated with the diseases, whereas for healthy older adults RSFC appears to be altered rather globally.
#Text=4.1 Conceptual Considerations
#Text=Our study demonstrates that machine-learning techniques can be successfully used to assess whether RSFC in functional systems known to be affected in SCZ, PD or advanced age exhibits high classification capacity for the respective condition.
134-1	25950-25954	This	_
134-2	25955-25964	indicates	_
134-3	25965-25969	that	_
134-4	25970-25978	specific	_
134-5	25979-25987	networks	_
134-6	25988-25991	are	_
134-7	25992-26000	affected	_
134-8	26001-26003	by	_
134-9	26004-26007	and	_
134-10	26008-26018	associated	_
134-11	26019-26023	with	_
134-12	26024-26027	the	_
134-13	26028-26036	diseases	_
134-14	26036-26037	,	_
134-15	26038-26045	whereas	_
134-16	26046-26049	for	_
134-17	26050-26057	healthy	_
134-18	26058-26063	older	_
134-19	26064-26070	adults	_
134-20	26071-26075	RSFC	_
134-21	26076-26083	appears	_
134-22	26084-26086	to	_
134-23	26087-26089	be	_
134-24	26090-26097	altered	_
134-25	26098-26104	rather	_
134-26	26105-26113	globally	_
134-27	26113-26114	.	_
134-28	26115-26118	4.1	_
134-29	26119-26129	Conceptual	_
134-30	26130-26144	Considerations	_
134-31	26145-26148	Our	_
134-32	26149-26154	study	_
134-33	26155-26167	demonstrates	_
134-34	26168-26172	that	_
134-35	26173-26189	machine-learning	_
134-36	26190-26200	techniques	_
134-37	26201-26204	can	_
134-38	26205-26207	be	_
134-39	26208-26220	successfully	_
134-40	26221-26225	used	_
134-41	26226-26228	to	_
134-42	26229-26235	assess	_
134-43	26236-26243	whether	_
134-44	26244-26248	RSFC	_
134-45	26249-26251	in	_
134-46	26252-26262	functional	_
134-47	26263-26270	systems	_
134-48	26271-26276	known	_
134-49	26277-26279	to	_
134-50	26280-26282	be	_
134-51	26283-26291	affected	_
134-52	26292-26294	in	_
134-53	26295-26298	SCZ	_
134-54	26298-26299	,	_
134-55	26300-26302	PD	_
134-56	26303-26305	or	_
134-57	26306-26314	advanced	_
134-58	26315-26318	age	_
134-59	26319-26327	exhibits	_
134-60	26328-26332	high	_
134-61	26333-26347	classification	_
134-62	26348-26356	capacity	_
134-63	26357-26360	for	_
134-64	26361-26364	the	_
134-65	26365-26375	respective	_
134-66	26376-26385	condition	_
134-67	26385-26386	.	_

#Text=Further, our approach compared the classification capacity of RSFC patterns between different functional networks and between several clinical and physiological states.
135-1	26387-26394	Further	_
135-2	26394-26395	,	_
135-3	26396-26399	our	_
135-4	26400-26408	approach	_
135-5	26409-26417	compared	_
135-6	26418-26421	the	_
135-7	26422-26436	classification	_
135-8	26437-26445	capacity	_
135-9	26446-26448	of	_
135-10	26449-26453	RSFC	_
135-11	26454-26462	patterns	_
135-12	26463-26470	between	_
135-13	26471-26480	different	_
135-14	26481-26491	functional	_
135-15	26492-26500	networks	_
135-16	26501-26504	and	_
135-17	26505-26512	between	_
135-18	26513-26520	several	_
135-19	26521-26529	clinical	_
135-20	26530-26533	and	_
135-21	26534-26547	physiological	_
135-22	26548-26554	states	_
135-23	26554-26555	.	_

#Text=Of note, for each classification, target and control groups (i.e., SCZ vs.
136-1	26556-26558	Of	_
136-2	26559-26563	note	_
136-3	26563-26564	,	_
136-4	26565-26568	for	_
136-5	26569-26573	each	_
136-6	26574-26588	classification	_
136-7	26588-26589	,	_
136-8	26590-26596	target	_
136-9	26597-26600	and	_
136-10	26601-26608	control	_
136-11	26609-26615	groups	_
136-12	26616-26617	(	_
136-13	26617-26620	i.e	_
136-14	26620-26621	.	_
136-15	26621-26622	,	_
136-16	26623-26626	SCZ	_
136-17	26627-26629	vs	_
136-18	26629-26630	.	_

#Text=HCscz, PD vs.
137-1	26631-26636	HCscz	_
137-2	26636-26637	,	_
137-3	26638-26640	PD	_
137-4	26641-26643	vs	_
137-5	26643-26644	.	_

#Text=HCPD, old vs. young) were well matched with respect to gender and – for the clinical samples – age.
138-1	26645-26649	HCPD	_
138-2	26649-26650	,	_
138-3	26651-26654	old	_
138-4	26655-26657	vs	_
138-5	26657-26658	.	_
138-6	26659-26664	young	_
138-7	26664-26665	)	_
138-8	26666-26670	were	_
138-9	26671-26675	well	_
138-10	26676-26683	matched	_
138-11	26684-26688	with	_
138-12	26689-26696	respect	_
138-13	26697-26699	to	_
138-14	26700-26706	gender	_
138-15	26707-26710	and	_
138-16	26711-26712	–	_
138-17	26713-26716	for	_
138-18	26717-26720	the	_
138-19	26721-26729	clinical	_
138-20	26730-26737	samples	_
138-21	26738-26739	–	_
138-22	26740-26743	age	_
138-23	26743-26744	.	_

#Text=In addition, RSFC variance attributable to these confounding factors or within-scanner movement were regressed out of the data before the SVM analyses.
139-1	26745-26747	In	_
139-2	26748-26756	addition	_
139-3	26756-26757	,	_
139-4	26758-26762	RSFC	_
139-5	26763-26771	variance	_
139-6	26772-26784	attributable	_
139-7	26785-26787	to	_
139-8	26788-26793	these	_
139-9	26794-26805	confounding	_
139-10	26806-26813	factors	_
139-11	26814-26816	or	_
139-12	26817-26831	within-scanner	_
139-13	26832-26840	movement	_
139-14	26841-26845	were	_
139-15	26846-26855	regressed	_
139-16	26856-26859	out	_
139-17	26860-26862	of	_
139-18	26863-26866	the	_
139-19	26867-26871	data	_
139-20	26872-26878	before	_
139-21	26879-26882	the	_
139-22	26883-26886	SVM	_
139-23	26887-26895	analyses	_
139-24	26895-26896	.	_

#Text=Therefore, these confounds were evidently heterogeneous across the three groups (SCZ, PD, NA) but should not have influenced classification accuracy within each condition.
140-1	26897-26906	Therefore	_
140-2	26906-26907	,	_
140-3	26908-26913	these	_
140-4	26914-26923	confounds	_
140-5	26924-26928	were	_
140-6	26929-26938	evidently	_
140-7	26939-26952	heterogeneous	_
140-8	26953-26959	across	_
140-9	26960-26963	the	_
140-10	26964-26969	three	_
140-11	26970-26976	groups	_
140-12	26977-26978	(	_
140-13	26978-26981	SCZ	_
140-14	26981-26982	,	_
140-15	26983-26985	PD	_
140-16	26985-26986	,	_
140-17	26987-26989	NA	_
140-18	26989-26990	)	_
140-19	26991-26994	but	_
140-20	26995-27001	should	_
140-21	27002-27005	not	_
140-22	27006-27010	have	_
140-23	27011-27021	influenced	_
140-24	27022-27036	classification	_
140-25	27037-27045	accuracy	_
140-26	27046-27052	within	_
140-27	27053-27057	each	_
140-28	27058-27067	condition	_
140-29	27067-27068	.	_

#Text=Although proper matching and state-of-the-art removal of variance related to motion (cf.), residual effects that only manifest in the multivariate pattern cannot be fully ruled out.
141-1	27069-27077	Although	_
141-2	27078-27084	proper	_
141-3	27085-27093	matching	_
141-4	27094-27097	and	_
141-5	27098-27114	state-of-the-art	_
141-6	27115-27122	removal	_
141-7	27123-27125	of	_
141-8	27126-27134	variance	_
141-9	27135-27142	related	_
141-10	27143-27145	to	_
141-11	27146-27152	motion	_
141-12	27153-27154	(	_
141-13	27154-27156	cf	_
141-14	27156-27157	.	_
141-15	27157-27158	)	_
141-16	27158-27159	,	_
141-17	27160-27168	residual	_
141-18	27169-27176	effects	_
141-19	27177-27181	that	_
141-20	27182-27186	only	_
141-21	27187-27195	manifest	_
141-22	27196-27198	in	_
141-23	27199-27202	the	_
141-24	27203-27215	multivariate	_
141-25	27216-27223	pattern	_
141-26	27224-27230	cannot	_
141-27	27231-27233	be	_
141-28	27234-27239	fully	_
141-29	27240-27245	ruled	_
141-30	27246-27249	out	_
141-31	27249-27250	.	_

#Text=However, one factor worth noting is that, for example, we observed differential classification performance across networks in the SCZ sample, largely ruling out a dominant general effect of head motion.
142-1	27251-27258	However	_
142-2	27258-27259	,	_
142-3	27260-27263	one	_
142-4	27264-27270	factor	_
142-5	27271-27276	worth	_
142-6	27277-27283	noting	_
142-7	27284-27286	is	_
142-8	27287-27291	that	_
142-9	27291-27292	,	_
142-10	27293-27296	for	_
142-11	27297-27304	example	_
142-12	27304-27305	,	_
142-13	27306-27308	we	_
142-14	27309-27317	observed	_
142-15	27318-27330	differential	_
142-16	27331-27345	classification	_
142-17	27346-27357	performance	_
142-18	27358-27364	across	_
142-19	27365-27373	networks	_
142-20	27374-27376	in	_
142-21	27377-27380	the	_
142-22	27381-27384	SCZ	_
142-23	27385-27391	sample	_
142-24	27391-27392	,	_
142-25	27393-27400	largely	_
142-26	27401-27407	ruling	_
142-27	27408-27411	out	_
142-28	27412-27413	a	_
142-29	27414-27422	dominant	_
142-30	27423-27430	general	_
142-31	27431-27437	effect	_
142-32	27438-27440	of	_
142-33	27441-27445	head	_
142-34	27446-27452	motion	_
142-35	27452-27453	.	_

#Text=Given that both groups were assessed under their regular medication, differences in classification performance may be influenced by pharmacological treatment.
143-1	27454-27459	Given	_
143-2	27460-27464	that	_
143-3	27465-27469	both	_
143-4	27470-27476	groups	_
143-5	27477-27481	were	_
143-6	27482-27490	assessed	_
143-7	27491-27496	under	_
143-8	27497-27502	their	_
143-9	27503-27510	regular	_
143-10	27511-27521	medication	_
143-11	27521-27522	,	_
143-12	27523-27534	differences	_
143-13	27535-27537	in	_
143-14	27538-27552	classification	_
143-15	27553-27564	performance	_
143-16	27565-27568	may	_
143-17	27569-27571	be	_
143-18	27572-27582	influenced	_
143-19	27583-27585	by	_
143-20	27586-27601	pharmacological	_
143-21	27602-27611	treatment	_
143-22	27611-27612	.	_

#Text=In particular, we cannot exclude that classification results of networks modulated via dopaminergic transmission (e.g. reward or motor system) might originate from interactions between disease condition and medication.
144-1	27613-27615	In	_
144-2	27616-27626	particular	_
144-3	27626-27627	,	_
144-4	27628-27630	we	_
144-5	27631-27637	cannot	_
144-6	27638-27645	exclude	_
144-7	27646-27650	that	_
144-8	27651-27665	classification	_
144-9	27666-27673	results	_
144-10	27674-27676	of	_
144-11	27677-27685	networks	_
144-12	27686-27695	modulated	_
144-13	27696-27699	via	_
144-14	27700-27712	dopaminergic	_
144-15	27713-27725	transmission	_
144-16	27726-27727	(	_
144-17	27727-27730	e.g	_
144-18	27730-27731	.	_
144-19	27732-27738	reward	_
144-20	27739-27741	or	_
144-21	27742-27747	motor	_
144-22	27748-27754	system	_
144-23	27754-27755	)	_
144-24	27756-27761	might	_
144-25	27762-27771	originate	_
144-26	27772-27776	from	_
144-27	27777-27789	interactions	_
144-28	27790-27797	between	_
144-29	27798-27805	disease	_
144-30	27806-27815	condition	_
144-31	27816-27819	and	_
144-32	27820-27830	medication	_
144-33	27830-27831	.	_

#Text=Unfortunately, however, we could not perform a more detailed assessment of the influence of medication, as the compounds, duration of treatment and doses varied considerably between subjects, with many receiving a combination of drugs.
145-1	27832-27845	Unfortunately	_
145-2	27845-27846	,	_
145-3	27847-27854	however	_
145-4	27854-27855	,	_
145-5	27856-27858	we	_
145-6	27859-27864	could	_
145-7	27865-27868	not	_
145-8	27869-27876	perform	_
145-9	27877-27878	a	_
145-10	27879-27883	more	_
145-11	27884-27892	detailed	_
145-12	27893-27903	assessment	_
145-13	27904-27906	of	_
145-14	27907-27910	the	_
145-15	27911-27920	influence	_
145-16	27921-27923	of	_
145-17	27924-27934	medication	_
145-18	27934-27935	,	_
145-19	27936-27938	as	_
145-20	27939-27942	the	_
145-21	27943-27952	compounds	_
145-22	27952-27953	,	_
145-23	27954-27962	duration	_
145-24	27963-27965	of	_
145-25	27966-27975	treatment	_
145-26	27976-27979	and	_
145-27	27980-27985	doses	_
145-28	27986-27992	varied	_
145-29	27993-28005	considerably	_
145-30	28006-28013	between	_
145-31	28014-28022	subjects	_
145-32	28022-28023	,	_
145-33	28024-28028	with	_
145-34	28029-28033	many	_
145-35	28034-28043	receiving	_
145-36	28044-28045	a	_
145-37	28046-28057	combination	_
145-38	28058-28060	of	_
145-39	28061-28066	drugs	_
145-40	28066-28067	.	_

#Text=When comparing classification performance to previous work based on whole-brain functional connectomes (cf.), we note that our approach yielded higher functional specificity, allowing inference on the amount of disease-specific information in well-defined functional systems.
146-1	28068-28072	When	_
146-2	28073-28082	comparing	_
146-3	28083-28097	classification	_
146-4	28098-28109	performance	_
146-5	28110-28112	to	_
146-6	28113-28121	previous	_
146-7	28122-28126	work	_
146-8	28127-28132	based	_
146-9	28133-28135	on	_
146-10	28136-28147	whole-brain	_
146-11	28148-28158	functional	_
146-12	28159-28170	connectomes	_
146-13	28171-28172	(	_
146-14	28172-28174	cf	_
146-15	28174-28175	.	_
146-16	28175-28176	)	_
146-17	28176-28177	,	_
146-18	28178-28180	we	_
146-19	28181-28185	note	_
146-20	28186-28190	that	_
146-21	28191-28194	our	_
146-22	28195-28203	approach	_
146-23	28204-28211	yielded	_
146-24	28212-28218	higher	_
146-25	28219-28229	functional	_
146-26	28230-28241	specificity	_
146-27	28241-28242	,	_
146-28	28243-28251	allowing	_
146-29	28252-28261	inference	_
146-30	28262-28264	on	_
146-31	28265-28268	the	_
146-32	28269-28275	amount	_
146-33	28276-28278	of	_
146-34	28279-28295	disease-specific	_
146-35	28296-28307	information	_
146-36	28308-28310	in	_
146-37	28311-28323	well-defined	_
146-38	28324-28334	functional	_
146-39	28335-28342	systems	_
146-40	28342-28343	.	_

#Text=We acknowledge the fact that even though most of the classifications well exceeded chance level, the achieved network-based classification accuracies are not strong enough for successful connectivity-based single-subject disease diagnosis.
147-1	28344-28346	We	_
147-2	28347-28358	acknowledge	_
147-3	28359-28362	the	_
147-4	28363-28367	fact	_
147-5	28368-28372	that	_
147-6	28373-28377	even	_
147-7	28378-28384	though	_
147-8	28385-28389	most	_
147-9	28390-28392	of	_
147-10	28393-28396	the	_
147-11	28397-28412	classifications	_
147-12	28413-28417	well	_
147-13	28418-28426	exceeded	_
147-14	28427-28433	chance	_
147-15	28434-28439	level	_
147-16	28439-28440	,	_
147-17	28441-28444	the	_
147-18	28445-28453	achieved	_
147-19	28454-28467	network-based	_
147-20	28468-28482	classification	_
147-21	28483-28493	accuracies	_
147-22	28494-28497	are	_
147-23	28498-28501	not	_
147-24	28502-28508	strong	_
147-25	28509-28515	enough	_
147-26	28516-28519	for	_
147-27	28520-28530	successful	_
147-28	28531-28549	connectivity-based	_
147-29	28550-28564	single-subject	_
147-30	28565-28572	disease	_
147-31	28573-28582	diagnosis	_
147-32	28582-28583	.	_

#Text=Still, our “sparse” approach achieved classification accuracies comparable to those reported in previous whole-brain studies, whose feature space obviously was substantially larger than ours.
148-1	28584-28589	Still	_
148-2	28589-28590	,	_
148-3	28591-28594	our	_
148-4	28595-28596	“	_
148-5	28596-28602	sparse	_
148-6	28602-28603	”	_
148-7	28604-28612	approach	_
148-8	28613-28621	achieved	_
148-9	28622-28636	classification	_
148-10	28637-28647	accuracies	_
148-11	28648-28658	comparable	_
148-12	28659-28661	to	_
148-13	28662-28667	those	_
148-14	28668-28676	reported	_
148-15	28677-28679	in	_
148-16	28680-28688	previous	_
148-17	28689-28700	whole-brain	_
148-18	28701-28708	studies	_
148-19	28708-28709	,	_
148-20	28710-28715	whose	_
148-21	28716-28723	feature	_
148-22	28724-28729	space	_
148-23	28730-28739	obviously	_
148-24	28740-28743	was	_
148-25	28744-28757	substantially	_
148-26	28758-28764	larger	_
148-27	28765-28769	than	_
148-28	28770-28774	ours	_
148-29	28774-28775	.	_

#Text=This is particularly noteworthy given that two further aspects besides feature space could be expected to decrease classifier performance in our study: First, all of our three groups were based on relatively large samples that were combined from two different measurement sites and hence should be more heterogeneous than usual.
149-1	28776-28780	This	_
149-2	28781-28783	is	_
149-3	28784-28796	particularly	_
149-4	28797-28807	noteworthy	_
149-5	28808-28813	given	_
149-6	28814-28818	that	_
149-7	28819-28822	two	_
149-8	28823-28830	further	_
149-9	28831-28838	aspects	_
149-10	28839-28846	besides	_
149-11	28847-28854	feature	_
149-12	28855-28860	space	_
149-13	28861-28866	could	_
149-14	28867-28869	be	_
149-15	28870-28878	expected	_
149-16	28879-28881	to	_
149-17	28882-28890	decrease	_
149-18	28891-28901	classifier	_
149-19	28902-28913	performance	_
149-20	28914-28916	in	_
149-21	28917-28920	our	_
149-22	28921-28926	study	_
149-23	28926-28927	:	_
149-24	28928-28933	First	_
149-25	28933-28934	,	_
149-26	28935-28938	all	_
149-27	28939-28941	of	_
149-28	28942-28945	our	_
149-29	28946-28951	three	_
149-30	28952-28958	groups	_
149-31	28959-28963	were	_
149-32	28964-28969	based	_
149-33	28970-28972	on	_
149-34	28973-28983	relatively	_
149-35	28984-28989	large	_
149-36	28990-28997	samples	_
149-37	28998-29002	that	_
149-38	29003-29007	were	_
149-39	29008-29016	combined	_
149-40	29017-29021	from	_
149-41	29022-29025	two	_
149-42	29026-29035	different	_
149-43	29036-29047	measurement	_
149-44	29048-29053	sites	_
149-45	29054-29057	and	_
149-46	29058-29063	hence	_
149-47	29064-29070	should	_
149-48	29071-29073	be	_
149-49	29074-29078	more	_
149-50	29079-29092	heterogeneous	_
149-51	29093-29097	than	_
149-52	29098-29103	usual	_
149-53	29103-29104	.	_

#Text=Second, we used replicated 10-fold cross-validation, rather than the more optimistic leave-one-out approach.
150-1	29105-29111	Second	_
150-2	29111-29112	,	_
150-3	29113-29115	we	_
150-4	29116-29120	used	_
150-5	29121-29131	replicated	_
150-6	29132-29134	10	_
150-7	29134-29135	-	_
150-8	29135-29139	fold	_
150-9	29140-29156	cross-validation	_
150-10	29156-29157	,	_
150-11	29158-29164	rather	_
150-12	29165-29169	than	_
150-13	29170-29173	the	_
150-14	29174-29178	more	_
150-15	29179-29189	optimistic	_
150-16	29190-29203	leave-one-out	_
150-17	29204-29212	approach	_
150-18	29212-29213	.	_

#Text=We thus argue that the chosen combination of examining robustly defined functional networks and optimized analysis through replicated and nested 10-fold cross-validation may provide valuable new insights into the pathophysiology of brain disorders that is not attainable through global analyses of the entire functional connectome.
#Text=4.2 Classification of Schizophrenia patients and controls
#Text=We found that the networks subserving emotional scene and face processing, empathic processing as well as cognitive action-control yielded the best performance.
151-1	29214-29216	We	_
151-2	29217-29221	thus	_
151-3	29222-29227	argue	_
151-4	29228-29232	that	_
151-5	29233-29236	the	_
151-6	29237-29243	chosen	_
151-7	29244-29255	combination	_
151-8	29256-29258	of	_
151-9	29259-29268	examining	_
151-10	29269-29277	robustly	_
151-11	29278-29285	defined	_
151-12	29286-29296	functional	_
151-13	29297-29305	networks	_
151-14	29306-29309	and	_
151-15	29310-29319	optimized	_
151-16	29320-29328	analysis	_
151-17	29329-29336	through	_
151-18	29337-29347	replicated	_
151-19	29348-29351	and	_
151-20	29352-29358	nested	_
151-21	29359-29361	10	_
151-22	29361-29362	-	_
151-23	29362-29366	fold	_
151-24	29367-29383	cross-validation	_
151-25	29384-29387	may	_
151-26	29388-29395	provide	_
151-27	29396-29404	valuable	_
151-28	29405-29408	new	_
151-29	29409-29417	insights	_
151-30	29418-29422	into	_
151-31	29423-29426	the	_
151-32	29427-29442	pathophysiology	_
151-33	29443-29445	of	_
151-34	29446-29451	brain	_
151-35	29452-29461	disorders	_
151-36	29462-29466	that	_
151-37	29467-29469	is	_
151-38	29470-29473	not	_
151-39	29474-29484	attainable	_
151-40	29485-29492	through	_
151-41	29493-29499	global	_
151-42	29500-29508	analyses	_
151-43	29509-29511	of	_
151-44	29512-29515	the	_
151-45	29516-29522	entire	_
151-46	29523-29533	functional	_
151-47	29534-29544	connectome	_
151-48	29544-29545	.	_
151-49	29546-29549	4.2	_
151-50	29550-29564	Classification	_
151-51	29565-29567	of	_
151-52	29568-29581	Schizophrenia	_
151-53	29582-29590	patients	_
151-54	29591-29594	and	_
151-55	29595-29603	controls	_
151-56	29604-29606	We	_
151-57	29607-29612	found	_
151-58	29613-29617	that	_
151-59	29618-29621	the	_
151-60	29622-29630	networks	_
151-61	29631-29641	subserving	_
151-62	29642-29651	emotional	_
151-63	29652-29657	scene	_
151-64	29658-29661	and	_
151-65	29662-29666	face	_
151-66	29667-29677	processing	_
151-67	29677-29678	,	_
151-68	29679-29687	empathic	_
151-69	29688-29698	processing	_
151-70	29699-29701	as	_
151-71	29702-29706	well	_
151-72	29707-29709	as	_
151-73	29710-29719	cognitive	_
151-74	29720-29734	action-control	_
151-75	29735-29742	yielded	_
151-76	29743-29746	the	_
151-77	29747-29751	best	_
151-78	29752-29763	performance	_
151-79	29763-29764	.	_

#Text=Aberrant processing of emotional stimuli and impaired abilities to relate to others’ affective states are features of SCZ and mirrored in the degree of SCZ-related information that is contained in the EmoSF (AUC = 0.79) and Empathy (AUC = 0.78) networks.
152-1	29765-29773	Aberrant	_
152-2	29774-29784	processing	_
152-3	29785-29787	of	_
152-4	29788-29797	emotional	_
152-5	29798-29805	stimuli	_
152-6	29806-29809	and	_
152-7	29810-29818	impaired	_
152-8	29819-29828	abilities	_
152-9	29829-29831	to	_
152-10	29832-29838	relate	_
152-11	29839-29841	to	_
152-12	29842-29848	others	_
152-13	29848-29849	’	_
152-14	29850-29859	affective	_
152-15	29860-29866	states	_
152-16	29867-29870	are	_
152-17	29871-29879	features	_
152-18	29880-29882	of	_
152-19	29883-29886	SCZ	_
152-20	29887-29890	and	_
152-21	29891-29899	mirrored	_
152-22	29900-29902	in	_
152-23	29903-29906	the	_
152-24	29907-29913	degree	_
152-25	29914-29916	of	_
152-26	29917-29928	SCZ-related	_
152-27	29929-29940	information	_
152-28	29941-29945	that	_
152-29	29946-29948	is	_
152-30	29949-29958	contained	_
152-31	29959-29961	in	_
152-32	29962-29965	the	_
152-33	29966-29971	EmoSF	_
152-34	29972-29973	(	_
152-35	29973-29976	AUC	_
152-36	29977-29978	=	_
152-37	29979-29983	0.79	_
152-38	29983-29984	)	_
152-39	29985-29988	and	_
152-40	29989-29996	Empathy	_
152-41	29997-29998	(	_
152-42	29998-30001	AUC	_
152-43	30002-30003	=	_
152-44	30004-30008	0.78	_
152-45	30008-30009	)	_
152-46	30010-30018	networks	_
152-47	30018-30019	.	_

#Text=Further, the good classification performance of the CogAC resonates well with alterations in cognitive control processes as a core deficit in SCZ [cf. ].
153-1	30020-30027	Further	_
153-2	30027-30028	,	_
153-3	30029-30032	the	_
153-4	30033-30037	good	_
153-5	30038-30052	classification	_
153-6	30053-30064	performance	_
153-7	30065-30067	of	_
153-8	30068-30071	the	_
153-9	30072-30077	CogAC	_
153-10	30078-30087	resonates	_
153-11	30088-30092	well	_
153-12	30093-30097	with	_
153-13	30098-30109	alterations	_
153-14	30110-30112	in	_
153-15	30113-30122	cognitive	_
153-16	30123-30130	control	_
153-17	30131-30140	processes	_
153-18	30141-30143	as	_
153-19	30144-30145	a	_
153-20	30146-30150	core	_
153-21	30151-30158	deficit	_
153-22	30159-30161	in	_
153-23	30162-30165	SCZ	_
153-24	30166-30167	[	_
153-25	30167-30169	cf	_
153-26	30169-30170	.	_
153-27	30171-30172	]	_
153-28	30172-30173	.	_

#Text=Somewhat surprisingly, the reward (Rew) network did not differentiate SCZ from HCs with high accuracy, given the prominent role of the dopaminergic system and aberrant salience processing in psychosis and the association with the reward system in this disorder.
154-1	30174-30182	Somewhat	_
154-2	30183-30195	surprisingly	_
154-3	30195-30196	,	_
154-4	30197-30200	the	_
154-5	30201-30207	reward	_
154-6	30208-30209	(	_
154-7	30209-30212	Rew	_
154-8	30212-30213	)	_
154-9	30214-30221	network	_
154-10	30222-30225	did	_
154-11	30226-30229	not	_
154-12	30230-30243	differentiate	_
154-13	30244-30247	SCZ	_
154-14	30248-30252	from	_
154-15	30253-30256	HCs	_
154-16	30257-30261	with	_
154-17	30262-30266	high	_
154-18	30267-30275	accuracy	_
154-19	30275-30276	,	_
154-20	30277-30282	given	_
154-21	30283-30286	the	_
154-22	30287-30296	prominent	_
154-23	30297-30301	role	_
154-24	30302-30304	of	_
154-25	30305-30308	the	_
154-26	30309-30321	dopaminergic	_
154-27	30322-30328	system	_
154-28	30329-30332	and	_
154-29	30333-30341	aberrant	_
154-30	30342-30350	salience	_
154-31	30351-30361	processing	_
154-32	30362-30364	in	_
154-33	30365-30374	psychosis	_
154-34	30375-30378	and	_
154-35	30379-30382	the	_
154-36	30383-30394	association	_
154-37	30395-30399	with	_
154-38	30400-30403	the	_
154-39	30404-30410	reward	_
154-40	30411-30417	system	_
154-41	30418-30420	in	_
154-42	30421-30425	this	_
154-43	30426-30434	disorder	_
154-44	30434-30435	.	_

#Text=We conjecture that this lack of predictive information could arise from the fact that in contrast to task-activation data, RSFC analyses primarily capture the tonic rather than phasic state of these networks.
#Text=4.3 Classification of Parkinson’s disease patients and controls
#Text=The superior classification performance observed for the motor execution network (AUC = 0.77) is hardly surprising, since motor impairments represent a key clinical feature of PD, and differences in action-related brain circuitry are well established in this disorder.
155-1	30436-30438	We	_
155-2	30439-30449	conjecture	_
155-3	30450-30454	that	_
155-4	30455-30459	this	_
155-5	30460-30464	lack	_
155-6	30465-30467	of	_
155-7	30468-30478	predictive	_
155-8	30479-30490	information	_
155-9	30491-30496	could	_
155-10	30497-30502	arise	_
155-11	30503-30507	from	_
155-12	30508-30511	the	_
155-13	30512-30516	fact	_
155-14	30517-30521	that	_
155-15	30522-30524	in	_
155-16	30525-30533	contrast	_
155-17	30534-30536	to	_
155-18	30537-30552	task-activation	_
155-19	30553-30557	data	_
155-20	30557-30558	,	_
155-21	30559-30563	RSFC	_
155-22	30564-30572	analyses	_
155-23	30573-30582	primarily	_
155-24	30583-30590	capture	_
155-25	30591-30594	the	_
155-26	30595-30600	tonic	_
155-27	30601-30607	rather	_
155-28	30608-30612	than	_
155-29	30613-30619	phasic	_
155-30	30620-30625	state	_
155-31	30626-30628	of	_
155-32	30629-30634	these	_
155-33	30635-30643	networks	_
155-34	30643-30644	.	_
155-35	30645-30648	4.3	_
155-36	30649-30663	Classification	_
155-37	30664-30666	of	_
155-38	30667-30676	Parkinson	_
155-39	30676-30677	’	_
155-40	30677-30678	s	_
155-41	30679-30686	disease	_
155-42	30687-30695	patients	_
155-43	30696-30699	and	_
155-44	30700-30708	controls	_
155-45	30709-30712	The	_
155-46	30713-30721	superior	_
155-47	30722-30736	classification	_
155-48	30737-30748	performance	_
155-49	30749-30757	observed	_
155-50	30758-30761	for	_
155-51	30762-30765	the	_
155-52	30766-30771	motor	_
155-53	30772-30781	execution	_
155-54	30782-30789	network	_
155-55	30790-30791	(	_
155-56	30791-30794	AUC	_
155-57	30795-30796	=	_
155-58	30797-30801	0.77	_
155-59	30801-30802	)	_
155-60	30803-30805	is	_
155-61	30806-30812	hardly	_
155-62	30813-30823	surprising	_
155-63	30823-30824	,	_
155-64	30825-30830	since	_
155-65	30831-30836	motor	_
155-66	30837-30848	impairments	_
155-67	30849-30858	represent	_
155-68	30859-30860	a	_
155-69	30861-30864	key	_
155-70	30865-30873	clinical	_
155-71	30874-30881	feature	_
155-72	30882-30884	of	_
155-73	30885-30887	PD	_
155-74	30887-30888	,	_
155-75	30889-30892	and	_
155-76	30893-30904	differences	_
155-77	30905-30907	in	_
155-78	30908-30922	action-related	_
155-79	30923-30928	brain	_
155-80	30929-30938	circuitry	_
155-81	30939-30942	are	_
155-82	30943-30947	well	_
155-83	30948-30959	established	_
155-84	30960-30962	in	_
155-85	30963-30967	this	_
155-86	30968-30976	disorder	_
155-87	30976-30977	.	_

#Text=The finding that the AM (AUC = 0.76) and SM (AUC = 0.75) networks also achieved a very good differentiation of PD patients from HCs was rather surprising, though.
156-1	30978-30981	The	_
156-2	30982-30989	finding	_
156-3	30990-30994	that	_
156-4	30995-30998	the	_
156-5	30999-31001	AM	_
156-6	31002-31003	(	_
156-7	31003-31006	AUC	_
156-8	31007-31008	=	_
156-9	31009-31013	0.76	_
156-10	31013-31014	)	_
156-11	31015-31018	and	_
156-12	31019-31021	SM	_
156-13	31022-31023	(	_
156-14	31023-31026	AUC	_
156-15	31027-31028	=	_
156-16	31029-31033	0.75	_
156-17	31033-31034	)	_
156-18	31035-31043	networks	_
156-19	31044-31048	also	_
156-20	31049-31057	achieved	_
156-21	31058-31059	a	_
156-22	31060-31064	very	_
156-23	31065-31069	good	_
156-24	31070-31085	differentiation	_
156-25	31086-31088	of	_
156-26	31089-31091	PD	_
156-27	31092-31100	patients	_
156-28	31101-31105	from	_
156-29	31106-31109	HCs	_
156-30	31110-31113	was	_
156-31	31114-31120	rather	_
156-32	31121-31131	surprising	_
156-33	31131-31132	,	_
156-34	31133-31139	though	_
156-35	31139-31140	.	_

#Text=While PD is a neurodegenerative disorder and dementia is common in PD patients, several patients showed evidence for mild cognitive impairment, using the Montreal Cognitive Assessment for screening.
157-1	31141-31146	While	_
157-2	31147-31149	PD	_
157-3	31150-31152	is	_
157-4	31153-31154	a	_
157-5	31155-31172	neurodegenerative	_
157-6	31173-31181	disorder	_
157-7	31182-31185	and	_
157-8	31186-31194	dementia	_
157-9	31195-31197	is	_
157-10	31198-31204	common	_
157-11	31205-31207	in	_
157-12	31208-31210	PD	_
157-13	31211-31219	patients	_
157-14	31219-31220	,	_
157-15	31221-31228	several	_
157-16	31229-31237	patients	_
157-17	31238-31244	showed	_
157-18	31245-31253	evidence	_
157-19	31254-31257	for	_
157-20	31258-31262	mild	_
157-21	31263-31272	cognitive	_
157-22	31273-31283	impairment	_
157-23	31283-31284	,	_
157-24	31285-31290	using	_
157-25	31291-31294	the	_
157-26	31295-31303	Montreal	_
157-27	31304-31313	Cognitive	_
157-28	31314-31324	Assessment	_
157-29	31325-31328	for	_
157-30	31329-31338	screening	_
157-31	31338-31339	.	_

#Text=We can hence only speculate that the RSFC differences in AM and SM networks may pick up these deficits as revealed by standard behavioral screening instruments.
158-1	31340-31342	We	_
158-2	31343-31346	can	_
158-3	31347-31352	hence	_
158-4	31353-31357	only	_
158-5	31358-31367	speculate	_
158-6	31368-31372	that	_
158-7	31373-31376	the	_
158-8	31377-31381	RSFC	_
158-9	31382-31393	differences	_
158-10	31394-31396	in	_
158-11	31397-31399	AM	_
158-12	31400-31403	and	_
158-13	31404-31406	SM	_
158-14	31407-31415	networks	_
158-15	31416-31419	may	_
158-16	31420-31424	pick	_
158-17	31425-31427	up	_
158-18	31428-31433	these	_
158-19	31434-31442	deficits	_
158-20	31443-31445	as	_
158-21	31446-31454	revealed	_
158-22	31455-31457	by	_
158-23	31458-31466	standard	_
158-24	31467-31477	behavioral	_
158-25	31478-31487	screening	_
158-26	31488-31499	instruments	_
158-27	31499-31500	.	_

#Text=Finally, the good classification performance achieved by the ToM network (AUC = 0.71) was unexpected but matches a growing literature of impaired social cognition in PD patients.
#Text=4.4 Age Group Classification
#Text=One of the most striking observations from this study was that every single network achieved a better classification with respect to age group than with respect to SCZ or PD.
159-1	31501-31508	Finally	_
159-2	31508-31509	,	_
159-3	31510-31513	the	_
159-4	31514-31518	good	_
159-5	31519-31533	classification	_
159-6	31534-31545	performance	_
159-7	31546-31554	achieved	_
159-8	31555-31557	by	_
159-9	31558-31561	the	_
159-10	31562-31565	ToM	_
159-11	31566-31573	network	_
159-12	31574-31575	(	_
159-13	31575-31578	AUC	_
159-14	31579-31580	=	_
159-15	31581-31585	0.71	_
159-16	31585-31586	)	_
159-17	31587-31590	was	_
159-18	31591-31601	unexpected	_
159-19	31602-31605	but	_
159-20	31606-31613	matches	_
159-21	31614-31615	a	_
159-22	31616-31623	growing	_
159-23	31624-31634	literature	_
159-24	31635-31637	of	_
159-25	31638-31646	impaired	_
159-26	31647-31653	social	_
159-27	31654-31663	cognition	_
159-28	31664-31666	in	_
159-29	31667-31669	PD	_
159-30	31670-31678	patients	_
159-31	31678-31679	.	_
159-32	31680-31683	4.4	_
159-33	31684-31687	Age	_
159-34	31688-31693	Group	_
159-35	31694-31708	Classification	_
159-36	31709-31712	One	_
159-37	31713-31715	of	_
159-38	31716-31719	the	_
159-39	31720-31724	most	_
159-40	31725-31733	striking	_
159-41	31734-31746	observations	_
159-42	31747-31751	from	_
159-43	31752-31756	this	_
159-44	31757-31762	study	_
159-45	31763-31766	was	_
159-46	31767-31771	that	_
159-47	31772-31777	every	_
159-48	31778-31784	single	_
159-49	31785-31792	network	_
159-50	31793-31801	achieved	_
159-51	31802-31803	a	_
159-52	31804-31810	better	_
159-53	31811-31825	classification	_
159-54	31826-31830	with	_
159-55	31831-31838	respect	_
159-56	31839-31841	to	_
159-57	31842-31845	age	_
159-58	31846-31851	group	_
159-59	31852-31856	than	_
159-60	31857-31861	with	_
159-61	31862-31869	respect	_
159-62	31870-31872	to	_
159-63	31873-31876	SCZ	_
159-64	31877-31879	or	_
159-65	31880-31882	PD	_
159-66	31882-31883	.	_

#Text=While we hypothesized that the broad spectrum of age-related changes in various mental functions would be reflected by changes in several networks, the consistency (across both networks and replications) of high classification accuracies is intriguing.
160-1	31884-31889	While	_
160-2	31890-31892	we	_
160-3	31893-31905	hypothesized	_
160-4	31906-31910	that	_
160-5	31911-31914	the	_
160-6	31915-31920	broad	_
160-7	31921-31929	spectrum	_
160-8	31930-31932	of	_
160-9	31933-31944	age-related	_
160-10	31945-31952	changes	_
160-11	31953-31955	in	_
160-12	31956-31963	various	_
160-13	31964-31970	mental	_
160-14	31971-31980	functions	_
160-15	31981-31986	would	_
160-16	31987-31989	be	_
160-17	31990-31999	reflected	_
160-18	32000-32002	by	_
160-19	32003-32010	changes	_
160-20	32011-32013	in	_
160-21	32014-32021	several	_
160-22	32022-32030	networks	_
160-23	32030-32031	,	_
160-24	32032-32035	the	_
160-25	32036-32047	consistency	_
160-26	32048-32049	(	_
160-27	32049-32055	across	_
160-28	32056-32060	both	_
160-29	32061-32069	networks	_
160-30	32070-32073	and	_
160-31	32074-32086	replications	_
160-32	32086-32087	)	_
160-33	32088-32090	of	_
160-34	32091-32095	high	_
160-35	32096-32110	classification	_
160-36	32111-32121	accuracies	_
160-37	32122-32124	is	_
160-38	32125-32135	intriguing	_
160-39	32135-32136	.	_

#Text=It stands to reason that the mechanisms underlying the discriminative changes in functional connectivity patterns may be diverse.
161-1	32137-32139	It	_
161-2	32140-32146	stands	_
161-3	32147-32149	to	_
161-4	32150-32156	reason	_
161-5	32157-32161	that	_
161-6	32162-32165	the	_
161-7	32166-32176	mechanisms	_
161-8	32177-32187	underlying	_
161-9	32188-32191	the	_
161-10	32192-32206	discriminative	_
161-11	32207-32214	changes	_
161-12	32215-32217	in	_
161-13	32218-32228	functional	_
161-14	32229-32241	connectivity	_
161-15	32242-32250	patterns	_
161-16	32251-32254	may	_
161-17	32255-32257	be	_
161-18	32258-32265	diverse	_
161-19	32265-32266	.	_

#Text=In particular, they should include neurodegeneration (cognitive networks), neurochemical changes (reward networks), altered affective processing (social-affective networks) and use-dependent plasticity (motor networks).
162-1	32267-32269	In	_
162-2	32270-32280	particular	_
162-3	32280-32281	,	_
162-4	32282-32286	they	_
162-5	32287-32293	should	_
162-6	32294-32301	include	_
162-7	32302-32319	neurodegeneration	_
162-8	32320-32321	(	_
162-9	32321-32330	cognitive	_
162-10	32331-32339	networks	_
162-11	32339-32340	)	_
162-12	32340-32341	,	_
162-13	32342-32355	neurochemical	_
162-14	32356-32363	changes	_
162-15	32364-32365	(	_
162-16	32365-32371	reward	_
162-17	32372-32380	networks	_
162-18	32380-32381	)	_
162-19	32381-32382	,	_
162-20	32383-32390	altered	_
162-21	32391-32400	affective	_
162-22	32401-32411	processing	_
162-23	32412-32413	(	_
162-24	32413-32429	social-affective	_
162-25	32430-32438	networks	_
162-26	32438-32439	)	_
162-27	32440-32443	and	_
162-28	32444-32457	use-dependent	_
162-29	32458-32468	plasticity	_
162-30	32469-32470	(	_
162-31	32470-32475	motor	_
162-32	32476-32484	networks	_
162-33	32484-32485	)	_
162-34	32485-32486	.	_

#Text=In addition, it may be argued that in spite of all inter-individual variability age-related changes represent a more homogeneous change of the neuro-functional architecture relative to the inevitable heterogeneity among clinical populations.
163-1	32487-32489	In	_
163-2	32490-32498	addition	_
163-3	32498-32499	,	_
163-4	32500-32502	it	_
163-5	32503-32506	may	_
163-6	32507-32509	be	_
163-7	32510-32516	argued	_
163-8	32517-32521	that	_
163-9	32522-32524	in	_
163-10	32525-32530	spite	_
163-11	32531-32533	of	_
163-12	32534-32537	all	_
163-13	32538-32554	inter-individual	_
163-14	32555-32566	variability	_
163-15	32567-32578	age-related	_
163-16	32579-32586	changes	_
163-17	32587-32596	represent	_
163-18	32597-32598	a	_
163-19	32599-32603	more	_
163-20	32604-32615	homogeneous	_
163-21	32616-32622	change	_
163-22	32623-32625	of	_
163-23	32626-32629	the	_
163-24	32630-32646	neuro-functional	_
163-25	32647-32659	architecture	_
163-26	32660-32668	relative	_
163-27	32669-32671	to	_
163-28	32672-32675	the	_
163-29	32676-32686	inevitable	_
163-30	32687-32700	heterogeneity	_
163-31	32701-32706	among	_
163-32	32707-32715	clinical	_
163-33	32716-32727	populations	_
163-34	32727-32728	.	_

#Text=Given that connectivity patterns of all systems differentiated very well between young and old participants, we acknowledge the possibility that the relevant drivers may be of non-neural origin.
164-1	32729-32734	Given	_
164-2	32735-32739	that	_
164-3	32740-32752	connectivity	_
164-4	32753-32761	patterns	_
164-5	32762-32764	of	_
164-6	32765-32768	all	_
164-7	32769-32776	systems	_
164-8	32777-32791	differentiated	_
164-9	32792-32796	very	_
164-10	32797-32801	well	_
164-11	32802-32809	between	_
164-12	32810-32815	young	_
164-13	32816-32819	and	_
164-14	32820-32823	old	_
164-15	32824-32836	participants	_
164-16	32836-32837	,	_
164-17	32838-32840	we	_
164-18	32841-32852	acknowledge	_
164-19	32853-32856	the	_
164-20	32857-32868	possibility	_
164-21	32869-32873	that	_
164-22	32874-32877	the	_
164-23	32878-32886	relevant	_
164-24	32887-32894	drivers	_
164-25	32895-32898	may	_
164-26	32899-32901	be	_
164-27	32902-32904	of	_
164-28	32905-32915	non-neural	_
164-29	32916-32922	origin	_
164-30	32922-32923	.	_

#Text=In particular, despite of our optimized confound removal, we cannot exclude that residual effects related to motion or brain atrophy as well as physiological effects such as macro- and microvascular changes and their cumulative impact on hemodynamic signals may have contributed to our findings.
165-1	32924-32926	In	_
165-2	32927-32937	particular	_
165-3	32937-32938	,	_
165-4	32939-32946	despite	_
165-5	32947-32949	of	_
165-6	32950-32953	our	_
165-7	32954-32963	optimized	_
165-8	32964-32972	confound	_
165-9	32973-32980	removal	_
165-10	32980-32981	,	_
165-11	32982-32984	we	_
165-12	32985-32991	cannot	_
165-13	32992-32999	exclude	_
165-14	33000-33004	that	_
165-15	33005-33013	residual	_
165-16	33014-33021	effects	_
165-17	33022-33029	related	_
165-18	33030-33032	to	_
165-19	33033-33039	motion	_
165-20	33040-33042	or	_
165-21	33043-33048	brain	_
165-22	33049-33056	atrophy	_
165-23	33057-33059	as	_
165-24	33060-33064	well	_
165-25	33065-33067	as	_
165-26	33068-33081	physiological	_
165-27	33082-33089	effects	_
165-28	33090-33094	such	_
165-29	33095-33097	as	_
165-30	33098-33103	macro	_
165-31	33103-33104	-	_
165-32	33105-33108	and	_
165-33	33109-33122	microvascular	_
165-34	33123-33130	changes	_
165-35	33131-33134	and	_
165-36	33135-33140	their	_
165-37	33141-33151	cumulative	_
165-38	33152-33158	impact	_
165-39	33159-33161	on	_
165-40	33162-33173	hemodynamic	_
165-41	33174-33181	signals	_
165-42	33182-33185	may	_
165-43	33186-33190	have	_
165-44	33191-33202	contributed	_
165-45	33203-33205	to	_
165-46	33206-33209	our	_
165-47	33210-33218	findings	_
165-48	33218-33219	.	_

#Text=While the contributions of neural and non-neural effects outlined in this section certainly warrant further investigation, one of the most critical conclusions that should be taken from the high classification accuracy between younger and older participants is the danger of obtaining spuriously high accuracies in clinical classification studies if patients and HCs are not carefully matched for age.
#Text=4.5 Conclusions & Outlook
#Text=We investigated the potential of RS connectivity patterns in a wide variety of functional networks to distinguish SCZ and PD patients from matched HCs as well as old from young adults.
166-1	33220-33225	While	_
166-2	33226-33229	the	_
166-3	33230-33243	contributions	_
166-4	33244-33246	of	_
166-5	33247-33253	neural	_
166-6	33254-33257	and	_
166-7	33258-33268	non-neural	_
166-8	33269-33276	effects	_
166-9	33277-33285	outlined	_
166-10	33286-33288	in	_
166-11	33289-33293	this	_
166-12	33294-33301	section	_
166-13	33302-33311	certainly	_
166-14	33312-33319	warrant	_
166-15	33320-33327	further	_
166-16	33328-33341	investigation	_
166-17	33341-33342	,	_
166-18	33343-33346	one	_
166-19	33347-33349	of	_
166-20	33350-33353	the	_
166-21	33354-33358	most	_
166-22	33359-33367	critical	_
166-23	33368-33379	conclusions	_
166-24	33380-33384	that	_
166-25	33385-33391	should	_
166-26	33392-33394	be	_
166-27	33395-33400	taken	_
166-28	33401-33405	from	_
166-29	33406-33409	the	_
166-30	33410-33414	high	_
166-31	33415-33429	classification	_
166-32	33430-33438	accuracy	_
166-33	33439-33446	between	_
166-34	33447-33454	younger	_
166-35	33455-33458	and	_
166-36	33459-33464	older	_
166-37	33465-33477	participants	_
166-38	33478-33480	is	_
166-39	33481-33484	the	_
166-40	33485-33491	danger	_
166-41	33492-33494	of	_
166-42	33495-33504	obtaining	_
166-43	33505-33515	spuriously	_
166-44	33516-33520	high	_
166-45	33521-33531	accuracies	_
166-46	33532-33534	in	_
166-47	33535-33543	clinical	_
166-48	33544-33558	classification	_
166-49	33559-33566	studies	_
166-50	33567-33569	if	_
166-51	33570-33578	patients	_
166-52	33579-33582	and	_
166-53	33583-33586	HCs	_
166-54	33587-33590	are	_
166-55	33591-33594	not	_
166-56	33595-33604	carefully	_
166-57	33605-33612	matched	_
166-58	33613-33616	for	_
166-59	33617-33620	age	_
166-60	33620-33621	.	_
166-61	33622-33625	4.5	_
166-62	33626-33637	Conclusions	_
166-63	33638-33639	&	_
166-64	33640-33647	Outlook	_
166-65	33648-33650	We	_
166-66	33651-33663	investigated	_
166-67	33664-33667	the	_
166-68	33668-33677	potential	_
166-69	33678-33680	of	_
166-70	33681-33683	RS	_
166-71	33684-33696	connectivity	_
166-72	33697-33705	patterns	_
166-73	33706-33708	in	_
166-74	33709-33710	a	_
166-75	33711-33715	wide	_
166-76	33716-33723	variety	_
166-77	33724-33726	of	_
166-78	33727-33737	functional	_
166-79	33738-33746	networks	_
166-80	33747-33749	to	_
166-81	33750-33761	distinguish	_
166-82	33762-33765	SCZ	_
166-83	33766-33769	and	_
166-84	33770-33772	PD	_
166-85	33773-33781	patients	_
166-86	33782-33786	from	_
166-87	33787-33794	matched	_
166-88	33795-33798	HCs	_
166-89	33799-33801	as	_
166-90	33802-33806	well	_
166-91	33807-33809	as	_
166-92	33810-33813	old	_
166-93	33814-33818	from	_
166-94	33819-33824	young	_
166-95	33825-33831	adults	_
166-96	33831-33832	.	_

#Text=We showed that networks defined by robust activation due to mental operations known to be affected in the respective condition indeed contained information on the respective condition that is captured by our pattern-classification approach and translates into good classification accuracies.
167-1	33833-33835	We	_
167-2	33836-33842	showed	_
167-3	33843-33847	that	_
167-4	33848-33856	networks	_
167-5	33857-33864	defined	_
167-6	33865-33867	by	_
167-7	33868-33874	robust	_
167-8	33875-33885	activation	_
167-9	33886-33889	due	_
167-10	33890-33892	to	_
167-11	33893-33899	mental	_
167-12	33900-33910	operations	_
167-13	33911-33916	known	_
167-14	33917-33919	to	_
167-15	33920-33922	be	_
167-16	33923-33931	affected	_
167-17	33932-33934	in	_
167-18	33935-33938	the	_
167-19	33939-33949	respective	_
167-20	33950-33959	condition	_
167-21	33960-33966	indeed	_
167-22	33967-33976	contained	_
167-23	33977-33988	information	_
167-24	33989-33991	on	_
167-25	33992-33995	the	_
167-26	33996-34006	respective	_
167-27	34007-34016	condition	_
167-28	34017-34021	that	_
167-29	34022-34024	is	_
167-30	34025-34033	captured	_
167-31	34034-34036	by	_
167-32	34037-34040	our	_
167-33	34041-34063	pattern-classification	_
167-34	34064-34072	approach	_
167-35	34073-34076	and	_
167-36	34077-34087	translates	_
167-37	34088-34092	into	_
167-38	34093-34097	good	_
167-39	34098-34112	classification	_
167-40	34113-34123	accuracies	_
167-41	34123-34124	.	_

#Text=Classification accuracies obtained through replicated, nested 10-fold cross-validation were not only generally comparable to those obtained from whole-brain analyses but also revealed a differentiated picture for both disorders in comparisons.
168-1	34125-34139	Classification	_
168-2	34140-34150	accuracies	_
168-3	34151-34159	obtained	_
168-4	34160-34167	through	_
168-5	34168-34178	replicated	_
168-6	34178-34179	,	_
168-7	34180-34186	nested	_
168-8	34187-34189	10	_
168-9	34189-34190	-	_
168-10	34190-34194	fold	_
168-11	34195-34211	cross-validation	_
168-12	34212-34216	were	_
168-13	34217-34220	not	_
168-14	34221-34225	only	_
168-15	34226-34235	generally	_
168-16	34236-34246	comparable	_
168-17	34247-34249	to	_
168-18	34250-34255	those	_
168-19	34256-34264	obtained	_
168-20	34265-34269	from	_
168-21	34270-34281	whole-brain	_
168-22	34282-34290	analyses	_
168-23	34291-34294	but	_
168-24	34295-34299	also	_
168-25	34300-34308	revealed	_
168-26	34309-34310	a	_
168-27	34311-34325	differentiated	_
168-28	34326-34333	picture	_
168-29	34334-34337	for	_
168-30	34338-34342	both	_
168-31	34343-34352	disorders	_
168-32	34353-34355	in	_
168-33	34356-34367	comparisons	_
168-34	34367-34368	.	_

#Text=Both SCZ and PD were specifically well predicted by distinct networks that resonate well with known clinical and pathophysiological features.
169-1	34369-34373	Both	_
169-2	34374-34377	SCZ	_
169-3	34378-34381	and	_
169-4	34382-34384	PD	_
169-5	34385-34389	were	_
169-6	34390-34402	specifically	_
169-7	34403-34407	well	_
169-8	34408-34417	predicted	_
169-9	34418-34420	by	_
169-10	34421-34429	distinct	_
169-11	34430-34438	networks	_
169-12	34439-34443	that	_
169-13	34444-34452	resonate	_
169-14	34453-34457	well	_
169-15	34458-34462	with	_
169-16	34463-34468	known	_
169-17	34469-34477	clinical	_
169-18	34478-34481	and	_
169-19	34482-34500	pathophysiological	_
169-20	34501-34509	features	_
169-21	34509-34510	.	_

#Text=The presented approach thus opens an avenue toward robust and more specific assessments of clinical and developmental differences in functional systems than previous whole-brain analyses.
170-1	34511-34514	The	_
170-2	34515-34524	presented	_
170-3	34525-34533	approach	_
170-4	34534-34538	thus	_
170-5	34539-34544	opens	_
170-6	34545-34547	an	_
170-7	34548-34554	avenue	_
170-8	34555-34561	toward	_
170-9	34562-34568	robust	_
170-10	34569-34572	and	_
170-11	34573-34577	more	_
170-12	34578-34586	specific	_
170-13	34587-34598	assessments	_
170-14	34599-34601	of	_
170-15	34602-34610	clinical	_
170-16	34611-34614	and	_
170-17	34615-34628	developmental	_
170-18	34629-34640	differences	_
170-19	34641-34643	in	_
170-20	34644-34654	functional	_
170-21	34655-34662	systems	_
170-22	34663-34667	than	_
170-23	34668-34676	previous	_
170-24	34677-34688	whole-brain	_
170-25	34689-34697	analyses	_
170-26	34697-34698	.	_

#Text=One of the most striking findings of this work was the fact that integrity in all networks was much better at identifying participants with advance age than with any of the two disorders.
171-1	34699-34702	One	_
171-2	34703-34705	of	_
171-3	34706-34709	the	_
171-4	34710-34714	most	_
171-5	34715-34723	striking	_
171-6	34724-34732	findings	_
171-7	34733-34735	of	_
171-8	34736-34740	this	_
171-9	34741-34745	work	_
171-10	34746-34749	was	_
171-11	34750-34753	the	_
171-12	34754-34758	fact	_
171-13	34759-34763	that	_
171-14	34764-34773	integrity	_
171-15	34774-34776	in	_
171-16	34777-34780	all	_
171-17	34781-34789	networks	_
171-18	34790-34793	was	_
171-19	34794-34798	much	_
171-20	34799-34805	better	_
171-21	34806-34808	at	_
171-22	34809-34820	identifying	_
171-23	34821-34833	participants	_
171-24	34834-34838	with	_
171-25	34839-34846	advance	_
171-26	34847-34850	age	_
171-27	34851-34855	than	_
171-28	34856-34860	with	_
171-29	34861-34864	any	_
171-30	34865-34867	of	_
171-31	34868-34871	the	_
171-32	34872-34875	two	_
171-33	34876-34885	disorders	_
171-34	34885-34886	.	_

#Text=While the most likely heterogeneous mechanisms behind this phenomenon certainly need to be addressed in more detail, the current findings highlight the importance of considering age-related effects as a potential source of bias in clinical classification studies.
172-1	34887-34892	While	_
172-2	34893-34896	the	_
172-3	34897-34901	most	_
172-4	34902-34908	likely	_
172-5	34909-34922	heterogeneous	_
172-6	34923-34933	mechanisms	_
172-7	34934-34940	behind	_
172-8	34941-34945	this	_
172-9	34946-34956	phenomenon	_
172-10	34957-34966	certainly	_
172-11	34967-34971	need	_
172-12	34972-34974	to	_
172-13	34975-34977	be	_
172-14	34978-34987	addressed	_
172-15	34988-34990	in	_
172-16	34991-34995	more	_
172-17	34996-35002	detail	_
172-18	35002-35003	,	_
172-19	35004-35007	the	_
172-20	35008-35015	current	_
172-21	35016-35024	findings	_
172-22	35025-35034	highlight	_
172-23	35035-35038	the	_
172-24	35039-35049	importance	_
172-25	35050-35052	of	_
172-26	35053-35064	considering	_
172-27	35065-35076	age-related	_
172-28	35077-35084	effects	_
172-29	35085-35087	as	_
172-30	35088-35089	a	_
172-31	35090-35099	potential	_
172-32	35100-35106	source	_
172-33	35107-35109	of	_
172-34	35110-35114	bias	_
172-35	35115-35117	in	_
172-36	35118-35126	clinical	_
172-37	35127-35141	classification	_
172-38	35142-35149	studies	_
172-39	35149-35150	.	_

#Text=Supplementary Material
#Text=           Financial Disclosures
#Text=These authors declare following conflicts of interest:
#Text=Risk of dementia in Parkinson’s disease: a community-based, prospective study
#Text=Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study
#Text=Cost of disorders of the brain in Europe
#Text=Single subject prediction of brain disorders in neuroimaging: Promises and pitfalls
#Text=Unified segmentation
#Text=The correlative triad among aging, dopamine, and cognition: current status and future prospects
#Text=The cognitive neuroscience of schizophrenia
#Text=
#Text=Functional and structural brain correlates of theory of mind and empathy deficits in schizophrenia
#Text=Theory of mind in Parkinson’s disease: A meta-analysis
#Text=Working memory, executive control, and aging
#Text=Social brain dysfunctions in schizophrenia: A review of neuroimaging studies
#Text=Studying variability in human brain aging in a population-based German cohort—rationale and design of 1000BRAINS
#Text=LIBSVM: a Library for Support Vector Machines
#Text=Discriminative analysis of Parkinson’s disease based on whole-brain functional connectivity
#Text=Differential and distributed effects of dopamine neuromodulations on resting-state network connectivity
#Text=Advances and Pitfalls in the Analysis and Interpretation of Resting-State FMRI Data
#Text=
#Text=Consistent resting-state networks across healthy subjects
#Text=The Exercising Brain: Changes in Functional Connectivity Induced by an Integrated Multimodal Cognitive and Whole-Body Coordination Training
#Text=Neuroimaging of healthy cognitive aging
#Text=Neural correlates of the core facets of empathy in schizophrenia
#Text=Reinforcement learning and dopamine in schizophrenia: dimensions of symptoms or specific features of a disease group?
173-1	35151-35164	Supplementary	_
173-2	35165-35173	Material	_
173-3	35185-35194	Financial	_
173-4	35195-35206	Disclosures	_
173-5	35216-35221	These	_
173-6	35222-35229	authors	_
173-7	35230-35237	declare	_
173-8	35238-35247	following	_
173-9	35248-35257	conflicts	_
173-10	35258-35260	of	_
173-11	35261-35269	interest	_
173-12	35269-35270	:	_
173-13	35271-35275	Risk	_
173-14	35276-35278	of	_
173-15	35279-35287	dementia	_
173-16	35288-35290	in	_
173-17	35291-35300	Parkinson	_
173-18	35300-35301	’	_
173-19	35301-35302	s	_
173-20	35303-35310	disease	_
173-21	35310-35311	:	_
173-22	35312-35313	a	_
173-23	35314-35329	community-based	_
173-24	35329-35330	,	_
173-25	35331-35342	prospective	_
173-26	35343-35348	study	_
173-27	35349-35359	Prevalence	_
173-28	35360-35363	and	_
173-29	35364-35379	characteristics	_
173-30	35380-35382	of	_
173-31	35383-35391	dementia	_
173-32	35392-35394	in	_
173-33	35395-35404	Parkinson	_
173-34	35405-35412	disease	_
173-35	35412-35413	:	_
173-36	35414-35416	an	_
173-37	35417-35418	8	_
173-38	35418-35419	-	_
173-39	35419-35423	year	_
173-40	35424-35435	prospective	_
173-41	35436-35441	study	_
173-42	35442-35446	Cost	_
173-43	35447-35449	of	_
173-44	35450-35459	disorders	_
173-45	35460-35462	of	_
173-46	35463-35466	the	_
173-47	35467-35472	brain	_
173-48	35473-35475	in	_
173-49	35476-35482	Europe	_
173-50	35483-35489	Single	_
173-51	35490-35497	subject	_
173-52	35498-35508	prediction	_
173-53	35509-35511	of	_
173-54	35512-35517	brain	_
173-55	35518-35527	disorders	_
173-56	35528-35530	in	_
173-57	35531-35543	neuroimaging	_
173-58	35543-35544	:	_
173-59	35545-35553	Promises	_
173-60	35554-35557	and	_
173-61	35558-35566	pitfalls	_
173-62	35567-35574	Unified	_
173-63	35575-35587	segmentation	_
173-64	35588-35591	The	_
173-65	35592-35603	correlative	_
173-66	35604-35609	triad	_
173-67	35610-35615	among	_
173-68	35616-35621	aging	_
173-69	35621-35622	,	_
173-70	35623-35631	dopamine	_
173-71	35631-35632	,	_
173-72	35633-35636	and	_
173-73	35637-35646	cognition	_
173-74	35646-35647	:	_
173-75	35648-35655	current	_
173-76	35656-35662	status	_
173-77	35663-35666	and	_
173-78	35667-35673	future	_
173-79	35674-35683	prospects	_
173-80	35684-35687	The	_
173-81	35688-35697	cognitive	_
173-82	35698-35710	neuroscience	_
173-83	35711-35713	of	_
173-84	35714-35727	schizophrenia	_
173-85	35729-35739	Functional	_
173-86	35740-35743	and	_
173-87	35744-35754	structural	_
173-88	35755-35760	brain	_
173-89	35761-35771	correlates	_
173-90	35772-35774	of	_
173-91	35775-35781	theory	_
173-92	35782-35784	of	_
173-93	35785-35789	mind	_
173-94	35790-35793	and	_
173-95	35794-35801	empathy	_
173-96	35802-35810	deficits	_
173-97	35811-35813	in	_
173-98	35814-35827	schizophrenia	_
173-99	35828-35834	Theory	_
173-100	35835-35837	of	_
173-101	35838-35842	mind	_
173-102	35843-35845	in	_
173-103	35846-35855	Parkinson	_
173-104	35855-35856	’	_
173-105	35856-35857	s	_
173-106	35858-35865	disease	_
173-107	35865-35866	:	_
173-108	35867-35868	A	_
173-109	35869-35882	meta-analysis	_
173-110	35883-35890	Working	_
173-111	35891-35897	memory	_
173-112	35897-35898	,	_
173-113	35899-35908	executive	_
173-114	35909-35916	control	_
173-115	35916-35917	,	_
173-116	35918-35921	and	_
173-117	35922-35927	aging	_
173-118	35928-35934	Social	_
173-119	35935-35940	brain	_
173-120	35941-35953	dysfunctions	_
173-121	35954-35956	in	_
173-122	35957-35970	schizophrenia	_
173-123	35970-35971	:	_
173-124	35972-35973	A	_
173-125	35974-35980	review	_
173-126	35981-35983	of	_
173-127	35984-35996	neuroimaging	_
173-128	35997-36004	studies	_
173-129	36005-36013	Studying	_
173-130	36014-36025	variability	_
173-131	36026-36028	in	_
173-132	36029-36034	human	_
173-133	36035-36040	brain	_
173-134	36041-36046	aging	_
173-135	36047-36049	in	_
173-136	36050-36051	a	_
173-137	36052-36068	population-based	_
173-138	36069-36075	German	_
173-139	36076-36092	cohort—rationale	_
173-140	36093-36096	and	_
173-141	36097-36103	design	_
173-142	36104-36106	of	_
173-143	36107-36117	1000BRAINS	_
173-144	36118-36124	LIBSVM	_
173-145	36124-36125	:	_
173-146	36126-36127	a	_
173-147	36128-36135	Library	_
173-148	36136-36139	for	_
173-149	36140-36147	Support	_
173-150	36148-36154	Vector	_
173-151	36155-36163	Machines	_
173-152	36164-36178	Discriminative	_
173-153	36179-36187	analysis	_
173-154	36188-36190	of	_
173-155	36191-36200	Parkinson	_
173-156	36200-36201	’	_
173-157	36201-36202	s	_
173-158	36203-36210	disease	_
173-159	36211-36216	based	_
173-160	36217-36219	on	_
173-161	36220-36231	whole-brain	_
173-162	36232-36242	functional	_
173-163	36243-36255	connectivity	_
173-164	36256-36268	Differential	_
173-165	36269-36272	and	_
173-166	36273-36284	distributed	_
173-167	36285-36292	effects	_
173-168	36293-36295	of	_
173-169	36296-36304	dopamine	_
173-170	36305-36321	neuromodulations	_
173-171	36322-36324	on	_
173-172	36325-36338	resting-state	_
173-173	36339-36346	network	_
173-174	36347-36359	connectivity	_
173-175	36360-36368	Advances	_
173-176	36369-36372	and	_
173-177	36373-36381	Pitfalls	_
173-178	36382-36384	in	_
173-179	36385-36388	the	_
173-180	36389-36397	Analysis	_
173-181	36398-36401	and	_
173-182	36402-36416	Interpretation	_
173-183	36417-36419	of	_
173-184	36420-36433	Resting-State	_
173-185	36434-36438	FMRI	_
173-186	36439-36443	Data	_
173-187	36445-36455	Consistent	_
173-188	36456-36469	resting-state	_
173-189	36470-36478	networks	_
173-190	36479-36485	across	_
173-191	36486-36493	healthy	_
173-192	36494-36502	subjects	_
173-193	36503-36506	The	_
173-194	36507-36517	Exercising	_
173-195	36518-36523	Brain	_
173-196	36523-36524	:	_
173-197	36525-36532	Changes	_
173-198	36533-36535	in	_
173-199	36536-36546	Functional	_
173-200	36547-36559	Connectivity	_
173-201	36560-36567	Induced	_
173-202	36568-36570	by	_
173-203	36571-36573	an	_
173-204	36574-36584	Integrated	_
173-205	36585-36595	Multimodal	_
173-206	36596-36605	Cognitive	_
173-207	36606-36609	and	_
173-208	36610-36620	Whole-Body	_
173-209	36621-36633	Coordination	_
173-210	36634-36642	Training	_
173-211	36643-36655	Neuroimaging	_
173-212	36656-36658	of	_
173-213	36659-36666	healthy	_
173-214	36667-36676	cognitive	_
173-215	36677-36682	aging	_
173-216	36683-36689	Neural	_
173-217	36690-36700	correlates	_
173-218	36701-36703	of	_
173-219	36704-36707	the	_
173-220	36708-36712	core	_
173-221	36713-36719	facets	_
173-222	36720-36722	of	_
173-223	36723-36730	empathy	_
173-224	36731-36733	in	_
173-225	36734-36747	schizophrenia	_
173-226	36748-36761	Reinforcement	_
173-227	36762-36770	learning	_
173-228	36771-36774	and	_
173-229	36775-36783	dopamine	_
173-230	36784-36786	in	_
173-231	36787-36800	schizophrenia	_
173-232	36800-36801	:	_
173-233	36802-36812	dimensions	_
173-234	36813-36815	of	_
173-235	36816-36824	symptoms	_
173-236	36825-36827	or	_
173-237	36828-36836	specific	_
173-238	36837-36845	features	_
173-239	36846-36848	of	_
173-240	36849-36850	a	_
173-241	36851-36858	disease	_
173-242	36859-36864	group	_
173-243	36864-36865	?	_

#Text=Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging
#Text=Neuroanatomical Correlates of Theory of Mind Deficit in Parkinson’s Disease: A Multimodal Imaging Study
#Text=Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson’s disease?
174-1	36866-36877	Alterations	_
174-2	36878-36880	in	_
174-3	36881-36884	the	_
174-4	36885-36889	BOLD	_
174-5	36890-36894	fMRI	_
174-6	36895-36901	signal	_
174-7	36902-36906	with	_
174-8	36907-36913	ageing	_
174-9	36914-36917	and	_
174-10	36918-36925	disease	_
174-11	36925-36926	:	_
174-12	36927-36928	a	_
174-13	36929-36938	challenge	_
174-14	36939-36942	for	_
174-15	36943-36955	neuroimaging	_
174-16	36956-36971	Neuroanatomical	_
174-17	36972-36982	Correlates	_
174-18	36983-36985	of	_
174-19	36986-36992	Theory	_
174-20	36993-36995	of	_
174-21	36996-37000	Mind	_
174-22	37001-37008	Deficit	_
174-23	37009-37011	in	_
174-24	37012-37021	Parkinson	_
174-25	37021-37022	’	_
174-26	37022-37023	s	_
174-27	37024-37031	Disease	_
174-28	37031-37032	:	_
174-29	37033-37034	A	_
174-30	37035-37045	Multimodal	_
174-31	37046-37053	Imaging	_
174-32	37054-37059	Study	_
174-33	37060-37068	Magnetic	_
174-34	37069-37078	resonance	_
174-35	37079-37086	imaging	_
174-36	37086-37087	:	_
174-37	37088-37089	a	_
174-38	37090-37099	biomarker	_
174-39	37100-37103	for	_
174-40	37104-37113	cognitive	_
174-41	37114-37124	impairment	_
174-42	37125-37127	in	_
174-43	37128-37137	Parkinson	_
174-44	37137-37138	’	_
174-45	37138-37139	s	_
174-46	37140-37147	disease	_
174-47	37147-37148	?	_

#Text=Structure and course of positive and negative symptoms in schizophrenia
#Text=Cognitive function in early Parkinson’s disease: a population-based study
#Text=
#Text=Aging Effects on Whole-Brain Functional Connectivity in Adults Free of Cognitive and Psychiatric Disorders
#Text=International Consensus Study of Antipsychotic Dosing
#Text=Changes in Cognitive Function in Human Aging
#Text=ABC Schizophrenia study: an overview of results since 1996
#Text=Multivariate pattern recognition for diagnosis and prognosis in clinical neuroimaging: state of the art, current challenges and future trends
#Text=Neural Substrates of Empathic Accuracy in People With Schizophrenia
#Text=Imaging Cognition in the Aging Human Brain
#Text=Dopaminergic dysfunction in schizophrenia: Salience attribution revisited
#Text=Functional neuroimaging of motor control in Parkinson’s disease: a meta-analysis
#Text=Parkinsonism: onset, progression and mortality
#Text=Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease
#Text=Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases
#Text=Parkinson’s disease: clinical features and diagnosis
#Text=DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia
#Text=Parkinson’s disease
#Text=Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=Resting-state anticorrelations between medial and lateral prefrontal cortex: association with working memory, aging, and individual differences
#Text=L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study
#Text=Circular analysis in systems neuroscience: the dangers of double dipping
#Text=Emotion deficits in people with Schizophrenia
#Text=Glutamate, dopamine, and schizophrenia: From pathophysiology to treatment
#Text=Introduction to machine learning for brain imaging
#Text=Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
#Text=Automatic classification of early Parkinson’s disease with multi-modal MR imaging
#Text=The affective neuroscience of Aging
#Text=Support vector machine classification and characterization of age-related reorganization of functional brain networks
#Text=The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations
#Text=Connectome and schizophrenia
#Text=The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
#Text=The intrinsic resting state voice network in Parkinson’s disease
#Text=Dopamine and the regulation of cognition and attention
#Text=Functional organization of the basal ganglia: therapeutic implications for Parkinson’s disease
#Text=Schizophrenia
#Text=Parkinson disease
#Text=Inferring mental states from neuroimaging data: from reverse inference to large-scale decoding
#Text=Theory of Mind in Parkinson’s disease
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Resting state functional magnetic resonance imaging in Parkinson’s disease
#Text=Ventral Striatal Activation During Reward Processing in Psychosis: A Neurofunctional Meta-Analysis
#Text=Region-specific changes in prefrontal function with age: a review of PET and fMRI studies on working and episodic memory
#Text=Parkinson’s disease as a result of aging
#Text=Modelling neural correlates of working memory: a coordinate-based meta-analysis
#Text=The motor system and its disorders
#Text=Emotional perception: meta-analyses of face and natural scene processing
#Text=Reorganization of brain networks in aging: a review of functional connectivity studies
#Text=An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data
#Text=Differential patterns of dysconnectivity in mirror neuron and mentalizing networks in Schizophrenia
#Text=Meta-analytically informed network analysis of resting state fMRI reveals hyperconnectivity in an introspective socio-affective network in Depression
#Text=Detecting neuroimaging biomarkers for psychiatric disorders: Sample size matters
#Text=A neural substrate of prediction and reward
#Text=Motor control and aging: links to age-related brain structural, functional, and biochemical effects
#Text=Correspondence of the brain’s functional architecture during activation and rest
#Text=Discriminative analysis of non-linear brain connectivity in Schizophrenia: an fMRI study
#Text=An fMRI study of differential neural response to affective pictures in Schizophrenia
#Text=Identify Schizophrenia using resting-state functional connectivity: an exploratory research and analysis
#Text=Sensorimotor connectivity in Parkinson’s disease: The role of functional neuroimaging
#Text=Dopamine hypothesis of schizophrenia: making sense of it all
#Text=Systematic review of levodopa dose equivalency reporting in Parkinson’s disease
#Text=Resting-state test-retest reliability of a priori defined canonical networks over different preprocessing steps
#Text=Assessing and tuning brain decoders: Cross-validation, caveats, and guidelines
#Text=Characterizing functional connectivity differences in aging adults using machine learning on resting state fMRI data
#Text=From estimating activation locality to predicting disorder: A review of pattern recognition for neuroimaging-based psychiatric diagnostics
#Text=BrainNet Viewer: A network visualization tool for human brain connectomics
#Text=Functional connectivity-based signatures of Schizophrenia revealed by multiclass pattern analysis of resting-state fMRI from schizophrenic patients and their healthy siblings
#Text=Linear Two-Class Support Vector Machine Nested 10-fold Cross-Validation Scheme
#Text=Illustration of a support vector machine example for classification of the schizophrenia sample based on the emotional scene and face processing network (EmoSF).
175-1	37149-37158	Structure	_
175-2	37159-37162	and	_
175-3	37163-37169	course	_
175-4	37170-37172	of	_
175-5	37173-37181	positive	_
175-6	37182-37185	and	_
175-7	37186-37194	negative	_
175-8	37195-37203	symptoms	_
175-9	37204-37206	in	_
175-10	37207-37220	schizophrenia	_
175-11	37221-37230	Cognitive	_
175-12	37231-37239	function	_
175-13	37240-37242	in	_
175-14	37243-37248	early	_
175-15	37249-37258	Parkinson	_
175-16	37258-37259	’	_
175-17	37259-37260	s	_
175-18	37261-37268	disease	_
175-19	37268-37269	:	_
175-20	37270-37271	a	_
175-21	37272-37288	population-based	_
175-22	37289-37294	study	_
175-23	37296-37301	Aging	_
175-24	37302-37309	Effects	_
175-25	37310-37312	on	_
175-26	37313-37324	Whole-Brain	_
175-27	37325-37335	Functional	_
175-28	37336-37348	Connectivity	_
175-29	37349-37351	in	_
175-30	37352-37358	Adults	_
175-31	37359-37363	Free	_
175-32	37364-37366	of	_
175-33	37367-37376	Cognitive	_
175-34	37377-37380	and	_
175-35	37381-37392	Psychiatric	_
175-36	37393-37402	Disorders	_
175-37	37403-37416	International	_
175-38	37417-37426	Consensus	_
175-39	37427-37432	Study	_
175-40	37433-37435	of	_
175-41	37436-37449	Antipsychotic	_
175-42	37450-37456	Dosing	_
175-43	37457-37464	Changes	_
175-44	37465-37467	in	_
175-45	37468-37477	Cognitive	_
175-46	37478-37486	Function	_
175-47	37487-37489	in	_
175-48	37490-37495	Human	_
175-49	37496-37501	Aging	_
175-50	37502-37505	ABC	_
175-51	37506-37519	Schizophrenia	_
175-52	37520-37525	study	_
175-53	37525-37526	:	_
175-54	37527-37529	an	_
175-55	37530-37538	overview	_
175-56	37539-37541	of	_
175-57	37542-37549	results	_
175-58	37550-37555	since	_
175-59	37556-37560	1996	_
175-60	37561-37573	Multivariate	_
175-61	37574-37581	pattern	_
175-62	37582-37593	recognition	_
175-63	37594-37597	for	_
175-64	37598-37607	diagnosis	_
175-65	37608-37611	and	_
175-66	37612-37621	prognosis	_
175-67	37622-37624	in	_
175-68	37625-37633	clinical	_
175-69	37634-37646	neuroimaging	_
175-70	37646-37647	:	_
175-71	37648-37653	state	_
175-72	37654-37656	of	_
175-73	37657-37660	the	_
175-74	37661-37664	art	_
175-75	37664-37665	,	_
175-76	37666-37673	current	_
175-77	37674-37684	challenges	_
175-78	37685-37688	and	_
175-79	37689-37695	future	_
175-80	37696-37702	trends	_
175-81	37703-37709	Neural	_
175-82	37710-37720	Substrates	_
175-83	37721-37723	of	_
175-84	37724-37732	Empathic	_
175-85	37733-37741	Accuracy	_
175-86	37742-37744	in	_
175-87	37745-37751	People	_
175-88	37752-37756	With	_
175-89	37757-37770	Schizophrenia	_
175-90	37771-37778	Imaging	_
175-91	37779-37788	Cognition	_
175-92	37789-37791	in	_
175-93	37792-37795	the	_
175-94	37796-37801	Aging	_
175-95	37802-37807	Human	_
175-96	37808-37813	Brain	_
175-97	37814-37826	Dopaminergic	_
175-98	37827-37838	dysfunction	_
175-99	37839-37841	in	_
175-100	37842-37855	schizophrenia	_
175-101	37855-37856	:	_
175-102	37857-37865	Salience	_
175-103	37866-37877	attribution	_
175-104	37878-37887	revisited	_
175-105	37888-37898	Functional	_
175-106	37899-37911	neuroimaging	_
175-107	37912-37914	of	_
175-108	37915-37920	motor	_
175-109	37921-37928	control	_
175-110	37929-37931	in	_
175-111	37932-37941	Parkinson	_
175-112	37941-37942	’	_
175-113	37942-37943	s	_
175-114	37944-37951	disease	_
175-115	37951-37952	:	_
175-116	37953-37954	a	_
175-117	37955-37968	meta-analysis	_
175-118	37969-37981	Parkinsonism	_
175-119	37981-37982	:	_
175-120	37983-37988	onset	_
175-121	37988-37989	,	_
175-122	37990-38001	progression	_
175-123	38002-38005	and	_
175-124	38006-38015	mortality	_
175-125	38016-38024	Validity	_
175-126	38025-38027	of	_
175-127	38028-38031	the	_
175-128	38032-38036	MoCA	_
175-129	38037-38040	and	_
175-130	38041-38045	MMSE	_
175-131	38046-38048	in	_
175-132	38049-38052	the	_
175-133	38053-38062	detection	_
175-134	38063-38065	of	_
175-135	38066-38069	MCI	_
175-136	38070-38073	and	_
175-137	38074-38082	dementia	_
175-138	38083-38085	in	_
175-139	38086-38095	Parkinson	_
175-140	38096-38103	disease	_
175-141	38104-38112	Accuracy	_
175-142	38113-38115	of	_
175-143	38116-38124	clinical	_
175-144	38125-38134	diagnosis	_
175-145	38135-38137	of	_
175-146	38138-38148	idiopathic	_
175-147	38149-38158	Parkinson	_
175-148	38158-38159	’	_
175-149	38159-38160	s	_
175-150	38161-38168	disease	_
175-151	38168-38169	:	_
175-152	38170-38171	a	_
175-153	38172-38192	clinico-pathological	_
175-154	38193-38198	study	_
175-155	38199-38201	of	_
175-156	38202-38205	100	_
175-157	38206-38211	cases	_
175-158	38212-38221	Parkinson	_
175-159	38221-38222	’	_
175-160	38222-38223	s	_
175-161	38224-38231	disease	_
175-162	38231-38232	:	_
175-163	38233-38241	clinical	_
175-164	38242-38250	features	_
175-165	38251-38254	and	_
175-166	38255-38264	diagnosis	_
175-167	38265-38272	DemTect	_
175-168	38272-38273	:	_
175-169	38274-38275	a	_
175-170	38276-38279	new	_
175-171	38279-38280	,	_
175-172	38281-38290	sensitive	_
175-173	38291-38300	cognitive	_
175-174	38301-38310	screening	_
175-175	38311-38315	test	_
175-176	38316-38318	to	_
175-177	38319-38326	support	_
175-178	38327-38330	the	_
175-179	38331-38340	diagnosis	_
175-180	38341-38343	of	_
175-181	38344-38348	mild	_
175-182	38349-38358	cognitive	_
175-183	38359-38369	impairment	_
175-184	38370-38373	and	_
175-185	38374-38379	early	_
175-186	38380-38388	dementia	_
175-187	38389-38398	Parkinson	_
175-188	38398-38399	’	_
175-189	38399-38400	s	_
175-190	38401-38408	disease	_
175-191	38409-38418	Detecting	_
175-192	38419-38431	neuroimaging	_
175-193	38432-38442	biomarkers	_
175-194	38443-38446	for	_
175-195	38447-38460	schizophrenia	_
175-196	38460-38461	:	_
175-197	38462-38463	a	_
175-198	38464-38477	meta-analysis	_
175-199	38478-38480	of	_
175-200	38481-38493	multivariate	_
175-201	38494-38501	pattern	_
175-202	38502-38513	recognition	_
175-203	38514-38521	studies	_
175-204	38522-38525	The	_
175-205	38526-38534	positive	_
175-206	38535-38538	and	_
175-207	38539-38547	negative	_
175-208	38548-38556	syndrome	_
175-209	38557-38562	scale	_
175-210	38563-38564	(	_
175-211	38564-38569	PANSS	_
175-212	38569-38570	)	_
175-213	38571-38574	for	_
175-214	38575-38588	schizophrenia	_
175-215	38589-38602	Resting-state	_
175-216	38603-38619	anticorrelations	_
175-217	38620-38627	between	_
175-218	38628-38634	medial	_
175-219	38635-38638	and	_
175-220	38639-38646	lateral	_
175-221	38647-38657	prefrontal	_
175-222	38658-38664	cortex	_
175-223	38664-38665	:	_
175-224	38666-38677	association	_
175-225	38678-38682	with	_
175-226	38683-38690	working	_
175-227	38691-38697	memory	_
175-228	38697-38698	,	_
175-229	38699-38704	aging	_
175-230	38704-38705	,	_
175-231	38706-38709	and	_
175-232	38710-38720	individual	_
175-233	38721-38732	differences	_
175-234	38733-38739	L-dopa	_
175-235	38740-38749	modulates	_
175-236	38750-38760	functional	_
175-237	38761-38773	connectivity	_
175-238	38774-38776	in	_
175-239	38777-38785	striatal	_
175-240	38786-38795	cognitive	_
175-241	38796-38799	and	_
175-242	38800-38805	motor	_
175-243	38806-38814	networks	_
175-244	38814-38815	:	_
175-245	38816-38817	a	_
175-246	38818-38830	double-blind	_
175-247	38831-38849	placebo-controlled	_
175-248	38850-38855	study	_
175-249	38856-38864	Circular	_
175-250	38865-38873	analysis	_
175-251	38874-38876	in	_
175-252	38877-38884	systems	_
175-253	38885-38897	neuroscience	_
175-254	38897-38898	:	_
175-255	38899-38902	the	_
175-256	38903-38910	dangers	_
175-257	38911-38913	of	_
175-258	38914-38920	double	_
175-259	38921-38928	dipping	_
175-260	38929-38936	Emotion	_
175-261	38937-38945	deficits	_
175-262	38946-38948	in	_
175-263	38949-38955	people	_
175-264	38956-38960	with	_
175-265	38961-38974	Schizophrenia	_
175-266	38975-38984	Glutamate	_
175-267	38984-38985	,	_
175-268	38986-38994	dopamine	_
175-269	38994-38995	,	_
175-270	38996-38999	and	_
175-271	39000-39013	schizophrenia	_
175-272	39013-39014	:	_
175-273	39015-39019	From	_
175-274	39020-39035	pathophysiology	_
175-275	39036-39038	to	_
175-276	39039-39048	treatment	_
175-277	39049-39061	Introduction	_
175-278	39062-39064	to	_
175-279	39065-39072	machine	_
175-280	39073-39081	learning	_
175-281	39082-39085	for	_
175-282	39086-39091	brain	_
175-283	39092-39099	imaging	_
175-284	39100-39109	Cognitive	_
175-285	39110-39117	Control	_
175-286	39118-39126	Deficits	_
175-287	39127-39129	in	_
175-288	39130-39143	Schizophrenia	_
175-289	39143-39144	:	_
175-290	39145-39155	Mechanisms	_
175-291	39156-39159	and	_
175-292	39160-39167	Meaning	_
175-293	39168-39177	Automatic	_
175-294	39178-39192	classification	_
175-295	39193-39195	of	_
175-296	39196-39201	early	_
175-297	39202-39211	Parkinson	_
175-298	39211-39212	’	_
175-299	39212-39213	s	_
175-300	39214-39221	disease	_
175-301	39222-39226	with	_
175-302	39227-39238	multi-modal	_
175-303	39239-39241	MR	_
175-304	39242-39249	imaging	_
175-305	39250-39253	The	_
175-306	39254-39263	affective	_
175-307	39264-39276	neuroscience	_
175-308	39277-39279	of	_
175-309	39280-39285	Aging	_
175-310	39286-39293	Support	_
175-311	39294-39300	vector	_
175-312	39301-39308	machine	_
175-313	39309-39323	classification	_
175-314	39324-39327	and	_
175-315	39328-39344	characterization	_
175-316	39345-39347	of	_
175-317	39348-39359	age-related	_
175-318	39360-39374	reorganization	_
175-319	39375-39377	of	_
175-320	39378-39388	functional	_
175-321	39389-39394	brain	_
175-322	39395-39403	networks	_
175-323	39404-39407	The	_
175-324	39408-39415	Unified	_
175-325	39416-39425	Parkinson	_
175-326	39425-39426	’	_
175-327	39426-39427	s	_
175-328	39428-39435	Disease	_
175-329	39436-39442	Rating	_
175-330	39443-39448	Scale	_
175-331	39449-39450	(	_
175-332	39450-39455	UPDRS	_
175-333	39455-39456	)	_
175-334	39456-39457	:	_
175-335	39458-39464	status	_
175-336	39465-39468	and	_
175-337	39469-39484	recommendations	_
175-338	39485-39495	Connectome	_
175-339	39496-39499	and	_
175-340	39500-39513	schizophrenia	_
175-341	39514-39517	The	_
175-342	39518-39526	Montreal	_
175-343	39527-39536	Cognitive	_
175-344	39537-39547	Assessment	_
175-345	39547-39548	,	_
175-346	39549-39553	MoCA	_
175-347	39553-39554	:	_
175-348	39555-39556	a	_
175-349	39557-39562	brief	_
175-350	39563-39572	screening	_
175-351	39573-39577	tool	_
175-352	39578-39581	for	_
175-353	39582-39586	mild	_
175-354	39587-39596	cognitive	_
175-355	39597-39607	impairment	_
175-356	39608-39611	The	_
175-357	39612-39621	intrinsic	_
175-358	39622-39629	resting	_
175-359	39630-39635	state	_
175-360	39636-39641	voice	_
175-361	39642-39649	network	_
175-362	39650-39652	in	_
175-363	39653-39662	Parkinson	_
175-364	39662-39663	’	_
175-365	39663-39664	s	_
175-366	39665-39672	disease	_
175-367	39673-39681	Dopamine	_
175-368	39682-39685	and	_
175-369	39686-39689	the	_
175-370	39690-39700	regulation	_
175-371	39701-39703	of	_
175-372	39704-39713	cognition	_
175-373	39714-39717	and	_
175-374	39718-39727	attention	_
175-375	39728-39738	Functional	_
175-376	39739-39751	organization	_
175-377	39752-39754	of	_
175-378	39755-39758	the	_
175-379	39759-39764	basal	_
175-380	39765-39772	ganglia	_
175-381	39772-39773	:	_
175-382	39774-39785	therapeutic	_
175-383	39786-39798	implications	_
175-384	39799-39802	for	_
175-385	39803-39812	Parkinson	_
175-386	39812-39813	’	_
175-387	39813-39814	s	_
175-388	39815-39822	disease	_
175-389	39823-39836	Schizophrenia	_
175-390	39837-39846	Parkinson	_
175-391	39847-39854	disease	_
175-392	39855-39864	Inferring	_
175-393	39865-39871	mental	_
175-394	39872-39878	states	_
175-395	39879-39883	from	_
175-396	39884-39896	neuroimaging	_
175-397	39897-39901	data	_
175-398	39901-39902	:	_
175-399	39903-39907	from	_
175-400	39908-39915	reverse	_
175-401	39916-39925	inference	_
175-402	39926-39928	to	_
175-403	39929-39940	large-scale	_
175-404	39941-39949	decoding	_
175-405	39950-39956	Theory	_
175-406	39957-39959	of	_
175-407	39960-39964	Mind	_
175-408	39965-39967	in	_
175-409	39968-39977	Parkinson	_
175-410	39977-39978	’	_
175-411	39978-39979	s	_
175-412	39980-39987	disease	_
175-413	39988-39996	Spurious	_
175-414	39997-40000	but	_
175-415	40001-40011	systematic	_
175-416	40012-40024	correlations	_
175-417	40025-40027	in	_
175-418	40028-40038	functional	_
175-419	40039-40051	connectivity	_
175-420	40052-40055	MRI	_
175-421	40056-40064	networks	_
175-422	40065-40070	arise	_
175-423	40071-40075	from	_
175-424	40076-40083	subject	_
175-425	40084-40090	motion	_
175-426	40091-40098	Resting	_
175-427	40099-40104	state	_
175-428	40105-40115	functional	_
175-429	40116-40124	magnetic	_
175-430	40125-40134	resonance	_
175-431	40135-40142	imaging	_
175-432	40143-40145	in	_
175-433	40146-40155	Parkinson	_
175-434	40155-40156	’	_
175-435	40156-40157	s	_
175-436	40158-40165	disease	_
175-437	40166-40173	Ventral	_
175-438	40174-40182	Striatal	_
175-439	40183-40193	Activation	_
175-440	40194-40200	During	_
175-441	40201-40207	Reward	_
175-442	40208-40218	Processing	_
175-443	40219-40221	in	_
175-444	40222-40231	Psychosis	_
175-445	40231-40232	:	_
175-446	40233-40234	A	_
175-447	40235-40250	Neurofunctional	_
175-448	40251-40264	Meta-Analysis	_
175-449	40265-40280	Region-specific	_
175-450	40281-40288	changes	_
175-451	40289-40291	in	_
175-452	40292-40302	prefrontal	_
175-453	40303-40311	function	_
175-454	40312-40316	with	_
175-455	40317-40320	age	_
175-456	40320-40321	:	_
175-457	40322-40323	a	_
175-458	40324-40330	review	_
175-459	40331-40333	of	_
175-460	40334-40337	PET	_
175-461	40338-40341	and	_
175-462	40342-40346	fMRI	_
175-463	40347-40354	studies	_
175-464	40355-40357	on	_
175-465	40358-40365	working	_
175-466	40366-40369	and	_
175-467	40370-40378	episodic	_
175-468	40379-40385	memory	_
175-469	40386-40395	Parkinson	_
175-470	40395-40396	’	_
175-471	40396-40397	s	_
175-472	40398-40405	disease	_
175-473	40406-40408	as	_
175-474	40409-40410	a	_
175-475	40411-40417	result	_
175-476	40418-40420	of	_
175-477	40421-40426	aging	_
175-478	40427-40436	Modelling	_
175-479	40437-40443	neural	_
175-480	40444-40454	correlates	_
175-481	40455-40457	of	_
175-482	40458-40465	working	_
175-483	40466-40472	memory	_
175-484	40472-40473	:	_
175-485	40474-40475	a	_
175-486	40476-40492	coordinate-based	_
175-487	40493-40506	meta-analysis	_
175-488	40507-40510	The	_
175-489	40511-40516	motor	_
175-490	40517-40523	system	_
175-491	40524-40527	and	_
175-492	40528-40531	its	_
175-493	40532-40541	disorders	_
175-494	40542-40551	Emotional	_
175-495	40552-40562	perception	_
175-496	40562-40563	:	_
175-497	40564-40577	meta-analyses	_
175-498	40578-40580	of	_
175-499	40581-40585	face	_
175-500	40586-40589	and	_
175-501	40590-40597	natural	_
175-502	40598-40603	scene	_
175-503	40604-40614	processing	_
175-504	40615-40629	Reorganization	_
175-505	40630-40632	of	_
175-506	40633-40638	brain	_
175-507	40639-40647	networks	_
175-508	40648-40650	in	_
175-509	40651-40656	aging	_
175-510	40656-40657	:	_
175-511	40658-40659	a	_
175-512	40660-40666	review	_
175-513	40667-40669	of	_
175-514	40670-40680	functional	_
175-515	40681-40693	connectivity	_
175-516	40694-40701	studies	_
175-517	40702-40704	An	_
175-518	40705-40713	improved	_
175-519	40714-40723	framework	_
175-520	40724-40727	for	_
175-521	40728-40736	confound	_
175-522	40737-40747	regression	_
175-523	40748-40751	and	_
175-524	40752-40761	filtering	_
175-525	40762-40765	for	_
175-526	40766-40773	control	_
175-527	40774-40776	of	_
175-528	40777-40783	motion	_
175-529	40784-40792	artifact	_
175-530	40793-40795	in	_
175-531	40796-40799	the	_
175-532	40800-40813	preprocessing	_
175-533	40814-40816	of	_
175-534	40817-40830	resting-state	_
175-535	40831-40841	functional	_
175-536	40842-40854	connectivity	_
175-537	40855-40859	data	_
175-538	40860-40872	Differential	_
175-539	40873-40881	patterns	_
175-540	40882-40884	of	_
175-541	40885-40900	dysconnectivity	_
175-542	40901-40903	in	_
175-543	40904-40910	mirror	_
175-544	40911-40917	neuron	_
175-545	40918-40921	and	_
175-546	40922-40933	mentalizing	_
175-547	40934-40942	networks	_
175-548	40943-40945	in	_
175-549	40946-40959	Schizophrenia	_
175-550	40960-40977	Meta-analytically	_
175-551	40978-40986	informed	_
175-552	40987-40994	network	_
175-553	40995-41003	analysis	_
175-554	41004-41006	of	_
175-555	41007-41014	resting	_
175-556	41015-41020	state	_
175-557	41021-41025	fMRI	_
175-558	41026-41033	reveals	_
175-559	41034-41051	hyperconnectivity	_
175-560	41052-41054	in	_
175-561	41055-41057	an	_
175-562	41058-41071	introspective	_
175-563	41072-41087	socio-affective	_
175-564	41088-41095	network	_
175-565	41096-41098	in	_
175-566	41099-41109	Depression	_
175-567	41110-41119	Detecting	_
175-568	41120-41132	neuroimaging	_
175-569	41133-41143	biomarkers	_
175-570	41144-41147	for	_
175-571	41148-41159	psychiatric	_
175-572	41160-41169	disorders	_
175-573	41169-41170	:	_
175-574	41171-41177	Sample	_
175-575	41178-41182	size	_
175-576	41183-41190	matters	_
175-577	41191-41192	A	_
175-578	41193-41199	neural	_
175-579	41200-41209	substrate	_
175-580	41210-41212	of	_
175-581	41213-41223	prediction	_
175-582	41224-41227	and	_
175-583	41228-41234	reward	_
175-584	41235-41240	Motor	_
175-585	41241-41248	control	_
175-586	41249-41252	and	_
175-587	41253-41258	aging	_
175-588	41258-41259	:	_
175-589	41260-41265	links	_
175-590	41266-41268	to	_
175-591	41269-41280	age-related	_
175-592	41281-41286	brain	_
175-593	41287-41297	structural	_
175-594	41297-41298	,	_
175-595	41299-41309	functional	_
175-596	41309-41310	,	_
175-597	41311-41314	and	_
175-598	41315-41326	biochemical	_
175-599	41327-41334	effects	_
175-600	41335-41349	Correspondence	_
175-601	41350-41352	of	_
175-602	41353-41356	the	_
175-603	41357-41362	brain	_
175-604	41362-41363	’	_
175-605	41363-41364	s	_
175-606	41365-41375	functional	_
175-607	41376-41388	architecture	_
175-608	41389-41395	during	_
175-609	41396-41406	activation	_
175-610	41407-41410	and	_
175-611	41411-41415	rest	_
175-612	41416-41430	Discriminative	_
175-613	41431-41439	analysis	_
175-614	41440-41442	of	_
175-615	41443-41453	non-linear	_
175-616	41454-41459	brain	_
175-617	41460-41472	connectivity	_
175-618	41473-41475	in	_
175-619	41476-41489	Schizophrenia	_
175-620	41489-41490	:	_
175-621	41491-41493	an	_
175-622	41494-41498	fMRI	_
175-623	41499-41504	study	_
175-624	41505-41507	An	_
175-625	41508-41512	fMRI	_
175-626	41513-41518	study	_
175-627	41519-41521	of	_
175-628	41522-41534	differential	_
175-629	41535-41541	neural	_
175-630	41542-41550	response	_
175-631	41551-41553	to	_
175-632	41554-41563	affective	_
175-633	41564-41572	pictures	_
175-634	41573-41575	in	_
175-635	41576-41589	Schizophrenia	_
175-636	41590-41598	Identify	_
175-637	41599-41612	Schizophrenia	_
175-638	41613-41618	using	_
175-639	41619-41632	resting-state	_
175-640	41633-41643	functional	_
175-641	41644-41656	connectivity	_
175-642	41656-41657	:	_
175-643	41658-41660	an	_
175-644	41661-41672	exploratory	_
175-645	41673-41681	research	_
175-646	41682-41685	and	_
175-647	41686-41694	analysis	_
175-648	41695-41707	Sensorimotor	_
175-649	41708-41720	connectivity	_
175-650	41721-41723	in	_
175-651	41724-41733	Parkinson	_
175-652	41733-41734	’	_
175-653	41734-41735	s	_
175-654	41736-41743	disease	_
175-655	41743-41744	:	_
175-656	41745-41748	The	_
175-657	41749-41753	role	_
175-658	41754-41756	of	_
175-659	41757-41767	functional	_
175-660	41768-41780	neuroimaging	_
175-661	41781-41789	Dopamine	_
175-662	41790-41800	hypothesis	_
175-663	41801-41803	of	_
175-664	41804-41817	schizophrenia	_
175-665	41817-41818	:	_
175-666	41819-41825	making	_
175-667	41826-41831	sense	_
175-668	41832-41834	of	_
175-669	41835-41837	it	_
175-670	41838-41841	all	_
175-671	41842-41852	Systematic	_
175-672	41853-41859	review	_
175-673	41860-41862	of	_
175-674	41863-41871	levodopa	_
175-675	41872-41876	dose	_
175-676	41877-41888	equivalency	_
175-677	41889-41898	reporting	_
175-678	41899-41901	in	_
175-679	41902-41911	Parkinson	_
175-680	41911-41912	’	_
175-681	41912-41913	s	_
175-682	41914-41921	disease	_
175-683	41922-41935	Resting-state	_
175-684	41936-41947	test-retest	_
175-685	41948-41959	reliability	_
175-686	41960-41962	of	_
175-687	41963-41964	a	_
175-688	41965-41971	priori	_
175-689	41972-41979	defined	_
175-690	41980-41989	canonical	_
175-691	41990-41998	networks	_
175-692	41999-42003	over	_
175-693	42004-42013	different	_
175-694	42014-42027	preprocessing	_
175-695	42028-42033	steps	_
175-696	42034-42043	Assessing	_
175-697	42044-42047	and	_
175-698	42048-42054	tuning	_
175-699	42055-42060	brain	_
175-700	42061-42069	decoders	_
175-701	42069-42070	:	_
175-702	42071-42087	Cross-validation	_
175-703	42087-42088	,	_
175-704	42089-42096	caveats	_
175-705	42096-42097	,	_
175-706	42098-42101	and	_
175-707	42102-42112	guidelines	_
175-708	42113-42127	Characterizing	_
175-709	42128-42138	functional	_
175-710	42139-42151	connectivity	_
175-711	42152-42163	differences	_
175-712	42164-42166	in	_
175-713	42167-42172	aging	_
175-714	42173-42179	adults	_
175-715	42180-42185	using	_
175-716	42186-42193	machine	_
175-717	42194-42202	learning	_
175-718	42203-42205	on	_
175-719	42206-42213	resting	_
175-720	42214-42219	state	_
175-721	42220-42224	fMRI	_
175-722	42225-42229	data	_
175-723	42230-42234	From	_
175-724	42235-42245	estimating	_
175-725	42246-42256	activation	_
175-726	42257-42265	locality	_
175-727	42266-42268	to	_
175-728	42269-42279	predicting	_
175-729	42280-42288	disorder	_
175-730	42288-42289	:	_
175-731	42290-42291	A	_
175-732	42292-42298	review	_
175-733	42299-42301	of	_
175-734	42302-42309	pattern	_
175-735	42310-42321	recognition	_
175-736	42322-42325	for	_
175-737	42326-42344	neuroimaging-based	_
175-738	42345-42356	psychiatric	_
175-739	42357-42368	diagnostics	_
175-740	42369-42377	BrainNet	_
175-741	42378-42384	Viewer	_
175-742	42384-42385	:	_
175-743	42386-42387	A	_
175-744	42388-42395	network	_
175-745	42396-42409	visualization	_
175-746	42410-42414	tool	_
175-747	42415-42418	for	_
175-748	42419-42424	human	_
175-749	42425-42430	brain	_
175-750	42431-42443	connectomics	_
175-751	42444-42454	Functional	_
175-752	42455-42473	connectivity-based	_
175-753	42474-42484	signatures	_
175-754	42485-42487	of	_
175-755	42488-42501	Schizophrenia	_
175-756	42502-42510	revealed	_
175-757	42511-42513	by	_
175-758	42514-42524	multiclass	_
175-759	42525-42532	pattern	_
175-760	42533-42541	analysis	_
175-761	42542-42544	of	_
175-762	42545-42558	resting-state	_
175-763	42559-42563	fMRI	_
175-764	42564-42568	from	_
175-765	42569-42582	schizophrenic	_
175-766	42583-42591	patients	_
175-767	42592-42595	and	_
175-768	42596-42601	their	_
175-769	42602-42609	healthy	_
175-770	42610-42618	siblings	_
175-771	42619-42625	Linear	_
175-772	42626-42635	Two-Class	_
175-773	42636-42643	Support	_
175-774	42644-42650	Vector	_
175-775	42651-42658	Machine	_
175-776	42659-42665	Nested	_
175-777	42666-42668	10	_
175-778	42668-42669	-	_
175-779	42669-42673	fold	_
175-780	42674-42690	Cross-Validation	_
175-781	42691-42697	Scheme	_
175-782	42698-42710	Illustration	_
175-783	42711-42713	of	_
175-784	42714-42715	a	_
175-785	42716-42723	support	_
175-786	42724-42730	vector	_
175-787	42731-42738	machine	_
175-788	42739-42746	example	_
175-789	42747-42750	for	_
175-790	42751-42765	classification	_
175-791	42766-42768	of	_
175-792	42769-42772	the	_
175-793	42773-42786	schizophrenia	_
175-794	42787-42793	sample	_
175-795	42794-42799	based	_
175-796	42800-42802	on	_
175-797	42803-42806	the	_
175-798	42807-42816	emotional	_
175-799	42817-42822	scene	_
175-800	42823-42826	and	_
175-801	42827-42831	face	_
175-802	42832-42842	processing	_
175-803	42843-42850	network	_
175-804	42851-42852	(	_
175-805	42852-42857	EmoSF	_
175-806	42857-42858	)	_
175-807	42858-42859	.	_

#Text=As input variables (DATA) (= features) served the subjects` RSFCs of all edges of every network.
176-1	42860-42862	As	_
176-2	42863-42868	input	_
176-3	42869-42878	variables	_
176-4	42879-42880	(	_
176-5	42880-42884	DATA	_
176-6	42884-42885	)	_
176-7	42886-42887	(	_
176-8	42887-42888	=	_
176-9	42889-42897	features	_
176-10	42897-42898	)	_
176-11	42899-42905	served	_
176-12	42906-42909	the	_
176-13	42910-42918	subjects	_
176-14	42918-42919	`	_
176-15	42920-42925	RSFCs	_
176-16	42926-42928	of	_
176-17	42929-42932	all	_
176-18	42933-42938	edges	_
176-19	42939-42941	of	_
176-20	42942-42947	every	_
176-21	42948-42955	network	_
176-22	42955-42956	.	_

#Text=The inner loop was performed in a 10-fold manner with 10 repetitions conducted as parameter setting optimization on a training sample.
177-1	42957-42960	The	_
177-2	42961-42966	inner	_
177-3	42967-42971	loop	_
177-4	42972-42975	was	_
177-5	42976-42985	performed	_
177-6	42986-42988	in	_
177-7	42989-42990	a	_
177-8	42991-42993	10	_
177-9	42993-42994	-	_
177-10	42994-42998	fold	_
177-11	42999-43005	manner	_
177-12	43006-43010	with	_
177-13	43011-43013	10	_
177-14	43014-43025	repetitions	_
177-15	43026-43035	conducted	_
177-16	43036-43038	as	_
177-17	43039-43048	parameter	_
177-18	43049-43056	setting	_
177-19	43057-43069	optimization	_
177-20	43070-43072	on	_
177-21	43073-43074	a	_
177-22	43075-43083	training	_
177-23	43084-43090	sample	_
177-24	43090-43091	.	_

#Text=The outer loop was performed in a 10-fold manner with 25 repetitions conducted as classification accuracy testing on an unseen test set.
178-1	43092-43095	The	_
178-2	43096-43101	outer	_
178-3	43102-43106	loop	_
178-4	43107-43110	was	_
178-5	43111-43120	performed	_
178-6	43121-43123	in	_
178-7	43124-43125	a	_
178-8	43126-43128	10	_
178-9	43128-43129	-	_
178-10	43129-43133	fold	_
178-11	43134-43140	manner	_
178-12	43141-43145	with	_
178-13	43146-43148	25	_
178-14	43149-43160	repetitions	_
178-15	43161-43170	conducted	_
178-16	43171-43173	as	_
178-17	43174-43188	classification	_
178-18	43189-43197	accuracy	_
178-19	43198-43205	testing	_
178-20	43206-43208	on	_
178-21	43209-43211	an	_
178-22	43212-43218	unseen	_
178-23	43219-43223	test	_
178-24	43224-43227	set	_
178-25	43227-43228	.	_

#Text=Classification performance measures are computed based on the confusion matrix.
179-1	43229-43243	Classification	_
179-2	43244-43255	performance	_
179-3	43256-43264	measures	_
179-4	43265-43268	are	_
179-5	43269-43277	computed	_
179-6	43278-43283	based	_
179-7	43284-43286	on	_
179-8	43287-43290	the	_
179-9	43291-43300	confusion	_
179-10	43301-43307	matrix	_
179-11	43307-43308	.	_

#Text=Acc.: accuracy; Sens.: sensitivity; Spec.: specificity; AUC: area under the receiver operating characteristics curve and d’ (see materials and methods section for explanation).
180-1	43309-43312	Acc	_
180-2	43312-43313	.	_
180-3	43313-43314	:	_
180-4	43315-43323	accuracy	_
180-5	43323-43324	;	_
180-6	43325-43329	Sens	_
180-7	43329-43330	.	_
180-8	43330-43331	:	_
180-9	43332-43343	sensitivity	_
180-10	43343-43344	;	_
180-11	43345-43349	Spec	_
180-12	43349-43350	.	_
180-13	43350-43351	:	_
180-14	43352-43363	specificity	_
180-15	43363-43364	;	_
180-16	43365-43368	AUC	_
180-17	43368-43369	:	_
180-18	43370-43374	area	_
180-19	43375-43380	under	_
180-20	43381-43384	the	_
180-21	43385-43393	receiver	_
180-22	43394-43403	operating	_
180-23	43404-43419	characteristics	_
180-24	43420-43425	curve	_
180-25	43426-43429	and	_
180-26	43430-43431	d	_
180-27	43431-43432	’	_
180-28	43433-43434	(	_
180-29	43434-43437	see	_
180-30	43438-43447	materials	_
180-31	43448-43451	and	_
180-32	43452-43459	methods	_
180-33	43460-43467	section	_
180-34	43468-43471	for	_
180-35	43472-43483	explanation	_
180-36	43483-43484	)	_
180-37	43484-43485	.	_

#Text=Group Classification Results of the Support Vector Machine
#Text=A) Polar plot of group classification accuracies based on all 12 networks for schizophrenia (in green), Parkinson’s disease (in blue) and normal aging (in yellow).
181-1	43486-43491	Group	_
181-2	43492-43506	Classification	_
181-3	43507-43514	Results	_
181-4	43515-43517	of	_
181-5	43518-43521	the	_
181-6	43522-43529	Support	_
181-7	43530-43536	Vector	_
181-8	43537-43544	Machine	_
181-9	43545-43546	A	_
181-10	43546-43547	)	_
181-11	43548-43553	Polar	_
181-12	43554-43558	plot	_
181-13	43559-43561	of	_
181-14	43562-43567	group	_
181-15	43568-43582	classification	_
181-16	43583-43593	accuracies	_
181-17	43594-43599	based	_
181-18	43600-43602	on	_
181-19	43603-43606	all	_
181-20	43607-43609	12	_
181-21	43610-43618	networks	_
181-22	43619-43622	for	_
181-23	43623-43636	schizophrenia	_
181-24	43637-43638	(	_
181-25	43638-43640	in	_
181-26	43641-43646	green	_
181-27	43646-43647	)	_
181-28	43647-43648	,	_
181-29	43649-43658	Parkinson	_
181-30	43658-43659	’	_
181-31	43659-43660	s	_
181-32	43661-43668	disease	_
181-33	43669-43670	(	_
181-34	43670-43672	in	_
181-35	43673-43677	blue	_
181-36	43677-43678	)	_
181-37	43679-43682	and	_
181-38	43683-43689	normal	_
181-39	43690-43695	aging	_
181-40	43696-43697	(	_
181-41	43697-43699	in	_
181-42	43700-43706	yellow	_
181-43	43706-43707	)	_
181-44	43707-43708	.	_

#Text=Accuracy refers to the proportion of subjects correctly classified as patients (PD, SCZ) or older age and subjects correctly classified as being healthy controls or younger age.
182-1	43709-43717	Accuracy	_
182-2	43718-43724	refers	_
182-3	43725-43727	to	_
182-4	43728-43731	the	_
182-5	43732-43742	proportion	_
182-6	43743-43745	of	_
182-7	43746-43754	subjects	_
182-8	43755-43764	correctly	_
182-9	43765-43775	classified	_
182-10	43776-43778	as	_
182-11	43779-43787	patients	_
182-12	43788-43789	(	_
182-13	43789-43791	PD	_
182-14	43791-43792	,	_
182-15	43793-43796	SCZ	_
182-16	43796-43797	)	_
182-17	43798-43800	or	_
182-18	43801-43806	older	_
182-19	43807-43810	age	_
182-20	43811-43814	and	_
182-21	43815-43823	subjects	_
182-22	43824-43833	correctly	_
182-23	43834-43844	classified	_
182-24	43845-43847	as	_
182-25	43848-43853	being	_
182-26	43854-43861	healthy	_
182-27	43862-43870	controls	_
182-28	43871-43873	or	_
182-29	43874-43881	younger	_
182-30	43882-43885	age	_
182-31	43885-43886	.	_

#Text=B) Polar plot of z-standardized accuracies (corrected for multiple comparisons) of patients classification for schizophrenia (in green) and Parkinson’s disease (in blue).
183-1	43887-43888	B	_
183-2	43888-43889	)	_
183-3	43890-43895	Polar	_
183-4	43896-43900	plot	_
183-5	43901-43903	of	_
183-6	43904-43918	z-standardized	_
183-7	43919-43929	accuracies	_
183-8	43930-43931	(	_
183-9	43931-43940	corrected	_
183-10	43941-43944	for	_
183-11	43945-43953	multiple	_
183-12	43954-43965	comparisons	_
183-13	43965-43966	)	_
183-14	43967-43969	of	_
183-15	43970-43978	patients	_
183-16	43979-43993	classification	_
183-17	43994-43997	for	_
183-18	43998-44011	schizophrenia	_
183-19	44012-44013	(	_
183-20	44013-44015	in	_
183-21	44016-44021	green	_
183-22	44021-44022	)	_
183-23	44023-44026	and	_
183-24	44027-44036	Parkinson	_
183-25	44036-44037	’	_
183-26	44037-44038	s	_
183-27	44039-44046	disease	_
183-28	44047-44048	(	_
183-29	44048-44050	in	_
183-30	44051-44055	blue	_
183-31	44055-44056	)	_
183-32	44056-44057	.	_

#Text=C) Log-likelihood ratios (LLRs) of classification performance for networks showing higher classification for one patient group vs. the other.
184-1	44058-44059	C	_
184-2	44059-44060	)	_
184-3	44061-44075	Log-likelihood	_
184-4	44076-44082	ratios	_
184-5	44083-44084	(	_
184-6	44084-44088	LLRs	_
184-7	44088-44089	)	_
184-8	44090-44092	of	_
184-9	44093-44107	classification	_
184-10	44108-44119	performance	_
184-11	44120-44123	for	_
184-12	44124-44132	networks	_
184-13	44133-44140	showing	_
184-14	44141-44147	higher	_
184-15	44148-44162	classification	_
184-16	44163-44166	for	_
184-17	44167-44170	one	_
184-18	44171-44178	patient	_
184-19	44179-44184	group	_
184-20	44185-44187	vs	_
184-21	44187-44188	.	_
184-22	44189-44192	the	_
184-23	44193-44198	other	_
184-24	44198-44199	.	_

#Text=Sample and group matching characteristics
#Text=Sample\tn(males)\tAge(years)\tHead Movement(DVARS)\tAge at Onset(years)\tIllness Duration(years)\tAntipsychotic/Dopaminergic Medication\tNeuropsychology & Psychopathology\t \tSchizophrenia Sample\t\t\t\t\t\tOZP-equivalent\tPANSS: Total/PS/NS/GEN\t \t\t\t\t\t\t\t\t \tCOBRE\t\t\t\t\t\t\t\t \tSCZ Patients\t55 (46)\t38 ± 14\t1.66 ± 0.55*\t20 ± 8\t17 ± 14\t13 ± 8\t58 ± 14/14 ± 5/14 ± 5/29 ± 8\t \tHCscz\t55 (42)\t38 ± 12\t1.44 ± 0.41\t\t\t\t\t \tGöttingen\t\t\t\t\t\t\t\t \tSCZ Patients\t31 (25)\t32 ± 10\t1.47 ± 0.30*\t25 ± 8\t7 ± 8\t14 ± 9\t52 ± 11/12 ± 3/13 ± 4/28 ± 6\t \tHCscz\t29 (22)\t32 ± 9\t1.31 ± 0.23\t\t\t\t\t \t Total\t\t\t\t\t\t\t\t \t SCZ Patients\t86 (71)\t36 ± 13\t1.59 ± 0.48*\t\t\t\t\t \t HCscz\t84 (64)\t36 ± 11\t1.39 ± 0.36\t\t\t\t\t \tParkinson’s Disease Sample\t\t\t\t\t\tLEDD\tH & Y Scale\tUPDRS-III\tMoCA\t \t\t\t\t\t\t\t\t \tAachen\t\t\t\t\t\t\t\t\t\t \tPD Patients\t32 (21)\t64 ± 9\t0.51 ± 0.16\t59 ± 8\t6 ± 5\t449 ± 238\t2 ± 1\t23 ± 12\t27 ± 2\t \tHCPD\t33 (20)\t63 ± 6\t0.62 ± 0.29\t\t\t\t\t\t\t \tDüsseldorf\t\t\t\t\t\t\t\t\t\t \tPD Patients\t48 (30)\t59 ± 9\t0.69 ± 0.26\t51 ± 9\t8 ± 6\t1029 ± 416\t2,5 ± 1\t16 ± 8\t24 ± 4\t \tHCPD\t51 (30)\t57 ± 9\t0.68 ± 0.22\t\t\t\t\t\t\t \t Total\t\t\t\t\t\t\t\t\t\t \t PD Patients\t80 (51)\t61 ± 9\t0.62 ± 0.24\t\t\t\t\t\t\t \t HCPD\t84 (50)\t59 ± 8\t0.66 ± 0.25\t\t\t\t\t\t\t \tNormal Aging Sample\t\t\t\t\t\t\tDemTect\t\tBDI-II\t \tJülich\t\t\t\t\t\t\t\t\t\t \tOld\t48 (26)\t61 ± 5\t1.58 ± 0.41*\t\t\t\t16 ± 2\t\t5 ± 5\t \tYoung\t52 (26)\t26 ± 3\t1.24 ± 0.24\t\t\t\t\t\t5 ± 4\t \t1000BRAINS Jülich\t\t\t\t\t\t\t\t\t\t \tOld\t47 (25)\t64 ± 4\t1.79 ± 0.43*\t\t\t\t15 ± 2\t\t6 ± 5\t \tYoung\t41 (23)\t28 ± 4\t1.28 ± 0.26\t\t\t\t\t\t4 ± 4\t \t Total\t\t\t\t\t\t\t\t\t\t \t Old\t95 (51)\t63 ± 5\t1.68 ± 0.43*\t\t\t\t\t\t\t \t Young\t93 (49)\t27 ± 4\t1.26 ± 0.25\t\t\t\t\t\t\t \t
#Text=SCZ: schizophrenia; PD: Parkinson’s disease; HCSCZ: matched healthy controls of schizophrenia sample; HCPD: matched healthy controls of Parkinson’s disease sample; characteristic values in mean ± standard deviation; DVARS: derivative of root mean squared variance over voxels (head movement parameter); significant difference in age (clinical samples), gender and movement are marked with
#Text=for p < .05;
#Text=: OZP-equivalent: Olanzapine equivalent dose; PANSS: Positive and Negative Symptom Scale, (PS: Positive Symptoms Scale/NS: Negative Symptoms Scale/GEN: General Psychopathology Scale);
#Text=: LEDD: Levodopa equivalent daily dose; H & Y scale: Hoehn and Yahr Scale; UPDRS-III: Unified Parkinson’s Disease Rating Scale Part III; MoCA: Montreal Cognitive Assessment;
#Text=: DemTect: Mild Cognitive Impairment and Early Dementia Detection; BDI-II: Beck Depression Inventory II.
185-1	44200-44206	Sample	_
185-2	44207-44210	and	_
185-3	44211-44216	group	_
185-4	44217-44225	matching	_
185-5	44226-44241	characteristics	_
185-6	44242-44248	Sample	_
185-7	44249-44250	n	_
185-8	44250-44251	(	_
185-9	44251-44256	males	_
185-10	44256-44257	)	_
185-11	44258-44261	Age	_
185-12	44261-44262	(	_
185-13	44262-44267	years	_
185-14	44267-44268	)	_
185-15	44269-44273	Head	_
185-16	44274-44282	Movement	_
185-17	44282-44283	(	_
185-18	44283-44288	DVARS	_
185-19	44288-44289	)	_
185-20	44290-44293	Age	_
185-21	44294-44296	at	_
185-22	44297-44302	Onset	_
185-23	44302-44303	(	_
185-24	44303-44308	years	_
185-25	44308-44309	)	_
185-26	44310-44317	Illness	_
185-27	44318-44326	Duration	_
185-28	44326-44327	(	_
185-29	44327-44332	years	_
185-30	44332-44333	)	_
185-31	44334-44347	Antipsychotic	_
185-32	44347-44348	/	_
185-33	44348-44360	Dopaminergic	_
185-34	44361-44371	Medication	_
185-35	44372-44387	Neuropsychology	_
185-36	44388-44389	&	_
185-37	44390-44405	Psychopathology	_
185-38	44408-44421	Schizophrenia	_
185-39	44422-44428	Sample	_
185-40	44434-44448	OZP-equivalent	_
185-41	44449-44454	PANSS	_
185-42	44454-44455	:	_
185-43	44456-44461	Total	_
185-44	44461-44462	/	_
185-45	44462-44464	PS	_
185-46	44464-44465	/	_
185-47	44465-44467	NS	_
185-48	44467-44468	/	_
185-49	44468-44471	GEN	_
185-50	44483-44488	COBRE	_
185-51	44498-44501	SCZ	_
185-52	44502-44510	Patients	_
185-53	44511-44513	55	_
185-54	44514-44515	(	_
185-55	44515-44517	46	_
185-56	44517-44518	)	_
185-57	44519-44521	38	_
185-58	44522-44523	±	_
185-59	44524-44526	14	_
185-60	44527-44531	1.66	_
185-61	44532-44533	±	_
185-62	44534-44538	0.55	_
185-63	44538-44539	*	_
185-64	44540-44542	20	_
185-65	44543-44544	±	_
185-66	44545-44546	8	_
185-67	44547-44549	17	_
185-68	44550-44551	±	_
185-69	44552-44554	14	_
185-70	44555-44557	13	_
185-71	44558-44559	±	_
185-72	44560-44561	8	_
185-73	44562-44564	58	_
185-74	44565-44566	±	_
185-75	44567-44569	14	_
185-76	44569-44570	/	_
185-77	44570-44572	14	_
185-78	44573-44574	±	_
185-79	44575-44576	5	_
185-80	44576-44577	/	_
185-81	44577-44579	14	_
185-82	44580-44581	±	_
185-83	44582-44583	5	_
185-84	44583-44584	/	_
185-85	44584-44586	29	_
185-86	44587-44588	±	_
185-87	44589-44590	8	_
185-88	44593-44598	HCscz	_
185-89	44599-44601	55	_
185-90	44602-44603	(	_
185-91	44603-44605	42	_
185-92	44605-44606	)	_
185-93	44607-44609	38	_
185-94	44610-44611	±	_
185-95	44612-44614	12	_
185-96	44615-44619	1.44	_
185-97	44620-44621	±	_
185-98	44622-44626	0.41	_
185-99	44633-44642	Göttingen	_
185-100	44652-44655	SCZ	_
185-101	44656-44664	Patients	_
185-102	44665-44667	31	_
185-103	44668-44669	(	_
185-104	44669-44671	25	_
185-105	44671-44672	)	_
185-106	44673-44675	32	_
185-107	44676-44677	±	_
185-108	44678-44680	10	_
185-109	44681-44685	1.47	_
185-110	44686-44687	±	_
185-111	44688-44692	0.30	_
185-112	44692-44693	*	_
185-113	44694-44696	25	_
185-114	44697-44698	±	_
185-115	44699-44700	8	_
185-116	44701-44702	7	_
185-117	44703-44704	±	_
185-118	44705-44706	8	_
185-119	44707-44709	14	_
185-120	44710-44711	±	_
185-121	44712-44713	9	_
185-122	44714-44716	52	_
185-123	44717-44718	±	_
185-124	44719-44721	11	_
185-125	44721-44722	/	_
185-126	44722-44724	12	_
185-127	44725-44726	±	_
185-128	44727-44728	3	_
185-129	44728-44729	/	_
185-130	44729-44731	13	_
185-131	44732-44733	±	_
185-132	44734-44735	4	_
185-133	44735-44736	/	_
185-134	44736-44738	28	_
185-135	44739-44740	±	_
185-136	44741-44742	6	_
185-137	44745-44750	HCscz	_
185-138	44751-44753	29	_
185-139	44754-44755	(	_
185-140	44755-44757	22	_
185-141	44757-44758	)	_
185-142	44759-44761	32	_
185-143	44762-44763	±	_
185-144	44764-44765	9	_
185-145	44766-44770	1.31	_
185-146	44771-44772	±	_
185-147	44773-44777	0.23	_
185-148	44785-44790	Total	_
185-149	44801-44804	SCZ	_
185-150	44805-44813	Patients	_
185-151	44814-44816	86	_
185-152	44817-44818	(	_
185-153	44818-44820	71	_
185-154	44820-44821	)	_
185-155	44822-44824	36	_
185-156	44825-44826	±	_
185-157	44827-44829	13	_
185-158	44830-44834	1.59	_
185-159	44835-44836	±	_
185-160	44837-44841	0.48	_
185-161	44841-44842	*	_
185-162	44850-44855	HCscz	_
185-163	44856-44858	84	_
185-164	44859-44860	(	_
185-165	44860-44862	64	_
185-166	44862-44863	)	_
185-167	44864-44866	36	_
185-168	44867-44868	±	_
185-169	44869-44871	11	_
185-170	44872-44876	1.39	_
185-171	44877-44878	±	_
185-172	44879-44883	0.36	_
185-173	44890-44899	Parkinson	_
185-174	44899-44900	’	_
185-175	44900-44901	s	_
185-176	44902-44909	Disease	_
185-177	44910-44916	Sample	_
185-178	44922-44926	LEDD	_
185-179	44927-44928	H	_
185-180	44929-44930	&	_
185-181	44931-44932	Y	_
185-182	44933-44938	Scale	_
185-183	44939-44948	UPDRS-III	_
185-184	44949-44953	MoCA	_
185-185	44965-44971	Aachen	_
185-186	44983-44985	PD	_
185-187	44986-44994	Patients	_
185-188	44995-44997	32	_
185-189	44998-44999	(	_
185-190	44999-45001	21	_
185-191	45001-45002	)	_
185-192	45003-45005	64	_
185-193	45006-45007	±	_
185-194	45008-45009	9	_
185-195	45010-45014	0.51	_
185-196	45015-45016	±	_
185-197	45017-45021	0.16	_
185-198	45022-45024	59	_
185-199	45025-45026	±	_
185-200	45027-45028	8	_
185-201	45029-45030	6	_
185-202	45031-45032	±	_
185-203	45033-45034	5	_
185-204	45035-45038	449	_
185-205	45039-45040	±	_
185-206	45041-45044	238	_
185-207	45045-45046	2	_
185-208	45047-45048	±	_
185-209	45049-45050	1	_
185-210	45051-45053	23	_
185-211	45054-45055	±	_
185-212	45056-45058	12	_
185-213	45059-45061	27	_
185-214	45062-45063	±	_
185-215	45064-45065	2	_
185-216	45068-45072	HCPD	_
185-217	45073-45075	33	_
185-218	45076-45077	(	_
185-219	45077-45079	20	_
185-220	45079-45080	)	_
185-221	45081-45083	63	_
185-222	45084-45085	±	_
185-223	45086-45087	6	_
185-224	45088-45092	0.62	_
185-225	45093-45094	±	_
185-226	45095-45099	0.29	_
185-227	45108-45118	Düsseldorf	_
185-228	45130-45132	PD	_
185-229	45133-45141	Patients	_
185-230	45142-45144	48	_
185-231	45145-45146	(	_
185-232	45146-45148	30	_
185-233	45148-45149	)	_
185-234	45150-45152	59	_
185-235	45153-45154	±	_
185-236	45155-45156	9	_
185-237	45157-45161	0.69	_
185-238	45162-45163	±	_
185-239	45164-45168	0.26	_
185-240	45169-45171	51	_
185-241	45172-45173	±	_
185-242	45174-45175	9	_
185-243	45176-45177	8	_
185-244	45178-45179	±	_
185-245	45180-45181	6	_
185-246	45182-45186	1029	_
185-247	45187-45188	±	_
185-248	45189-45192	416	_
185-249	45193-45196	2,5	_
185-250	45197-45198	±	_
185-251	45199-45200	1	_
185-252	45201-45203	16	_
185-253	45204-45205	±	_
185-254	45206-45207	8	_
185-255	45208-45210	24	_
185-256	45211-45212	±	_
185-257	45213-45214	4	_
185-258	45217-45221	HCPD	_
185-259	45222-45224	51	_
185-260	45225-45226	(	_
185-261	45226-45228	30	_
185-262	45228-45229	)	_
185-263	45230-45232	57	_
185-264	45233-45234	±	_
185-265	45235-45236	9	_
185-266	45237-45241	0.68	_
185-267	45242-45243	±	_
185-268	45244-45248	0.22	_
185-269	45258-45263	Total	_
185-270	45276-45278	PD	_
185-271	45279-45287	Patients	_
185-272	45288-45290	80	_
185-273	45291-45292	(	_
185-274	45292-45294	51	_
185-275	45294-45295	)	_
185-276	45296-45298	61	_
185-277	45299-45300	±	_
185-278	45301-45302	9	_
185-279	45303-45307	0.62	_
185-280	45308-45309	±	_
185-281	45310-45314	0.24	_
185-282	45324-45328	HCPD	_
185-283	45329-45331	84	_
185-284	45332-45333	(	_
185-285	45333-45335	50	_
185-286	45335-45336	)	_
185-287	45337-45339	59	_
185-288	45340-45341	±	_
185-289	45342-45343	8	_
185-290	45344-45348	0.66	_
185-291	45349-45350	±	_
185-292	45351-45355	0.25	_
185-293	45364-45370	Normal	_
185-294	45371-45376	Aging	_
185-295	45377-45383	Sample	_
185-296	45390-45397	DemTect	_
185-297	45399-45405	BDI-II	_
185-298	45408-45414	Jülich	_
185-299	45426-45429	Old	_
185-300	45430-45432	48	_
185-301	45433-45434	(	_
185-302	45434-45436	26	_
185-303	45436-45437	)	_
185-304	45438-45440	61	_
185-305	45441-45442	±	_
185-306	45443-45444	5	_
185-307	45445-45449	1.58	_
185-308	45450-45451	±	_
185-309	45452-45456	0.41	_
185-310	45456-45457	*	_
185-311	45461-45463	16	_
185-312	45464-45465	±	_
185-313	45466-45467	2	_
185-314	45469-45470	5	_
185-315	45471-45472	±	_
185-316	45473-45474	5	_
185-317	45477-45482	Young	_
185-318	45483-45485	52	_
185-319	45486-45487	(	_
185-320	45487-45489	26	_
185-321	45489-45490	)	_
185-322	45491-45493	26	_
185-323	45494-45495	±	_
185-324	45496-45497	3	_
185-325	45498-45502	1.24	_
185-326	45503-45504	±	_
185-327	45505-45509	0.24	_
185-328	45515-45516	5	_
185-329	45517-45518	±	_
185-330	45519-45520	4	_
185-331	45523-45533	1000BRAINS	_
185-332	45534-45540	Jülich	_
185-333	45552-45555	Old	_
185-334	45556-45558	47	_
185-335	45559-45560	(	_
185-336	45560-45562	25	_
185-337	45562-45563	)	_
185-338	45564-45566	64	_
185-339	45567-45568	±	_
185-340	45569-45570	4	_
185-341	45571-45575	1.79	_
185-342	45576-45577	±	_
185-343	45578-45582	0.43	_
185-344	45582-45583	*	_
185-345	45587-45589	15	_
185-346	45590-45591	±	_
185-347	45592-45593	2	_
185-348	45595-45596	6	_
185-349	45597-45598	±	_
185-350	45599-45600	5	_
185-351	45603-45608	Young	_
185-352	45609-45611	41	_
185-353	45612-45613	(	_
185-354	45613-45615	23	_
185-355	45615-45616	)	_
185-356	45617-45619	28	_
185-357	45620-45621	±	_
185-358	45622-45623	4	_
185-359	45624-45628	1.28	_
185-360	45629-45630	±	_
185-361	45631-45635	0.26	_
185-362	45641-45642	4	_
185-363	45643-45644	±	_
185-364	45645-45646	4	_
185-365	45650-45655	Total	_
185-366	45668-45671	Old	_
185-367	45672-45674	95	_
185-368	45675-45676	(	_
185-369	45676-45678	51	_
185-370	45678-45679	)	_
185-371	45680-45682	63	_
185-372	45683-45684	±	_
185-373	45685-45686	5	_
185-374	45687-45691	1.68	_
185-375	45692-45693	±	_
185-376	45694-45698	0.43	_
185-377	45698-45699	*	_
185-378	45709-45714	Young	_
185-379	45715-45717	93	_
185-380	45718-45719	(	_
185-381	45719-45721	49	_
185-382	45721-45722	)	_
185-383	45723-45725	27	_
185-384	45726-45727	±	_
185-385	45728-45729	4	_
185-386	45730-45734	1.26	_
185-387	45735-45736	±	_
185-388	45737-45741	0.25	_
185-389	45751-45754	SCZ	_
185-390	45754-45755	:	_
185-391	45756-45769	schizophrenia	_
185-392	45769-45770	;	_
185-393	45771-45773	PD	_
185-394	45773-45774	:	_
185-395	45775-45784	Parkinson	_
185-396	45784-45785	’	_
185-397	45785-45786	s	_
185-398	45787-45794	disease	_
185-399	45794-45795	;	_
185-400	45796-45801	HCSCZ	_
185-401	45801-45802	:	_
185-402	45803-45810	matched	_
185-403	45811-45818	healthy	_
185-404	45819-45827	controls	_
185-405	45828-45830	of	_
185-406	45831-45844	schizophrenia	_
185-407	45845-45851	sample	_
185-408	45851-45852	;	_
185-409	45853-45857	HCPD	_
185-410	45857-45858	:	_
185-411	45859-45866	matched	_
185-412	45867-45874	healthy	_
185-413	45875-45883	controls	_
185-414	45884-45886	of	_
185-415	45887-45896	Parkinson	_
185-416	45896-45897	’	_
185-417	45897-45898	s	_
185-418	45899-45906	disease	_
185-419	45907-45913	sample	_
185-420	45913-45914	;	_
185-421	45915-45929	characteristic	_
185-422	45930-45936	values	_
185-423	45937-45939	in	_
185-424	45940-45944	mean	_
185-425	45945-45946	±	_
185-426	45947-45955	standard	_
185-427	45956-45965	deviation	_
185-428	45965-45966	;	_
185-429	45967-45972	DVARS	_
185-430	45972-45973	:	_
185-431	45974-45984	derivative	_
185-432	45985-45987	of	_
185-433	45988-45992	root	_
185-434	45993-45997	mean	_
185-435	45998-46005	squared	_
185-436	46006-46014	variance	_
185-437	46015-46019	over	_
185-438	46020-46026	voxels	_
185-439	46027-46028	(	_
185-440	46028-46032	head	_
185-441	46033-46041	movement	_
185-442	46042-46051	parameter	_
185-443	46051-46052	)	_
185-444	46052-46053	;	_
185-445	46054-46065	significant	_
185-446	46066-46076	difference	_
185-447	46077-46079	in	_
185-448	46080-46083	age	_
185-449	46084-46085	(	_
185-450	46085-46093	clinical	_
185-451	46094-46101	samples	_
185-452	46101-46102	)	_
185-453	46102-46103	,	_
185-454	46104-46110	gender	_
185-455	46111-46114	and	_
185-456	46115-46123	movement	_
185-457	46124-46127	are	_
185-458	46128-46134	marked	_
185-459	46135-46139	with	_
185-460	46140-46143	for	_
185-461	46144-46145	p	_
185-462	46146-46147	<	_
185-463	46148-46151	.05	_
185-464	46151-46152	;	_
185-465	46154-46155	:	_
185-466	46156-46170	OZP-equivalent	_
185-467	46170-46171	:	_
185-468	46172-46182	Olanzapine	_
185-469	46183-46193	equivalent	_
185-470	46194-46198	dose	_
185-471	46198-46199	;	_
185-472	46200-46205	PANSS	_
185-473	46205-46206	:	_
185-474	46207-46215	Positive	_
185-475	46216-46219	and	_
185-476	46220-46228	Negative	_
185-477	46229-46236	Symptom	_
185-478	46237-46242	Scale	_
185-479	46242-46243	,	_
185-480	46244-46245	(	_
185-481	46245-46247	PS	_
185-482	46247-46248	:	_
185-483	46249-46257	Positive	_
185-484	46258-46266	Symptoms	_
185-485	46267-46272	Scale	_
185-486	46272-46273	/	_
185-487	46273-46275	NS	_
185-488	46275-46276	:	_
185-489	46277-46285	Negative	_
185-490	46286-46294	Symptoms	_
185-491	46295-46300	Scale	_
185-492	46300-46301	/	_
185-493	46301-46304	GEN	_
185-494	46304-46305	:	_
185-495	46306-46313	General	_
185-496	46314-46329	Psychopathology	_
185-497	46330-46335	Scale	_
185-498	46335-46336	)	_
185-499	46336-46337	;	_
185-500	46339-46340	:	_
185-501	46341-46345	LEDD	_
185-502	46345-46346	:	_
185-503	46347-46355	Levodopa	_
185-504	46356-46366	equivalent	_
185-505	46367-46372	daily	_
185-506	46373-46377	dose	_
185-507	46377-46378	;	_
185-508	46379-46380	H	_
185-509	46381-46382	&	_
185-510	46383-46384	Y	_
185-511	46385-46390	scale	_
185-512	46390-46391	:	_
185-513	46392-46397	Hoehn	_
185-514	46398-46401	and	_
185-515	46402-46406	Yahr	_
185-516	46407-46412	Scale	_
185-517	46412-46413	;	_
185-518	46414-46423	UPDRS-III	_
185-519	46423-46424	:	_
185-520	46425-46432	Unified	_
185-521	46433-46442	Parkinson	_
185-522	46442-46443	’	_
185-523	46443-46444	s	_
185-524	46445-46452	Disease	_
185-525	46453-46459	Rating	_
185-526	46460-46465	Scale	_
185-527	46466-46470	Part	_
185-528	46471-46474	III	_
185-529	46474-46475	;	_
185-530	46476-46480	MoCA	_
185-531	46480-46481	:	_
185-532	46482-46490	Montreal	_
185-533	46491-46500	Cognitive	_
185-534	46501-46511	Assessment	_
185-535	46511-46512	;	_
185-536	46514-46515	:	_
185-537	46516-46523	DemTect	_
185-538	46523-46524	:	_
185-539	46525-46529	Mild	_
185-540	46530-46539	Cognitive	_
185-541	46540-46550	Impairment	_
185-542	46551-46554	and	_
185-543	46555-46560	Early	_
185-544	46561-46569	Dementia	_
185-545	46570-46579	Detection	_
185-546	46579-46580	;	_
185-547	46581-46587	BDI-II	_
185-548	46587-46588	:	_
185-549	46589-46593	Beck	_
185-550	46594-46604	Depression	_
185-551	46605-46614	Inventory	_
185-552	46615-46617	II	_
185-553	46617-46618	.	_

#Text=Network overview
#Text=Network(Abbr.)
186-1	46619-46626	Network	_
186-2	46627-46635	overview	_
186-3	46636-46643	Network	_
186-4	46643-46644	(	_
186-5	46644-46648	Abbr	_
186-6	46648-46649	.	_
186-7	46649-46650	)	_

#Text=Network\tContrast\tNodes\tPublication\t \tEmoSF\temotional scene and face processing\temotional scene > neutral scene and emotional face>neutral face\t24\t\t \tER\tcognitive emotion regulation\treappraise > naturalistic emotional responses\t14\t[Buhle et al., 2014]\t \tToM\tTheory-of-mind cognition\tTheory-of-mind > non-social baseline\t15\t[Bzdok et al., 2012]\t \tEmpathy\tempathic processing\t“feel into” affect-laden social situations > watched or listened passively\t19\t[Bzdok et al., 2012]\t \tRew\treward-related decision making\tME: reward valence and decision stages\t25\t[Liu et al., 2011]\t \tAM\tautobiographical memory\tautobiographical memory > non-autobiographical baseline\t22\t[Spreng et al., 2009]\t \tSM\tsemantic memory\taccess to word meaning > processing word structure\t23\t[Binder et al., 2009]\t \tWM\tworking memory\tME: n-back, sternberg, delayed matching to sample and delayed simple matching tasks\t23\t\t \tCogAC\tcognitive action-control\tME: stroop-task, spatial interference task, stop-signal task and go/no-go task\t19\t[Cieslik et al., 2015]\t \tVigAtt\tvigilant attention\tME: detection task, discrimination task\t16\t[Langner and Eickhoff, 2013]\t \tMNS\tmirror neuron system\taction observation ∩ action imitation\t11\t[Caspers et al., 2010]\t \tMotor\tmotor execution\tfinger tapping > baseline; excl. regions associated with visually paced finger-tapping tasks\t10\t[Witt et al., 2008]\t \t
#Text=ME: main effect.
187-1	46651-46658	Network	_
187-2	46659-46667	Contrast	_
187-3	46668-46673	Nodes	_
187-4	46674-46685	Publication	_
187-5	46688-46693	EmoSF	_
187-6	46694-46703	emotional	_
187-7	46704-46709	scene	_
187-8	46710-46713	and	_
187-9	46714-46718	face	_
187-10	46719-46729	processing	_
187-11	46730-46739	emotional	_
187-12	46740-46745	scene	_
187-13	46746-46747	>	_
187-14	46748-46755	neutral	_
187-15	46756-46761	scene	_
187-16	46762-46765	and	_
187-17	46766-46775	emotional	_
187-18	46776-46780	face	_
187-19	46780-46781	>	_
187-20	46781-46788	neutral	_
187-21	46789-46793	face	_
187-22	46794-46796	24	_
187-23	46800-46802	ER	_
187-24	46803-46812	cognitive	_
187-25	46813-46820	emotion	_
187-26	46821-46831	regulation	_
187-27	46832-46842	reappraise	_
187-28	46843-46844	>	_
187-29	46845-46857	naturalistic	_
187-30	46858-46867	emotional	_
187-31	46868-46877	responses	_
187-32	46878-46880	14	_
187-33	46881-46882	[	_
187-34	46882-46887	Buhle	_
187-35	46888-46890	et	_
187-36	46891-46893	al	_
187-37	46893-46894	.	_
187-38	46894-46895	,	_
187-39	46896-46900	2014	_
187-40	46900-46901	]	_
187-41	46904-46907	ToM	_
187-42	46908-46922	Theory-of-mind	_
187-43	46923-46932	cognition	_
187-44	46933-46947	Theory-of-mind	_
187-45	46948-46949	>	_
187-46	46950-46960	non-social	_
187-47	46961-46969	baseline	_
187-48	46970-46972	15	_
187-49	46973-46974	[	_
187-50	46974-46979	Bzdok	_
187-51	46980-46982	et	_
187-52	46983-46985	al	_
187-53	46985-46986	.	_
187-54	46986-46987	,	_
187-55	46988-46992	2012	_
187-56	46992-46993	]	_
187-57	46996-47003	Empathy	_
187-58	47004-47012	empathic	_
187-59	47013-47023	processing	_
187-60	47024-47025	“	_
187-61	47025-47029	feel	_
187-62	47030-47034	into	_
187-63	47034-47035	”	_
187-64	47036-47048	affect-laden	_
187-65	47049-47055	social	_
187-66	47056-47066	situations	_
187-67	47067-47068	>	_
187-68	47069-47076	watched	_
187-69	47077-47079	or	_
187-70	47080-47088	listened	_
187-71	47089-47098	passively	_
187-72	47099-47101	19	_
187-73	47102-47103	[	_
187-74	47103-47108	Bzdok	_
187-75	47109-47111	et	_
187-76	47112-47114	al	_
187-77	47114-47115	.	_
187-78	47115-47116	,	_
187-79	47117-47121	2012	_
187-80	47121-47122	]	_
187-81	47125-47128	Rew	_
187-82	47129-47143	reward-related	_
187-83	47144-47152	decision	_
187-84	47153-47159	making	_
187-85	47160-47162	ME	_
187-86	47162-47163	:	_
187-87	47164-47170	reward	_
187-88	47171-47178	valence	_
187-89	47179-47182	and	_
187-90	47183-47191	decision	_
187-91	47192-47198	stages	_
187-92	47199-47201	25	_
187-93	47202-47203	[	_
187-94	47203-47206	Liu	_
187-95	47207-47209	et	_
187-96	47210-47212	al	_
187-97	47212-47213	.	_
187-98	47213-47214	,	_
187-99	47215-47219	2011	_
187-100	47219-47220	]	_
187-101	47223-47225	AM	_
187-102	47226-47242	autobiographical	_
187-103	47243-47249	memory	_
187-104	47250-47266	autobiographical	_
187-105	47267-47273	memory	_
187-106	47274-47275	>	_
187-107	47276-47296	non-autobiographical	_
187-108	47297-47305	baseline	_
187-109	47306-47308	22	_
187-110	47309-47310	[	_
187-111	47310-47316	Spreng	_
187-112	47317-47319	et	_
187-113	47320-47322	al	_
187-114	47322-47323	.	_
187-115	47323-47324	,	_
187-116	47325-47329	2009	_
187-117	47329-47330	]	_
187-118	47333-47335	SM	_
187-119	47336-47344	semantic	_
187-120	47345-47351	memory	_
187-121	47352-47358	access	_
187-122	47359-47361	to	_
187-123	47362-47366	word	_
187-124	47367-47374	meaning	_
187-125	47375-47376	>	_
187-126	47377-47387	processing	_
187-127	47388-47392	word	_
187-128	47393-47402	structure	_
187-129	47403-47405	23	_
187-130	47406-47407	[	_
187-131	47407-47413	Binder	_
187-132	47414-47416	et	_
187-133	47417-47419	al	_
187-134	47419-47420	.	_
187-135	47420-47421	,	_
187-136	47422-47426	2009	_
187-137	47426-47427	]	_
187-138	47430-47432	WM	_
187-139	47433-47440	working	_
187-140	47441-47447	memory	_
187-141	47448-47450	ME	_
187-142	47450-47451	:	_
187-143	47452-47458	n-back	_
187-144	47458-47459	,	_
187-145	47460-47469	sternberg	_
187-146	47469-47470	,	_
187-147	47471-47478	delayed	_
187-148	47479-47487	matching	_
187-149	47488-47490	to	_
187-150	47491-47497	sample	_
187-151	47498-47501	and	_
187-152	47502-47509	delayed	_
187-153	47510-47516	simple	_
187-154	47517-47525	matching	_
187-155	47526-47531	tasks	_
187-156	47532-47534	23	_
187-157	47538-47543	CogAC	_
187-158	47544-47553	cognitive	_
187-159	47554-47568	action-control	_
187-160	47569-47571	ME	_
187-161	47571-47572	:	_
187-162	47573-47584	stroop-task	_
187-163	47584-47585	,	_
187-164	47586-47593	spatial	_
187-165	47594-47606	interference	_
187-166	47607-47611	task	_
187-167	47611-47612	,	_
187-168	47613-47624	stop-signal	_
187-169	47625-47629	task	_
187-170	47630-47633	and	_
187-171	47634-47636	go	_
187-172	47636-47637	/	_
187-173	47637-47642	no-go	_
187-174	47643-47647	task	_
187-175	47648-47650	19	_
187-176	47651-47652	[	_
187-177	47652-47659	Cieslik	_
187-178	47660-47662	et	_
187-179	47663-47665	al	_
187-180	47665-47666	.	_
187-181	47666-47667	,	_
187-182	47668-47672	2015	_
187-183	47672-47673	]	_
187-184	47676-47682	VigAtt	_
187-185	47683-47691	vigilant	_
187-186	47692-47701	attention	_
187-187	47702-47704	ME	_
187-188	47704-47705	:	_
187-189	47706-47715	detection	_
187-190	47716-47720	task	_
187-191	47720-47721	,	_
187-192	47722-47736	discrimination	_
187-193	47737-47741	task	_
187-194	47742-47744	16	_
187-195	47745-47746	[	_
187-196	47746-47753	Langner	_
187-197	47754-47757	and	_
187-198	47758-47766	Eickhoff	_
187-199	47766-47767	,	_
187-200	47768-47772	2013	_
187-201	47772-47773	]	_
187-202	47776-47779	MNS	_
187-203	47780-47786	mirror	_
187-204	47787-47793	neuron	_
187-205	47794-47800	system	_
187-206	47801-47807	action	_
187-207	47808-47819	observation	_
187-208	47820-47821	∩	_
187-209	47822-47828	action	_
187-210	47829-47838	imitation	_
187-211	47839-47841	11	_
187-212	47842-47843	[	_
187-213	47843-47850	Caspers	_
187-214	47851-47853	et	_
187-215	47854-47856	al	_
187-216	47856-47857	.	_
187-217	47857-47858	,	_
187-218	47859-47863	2010	_
187-219	47863-47864	]	_
187-220	47867-47872	Motor	_
187-221	47873-47878	motor	_
187-222	47879-47888	execution	_
187-223	47889-47895	finger	_
187-224	47896-47903	tapping	_
187-225	47904-47905	>	_
187-226	47906-47914	baseline	_
187-227	47914-47915	;	_
187-228	47916-47920	excl	_
187-229	47920-47921	.	_
187-230	47922-47929	regions	_
187-231	47930-47940	associated	_
187-232	47941-47945	with	_
187-233	47946-47954	visually	_
187-234	47955-47960	paced	_
187-235	47961-47975	finger-tapping	_
187-236	47976-47981	tasks	_
187-237	47982-47984	10	_
187-238	47985-47986	[	_
187-239	47986-47990	Witt	_
187-240	47991-47993	et	_
187-241	47994-47996	al	_
187-242	47996-47997	.	_
187-243	47997-47998	,	_
187-244	47999-48003	2008	_
187-245	48003-48004	]	_
187-246	48008-48010	ME	_
187-247	48010-48011	:	_
187-248	48012-48016	main	_
187-249	48017-48023	effect	_
187-250	48023-48024	.	_

#Text=Classification results of the support vector machine of all groups based on specific networks
#Text=Network\tSCZ vs.
188-1	48025-48039	Classification	_
188-2	48040-48047	results	_
188-3	48048-48050	of	_
188-4	48051-48054	the	_
188-5	48055-48062	support	_
188-6	48063-48069	vector	_
188-7	48070-48077	machine	_
188-8	48078-48080	of	_
188-9	48081-48084	all	_
188-10	48085-48091	groups	_
188-11	48092-48097	based	_
188-12	48098-48100	on	_
188-13	48101-48109	specific	_
188-14	48110-48118	networks	_
188-15	48119-48126	Network	_
188-16	48127-48130	SCZ	_
188-17	48131-48133	vs	_
188-18	48133-48134	.	_

#Text=HCSCZ\tPD vs.
189-1	48135-48140	HCSCZ	_
189-2	48141-48143	PD	_
189-3	48144-48146	vs	_
189-4	48146-48147	.	_

#Text=HCPD\tOld vs.
190-1	48148-48152	HCPD	_
190-2	48153-48156	Old	_
190-3	48157-48159	vs	_
190-4	48159-48160	.	_

#Text=Young\t \t(Abbr.)
191-1	48161-48166	Young	_
191-2	48169-48170	(	_
191-3	48170-48174	Abbr	_
191-4	48174-48175	.	_
191-5	48175-48176	)	_

#Text=Acc.
192-1	48177-48180	Acc	_
192-2	48180-48181	.	_

#Text=(Sens.
193-1	48182-48183	(	_
193-2	48183-48187	Sens	_
193-3	48187-48188	.	_

#Text=/Spec.)
194-1	48188-48189	/	_
194-2	48189-48193	Spec	_
194-3	48193-48194	.	_
194-4	48194-48195	)	_

#Text=AUC*\tAcc.
195-1	48196-48199	AUC	_
195-2	48199-48200	*	_
195-3	48201-48204	Acc	_
195-4	48204-48205	.	_

#Text=(Sens.
196-1	48206-48207	(	_
196-2	48207-48211	Sens	_
196-3	48211-48212	.	_

#Text=/Spec.)
197-1	48212-48213	/	_
197-2	48213-48217	Spec	_
197-3	48217-48218	.	_
197-4	48218-48219	)	_

#Text=AUC\tAcc.
198-1	48220-48223	AUC	_
198-2	48224-48227	Acc	_
198-3	48227-48228	.	_

#Text=(Sens.
199-1	48229-48230	(	_
199-2	48230-48234	Sens	_
199-3	48234-48235	.	_

#Text=/Spec.)
200-1	48235-48236	/	_
200-2	48236-48240	Spec	_
200-3	48240-48241	.	_
200-4	48241-48242	)	_

#Text=AUC\t \tEmoSF\t72% (77%/68%) 0.79\t63% (64%/63%) 0.68\t88% (89%/86%) 0.93\t \tER\t71% (77%/65%) 0.76\t69% (74%/64%) 0.74\t78% (79%/76%) 0.86\t \tToM\t61% (74%/46%) 0.62#\t67% (70%/64%) 0.71\t78% (77%/80%) 0.84\t \tEmpathy\t71% (73%/69%) 0.78\t63% (61%/65%) 0.69\t78% (80%/75%) 0.83\t \tRew\t68% (73%/62%) 0.73\t66% (70%/63%) 0.71\t87% (85%/88%) 0.93\t \tAM\t62% (67%/57%) 0.71\t75% (78%/73%) 0.76\t80% (80%/80%) 0.89\t \tSM\t61% (67%/54%) 0.68#\t69% (65%/73%) 0.75\t84% (85%/83%) 0.90\t \tWM\t62% (65%/60%) 0.66\t65% (68%/63%) 0.71\t79% (80%/77%) 0.84\t \tCogAC\t68% (73%/63%) 0.69\t62% (66%/57%) 0.67\t73% (73%/74%) 0.83\t \tVigAtt\t68% (72%/63%) 0.72\t65% (68%/63%) 0.67\t80% (78%/83%) 0.89\t \tMNS\t64% (65%/63%) 0.73\t57% (64%/51%) 0.53#\t84% (83%/84%) 0.91\t \tMotor\t61% (72%/50%) 0.61\t70% (68%/73%) 0.77\t80% (79%/81%) 0.90\t \t
#Text=Abbreviations: Acc.: Accuracy (in %)/Sens.: Sensitivity (in %) /Spec.: Specificity (in %)/AUC: Area under the receiver operating characteristics curve.
201-1	48243-48246	AUC	_
201-2	48249-48254	EmoSF	_
201-3	48255-48258	72%	_
201-4	48259-48260	(	_
201-5	48260-48263	77%	_
201-6	48263-48264	/	_
201-7	48264-48267	68%	_
201-8	48267-48268	)	_
201-9	48269-48273	0.79	_
201-10	48274-48277	63%	_
201-11	48278-48279	(	_
201-12	48279-48282	64%	_
201-13	48282-48283	/	_
201-14	48283-48286	63%	_
201-15	48286-48287	)	_
201-16	48288-48292	0.68	_
201-17	48293-48296	88%	_
201-18	48297-48298	(	_
201-19	48298-48301	89%	_
201-20	48301-48302	/	_
201-21	48302-48305	86%	_
201-22	48305-48306	)	_
201-23	48307-48311	0.93	_
201-24	48314-48316	ER	_
201-25	48317-48320	71%	_
201-26	48321-48322	(	_
201-27	48322-48325	77%	_
201-28	48325-48326	/	_
201-29	48326-48329	65%	_
201-30	48329-48330	)	_
201-31	48331-48335	0.76	_
201-32	48336-48339	69%	_
201-33	48340-48341	(	_
201-34	48341-48344	74%	_
201-35	48344-48345	/	_
201-36	48345-48348	64%	_
201-37	48348-48349	)	_
201-38	48350-48354	0.74	_
201-39	48355-48358	78%	_
201-40	48359-48360	(	_
201-41	48360-48363	79%	_
201-42	48363-48364	/	_
201-43	48364-48367	76%	_
201-44	48367-48368	)	_
201-45	48369-48373	0.86	_
201-46	48376-48379	ToM	_
201-47	48380-48383	61%	_
201-48	48384-48385	(	_
201-49	48385-48388	74%	_
201-50	48388-48389	/	_
201-51	48389-48392	46%	_
201-52	48392-48393	)	_
201-53	48394-48398	0.62	_
201-54	48398-48399	#	_
201-55	48400-48403	67%	_
201-56	48404-48405	(	_
201-57	48405-48408	70%	_
201-58	48408-48409	/	_
201-59	48409-48412	64%	_
201-60	48412-48413	)	_
201-61	48414-48418	0.71	_
201-62	48419-48422	78%	_
201-63	48423-48424	(	_
201-64	48424-48427	77%	_
201-65	48427-48428	/	_
201-66	48428-48431	80%	_
201-67	48431-48432	)	_
201-68	48433-48437	0.84	_
201-69	48440-48447	Empathy	_
201-70	48448-48451	71%	_
201-71	48452-48453	(	_
201-72	48453-48456	73%	_
201-73	48456-48457	/	_
201-74	48457-48460	69%	_
201-75	48460-48461	)	_
201-76	48462-48466	0.78	_
201-77	48467-48470	63%	_
201-78	48471-48472	(	_
201-79	48472-48475	61%	_
201-80	48475-48476	/	_
201-81	48476-48479	65%	_
201-82	48479-48480	)	_
201-83	48481-48485	0.69	_
201-84	48486-48489	78%	_
201-85	48490-48491	(	_
201-86	48491-48494	80%	_
201-87	48494-48495	/	_
201-88	48495-48498	75%	_
201-89	48498-48499	)	_
201-90	48500-48504	0.83	_
201-91	48507-48510	Rew	_
201-92	48511-48514	68%	_
201-93	48515-48516	(	_
201-94	48516-48519	73%	_
201-95	48519-48520	/	_
201-96	48520-48523	62%	_
201-97	48523-48524	)	_
201-98	48525-48529	0.73	_
201-99	48530-48533	66%	_
201-100	48534-48535	(	_
201-101	48535-48538	70%	_
201-102	48538-48539	/	_
201-103	48539-48542	63%	_
201-104	48542-48543	)	_
201-105	48544-48548	0.71	_
201-106	48549-48552	87%	_
201-107	48553-48554	(	_
201-108	48554-48557	85%	_
201-109	48557-48558	/	_
201-110	48558-48561	88%	_
201-111	48561-48562	)	_
201-112	48563-48567	0.93	_
201-113	48570-48572	AM	_
201-114	48573-48576	62%	_
201-115	48577-48578	(	_
201-116	48578-48581	67%	_
201-117	48581-48582	/	_
201-118	48582-48585	57%	_
201-119	48585-48586	)	_
201-120	48587-48591	0.71	_
201-121	48592-48595	75%	_
201-122	48596-48597	(	_
201-123	48597-48600	78%	_
201-124	48600-48601	/	_
201-125	48601-48604	73%	_
201-126	48604-48605	)	_
201-127	48606-48610	0.76	_
201-128	48611-48614	80%	_
201-129	48615-48616	(	_
201-130	48616-48619	80%	_
201-131	48619-48620	/	_
201-132	48620-48623	80%	_
201-133	48623-48624	)	_
201-134	48625-48629	0.89	_
201-135	48632-48634	SM	_
201-136	48635-48638	61%	_
201-137	48639-48640	(	_
201-138	48640-48643	67%	_
201-139	48643-48644	/	_
201-140	48644-48647	54%	_
201-141	48647-48648	)	_
201-142	48649-48653	0.68	_
201-143	48653-48654	#	_
201-144	48655-48658	69%	_
201-145	48659-48660	(	_
201-146	48660-48663	65%	_
201-147	48663-48664	/	_
201-148	48664-48667	73%	_
201-149	48667-48668	)	_
201-150	48669-48673	0.75	_
201-151	48674-48677	84%	_
201-152	48678-48679	(	_
201-153	48679-48682	85%	_
201-154	48682-48683	/	_
201-155	48683-48686	83%	_
201-156	48686-48687	)	_
201-157	48688-48692	0.90	_
201-158	48695-48697	WM	_
201-159	48698-48701	62%	_
201-160	48702-48703	(	_
201-161	48703-48706	65%	_
201-162	48706-48707	/	_
201-163	48707-48710	60%	_
201-164	48710-48711	)	_
201-165	48712-48716	0.66	_
201-166	48717-48720	65%	_
201-167	48721-48722	(	_
201-168	48722-48725	68%	_
201-169	48725-48726	/	_
201-170	48726-48729	63%	_
201-171	48729-48730	)	_
201-172	48731-48735	0.71	_
201-173	48736-48739	79%	_
201-174	48740-48741	(	_
201-175	48741-48744	80%	_
201-176	48744-48745	/	_
201-177	48745-48748	77%	_
201-178	48748-48749	)	_
201-179	48750-48754	0.84	_
201-180	48757-48762	CogAC	_
201-181	48763-48766	68%	_
201-182	48767-48768	(	_
201-183	48768-48771	73%	_
201-184	48771-48772	/	_
201-185	48772-48775	63%	_
201-186	48775-48776	)	_
201-187	48777-48781	0.69	_
201-188	48782-48785	62%	_
201-189	48786-48787	(	_
201-190	48787-48790	66%	_
201-191	48790-48791	/	_
201-192	48791-48794	57%	_
201-193	48794-48795	)	_
201-194	48796-48800	0.67	_
201-195	48801-48804	73%	_
201-196	48805-48806	(	_
201-197	48806-48809	73%	_
201-198	48809-48810	/	_
201-199	48810-48813	74%	_
201-200	48813-48814	)	_
201-201	48815-48819	0.83	_
201-202	48822-48828	VigAtt	_
201-203	48829-48832	68%	_
201-204	48833-48834	(	_
201-205	48834-48837	72%	_
201-206	48837-48838	/	_
201-207	48838-48841	63%	_
201-208	48841-48842	)	_
201-209	48843-48847	0.72	_
201-210	48848-48851	65%	_
201-211	48852-48853	(	_
201-212	48853-48856	68%	_
201-213	48856-48857	/	_
201-214	48857-48860	63%	_
201-215	48860-48861	)	_
201-216	48862-48866	0.67	_
201-217	48867-48870	80%	_
201-218	48871-48872	(	_
201-219	48872-48875	78%	_
201-220	48875-48876	/	_
201-221	48876-48879	83%	_
201-222	48879-48880	)	_
201-223	48881-48885	0.89	_
201-224	48888-48891	MNS	_
201-225	48892-48895	64%	_
201-226	48896-48897	(	_
201-227	48897-48900	65%	_
201-228	48900-48901	/	_
201-229	48901-48904	63%	_
201-230	48904-48905	)	_
201-231	48906-48910	0.73	_
201-232	48911-48914	57%	_
201-233	48915-48916	(	_
201-234	48916-48919	64%	_
201-235	48919-48920	/	_
201-236	48920-48923	51%	_
201-237	48923-48924	)	_
201-238	48925-48929	0.53	_
201-239	48929-48930	#	_
201-240	48931-48934	84%	_
201-241	48935-48936	(	_
201-242	48936-48939	83%	_
201-243	48939-48940	/	_
201-244	48940-48943	84%	_
201-245	48943-48944	)	_
201-246	48945-48949	0.91	_
201-247	48952-48957	Motor	_
201-248	48958-48961	61%	_
201-249	48962-48963	(	_
201-250	48963-48966	72%	_
201-251	48966-48967	/	_
201-252	48967-48970	50%	_
201-253	48970-48971	)	_
201-254	48972-48976	0.61	_
201-255	48977-48980	70%	_
201-256	48981-48982	(	_
201-257	48982-48985	68%	_
201-258	48985-48986	/	_
201-259	48986-48989	73%	_
201-260	48989-48990	)	_
201-261	48991-48995	0.77	_
201-262	48996-48999	80%	_
201-263	49000-49001	(	_
201-264	49001-49004	79%	_
201-265	49004-49005	/	_
201-266	49005-49008	81%	_
201-267	49008-49009	)	_
201-268	49010-49014	0.90	_
201-269	49018-49031	Abbreviations	_
201-270	49031-49032	:	_
201-271	49033-49036	Acc	_
201-272	49036-49037	.	_
201-273	49037-49038	:	_
201-274	49039-49047	Accuracy	_
201-275	49048-49049	(	_
201-276	49049-49051	in	_
201-277	49052-49053	%	_
201-278	49053-49054	)	_
201-279	49054-49055	/	_
201-280	49055-49059	Sens	_
201-281	49059-49060	.	_
201-282	49060-49061	:	_
201-283	49062-49073	Sensitivity	_
201-284	49074-49075	(	_
201-285	49075-49077	in	_
201-286	49078-49079	%	_
201-287	49079-49080	)	_
201-288	49081-49082	/	_
201-289	49082-49086	Spec	_
201-290	49086-49087	.	_
201-291	49087-49088	:	_
201-292	49089-49100	Specificity	_
201-293	49101-49102	(	_
201-294	49102-49104	in	_
201-295	49105-49106	%	_
201-296	49106-49107	)	_
201-297	49107-49108	/	_
201-298	49108-49111	AUC	_
201-299	49111-49112	:	_
201-300	49113-49117	Area	_
201-301	49118-49123	under	_
201-302	49124-49127	the	_
201-303	49128-49136	receiver	_
201-304	49137-49146	operating	_
201-305	49147-49162	characteristics	_
201-306	49163-49168	curve	_
201-307	49168-49169	.	_

#Text=Network with no significant classification result.
202-1	49170-49177	Network	_
202-2	49178-49182	with	_
202-3	49183-49185	no	_
202-4	49186-49197	significant	_
202-5	49198-49212	classification	_
202-6	49213-49219	result	_
202-7	49219-49220	.	_

#Text=Accuracy refers to the proportion of subjects correctly classified as patients (PD, SCZ) or older age and subjects correctly classified as being healthy or younger age (mean of Sensitivity and Specificity).
203-1	49221-49229	Accuracy	_
203-2	49230-49236	refers	_
203-3	49237-49239	to	_
203-4	49240-49243	the	_
203-5	49244-49254	proportion	_
203-6	49255-49257	of	_
203-7	49258-49266	subjects	_
203-8	49267-49276	correctly	_
203-9	49277-49287	classified	_
203-10	49288-49290	as	_
203-11	49291-49299	patients	_
203-12	49300-49301	(	_
203-13	49301-49303	PD	_
203-14	49303-49304	,	_
203-15	49305-49308	SCZ	_
203-16	49308-49309	)	_
203-17	49310-49312	or	_
203-18	49313-49318	older	_
203-19	49319-49322	age	_
203-20	49323-49326	and	_
203-21	49327-49335	subjects	_
203-22	49336-49345	correctly	_
203-23	49346-49356	classified	_
203-24	49357-49359	as	_
203-25	49360-49365	being	_
203-26	49366-49373	healthy	_
203-27	49374-49376	or	_
203-28	49377-49384	younger	_
203-29	49385-49388	age	_
203-30	49389-49390	(	_
203-31	49390-49394	mean	_
203-32	49395-49397	of	_
203-33	49398-49409	Sensitivity	_
203-34	49410-49413	and	_
203-35	49414-49425	Specificity	_
203-36	49425-49426	)	_
203-37	49426-49427	.	_

#Text=Sensitivity relates to the percentage of patients (SCZ or PD) correctly classified as being ill or else subjects correctly identified as old in the aging sample (true positives).
204-1	49428-49439	Sensitivity	_
204-2	49440-49447	relates	_
204-3	49448-49450	to	_
204-4	49451-49454	the	_
204-5	49455-49465	percentage	_
204-6	49466-49468	of	_
204-7	49469-49477	patients	_
204-8	49478-49479	(	_
204-9	49479-49482	SCZ	_
204-10	49483-49485	or	_
204-11	49486-49488	PD	_
204-12	49488-49489	)	_
204-13	49490-49499	correctly	_
204-14	49500-49510	classified	_
204-15	49511-49513	as	_
204-16	49514-49519	being	_
204-17	49520-49523	ill	_
204-18	49524-49526	or	_
204-19	49527-49531	else	_
204-20	49532-49540	subjects	_
204-21	49541-49550	correctly	_
204-22	49551-49561	identified	_
204-23	49562-49564	as	_
204-24	49565-49568	old	_
204-25	49569-49571	in	_
204-26	49572-49575	the	_
204-27	49576-49581	aging	_
204-28	49582-49588	sample	_
204-29	49589-49590	(	_
204-30	49590-49594	true	_
204-31	49595-49604	positives	_
204-32	49604-49605	)	_
204-33	49605-49606	.	_

#Text=Specificity relates to the percentage of healthy subjects correctly classified as being healthy or else subjects correctly identified as young in the aging sample (true negatives).
205-1	49607-49618	Specificity	_
205-2	49619-49626	relates	_
205-3	49627-49629	to	_
205-4	49630-49633	the	_
205-5	49634-49644	percentage	_
205-6	49645-49647	of	_
205-7	49648-49655	healthy	_
205-8	49656-49664	subjects	_
205-9	49665-49674	correctly	_
205-10	49675-49685	classified	_
205-11	49686-49688	as	_
205-12	49689-49694	being	_
205-13	49695-49702	healthy	_
205-14	49703-49705	or	_
205-15	49706-49710	else	_
205-16	49711-49719	subjects	_
205-17	49720-49729	correctly	_
205-18	49730-49740	identified	_
205-19	49741-49743	as	_
205-20	49744-49749	young	_
205-21	49750-49752	in	_
205-22	49753-49756	the	_
205-23	49757-49762	aging	_
205-24	49763-49769	sample	_
205-25	49770-49771	(	_
205-26	49771-49775	true	_
205-27	49776-49785	negatives	_
205-28	49785-49786	)	_
205-29	49786-49787	.	_

#Text=AUC refers to the area under the receiver operating characteristics (ROC) curve.
206-1	49788-49791	AUC	_
206-2	49792-49798	refers	_
206-3	49799-49801	to	_
206-4	49802-49805	the	_
206-5	49806-49810	area	_
206-6	49811-49816	under	_
206-7	49817-49820	the	_
206-8	49821-49829	receiver	_
206-9	49830-49839	operating	_
206-10	49840-49855	characteristics	_
206-11	49856-49857	(	_
206-12	49857-49860	ROC	_
206-13	49860-49861	)	_
206-14	49862-49867	curve	_
206-15	49867-49868	.	_

#Text=ROC curve depicts the relationship between true positive rate and false positive rate.
207-1	49869-49872	ROC	_
207-2	49873-49878	curve	_
207-3	49879-49886	depicts	_
207-4	49887-49890	the	_
207-5	49891-49903	relationship	_
207-6	49904-49911	between	_
207-7	49912-49916	true	_
207-8	49917-49925	positive	_
207-9	49926-49930	rate	_
207-10	49931-49934	and	_
207-11	49935-49940	false	_
207-12	49941-49949	positive	_
207-13	49950-49954	rate	_
207-14	49954-49955	.	_
